



Metagenomic next generation sequencing for 
viral pathogens:  
Application and validation of a deployable 
sequencer for virus identification  
 
 




















Thesis submitted in accordance with the requirements of the University of Liverpool 




     
    
    
     
      
I declare that the work in this thesis was carried out in accordance with the 
regulations of the University of Liverpool. The work is original except where 
indicated by special reference in the text and no part of the dissertation has 
been submitted for any other degree. 
      
Any views expressed in the thesis are those of the author and in no way 
represent the University of Liverpool. 
      
The thesis has not been presented to any other University for examination 
either in the United Kingdom or overseas. 
      





   
It's more than once that people told me a PhD is a very lonely process, having 
now completed mine I have to admit the last four years were anything but lonely. I 
gained new colleagues, came closer with older ones and most importantly, after these 
4 years found myself with more friends than I ever thought possible. The moment has 
come to write the last thing left on the thesis to-do list and it might go without saying 
but none of the things I have included are obvious, expected or assumed; I am a 
better version of myself and complete this project having gained so much not only in 
knowledge but also in experiences, people and friends. 
      
First and foremost, I would like to thank Steve Pullan for being such an 
awesome supervisor, for all the support through the highs and lows and for patiently 
(emphasis on patiently) guiding me throughout this whole process. I could not have 
asked for a better supervisor and it has really been an amazing 4 years. I have learned 
so much working under your guidance and feel really lucky I had such a great time 
during my PhD. I always felt I could reach out and you did a great job keeping me in 
check during the whole process, for which I am very grateful and always will be. Big 
thank you also goes to my second supervisor, Richard Vipond, who always made 
time for thesis catch-ups and regularly checked how I was doing, both project 
progress-wise and personally; always making sure that I (at least tried to) keep a 
balance. Thank you for supporting this project and me for the whole duration. Miles 
Carroll, Julian Hiscox and Richard Vipond, this project would not have been there 
without you all, and to be fair neither would have I. Thank you for entrusting me with 
this project, supporting me at all the different time-points and always being available 
when most needed. Thank you to Roger Hewson for all the cool science chats and 
finding time despite your busy schedule. 
      
Thank you to everyone in the Genomics Team, RIPL, DSP and V&P who 
assisted whenever I needed help and particularly because they were always happy 
to do so. Specifically, I am grateful to Kui Lewandowski, Dan Carter, Ant Crook, Sarah 
Lumley for their help, both scientifically and personally. 
      
The biggest impact of this thesis came from work built on a collaboration and 
for this I am grateful to Stephan Günther, for trusting in me when I first approached 
him about initiating this part of the project and for giving me the amazing opportunity 
to pursue this collaboration. I also owe a huge thank you to Sophie Duraffour, who's 
passion for her work inspired me in our first encounter and continues to do so to-date; 





Thank you to everyone in the BNITM and ISTH team, as everyone's 
commitment and help brought this work together, it would not have been possible 
without them. I would like to particularly thank Lisa Oestereich, Anke Thielebein, 
Meike Pahlmann, David Wozniak, Annick Renevey and Julia Hinzmann who all 
helped at various time-points and in different aspects with setting up, logistics and the 
more practical side of things. 
 
A big thank you also to Phillippe Lemey, not only for the involvement in my 
PhD, but also for providing the next step for my research and above all for his support 
and understanding during the last year. I am really excited to be part of your research 
group and looking forward to the opportunities and challenges ahead. 
 
Deborah, my sweet friend, thank you for being there every step of the way and 
always taking care of everyone and everything you possibly could, particularly me. All 
the trips to the airport definitely made the travel less bitter and more interesting - 
especially when the car decides to give up on us! Lizzy and Scottyroddy your 
combined efforts to encourage me definitely worked, it was lovely to have a short-
term flatmate and neighbour around the corner for all those tired evenings when 
heading back home alone just didn't cut it, thank you for being there even when not 
in lovely Salisbury anymore! Nadina, you made me feel like part of your lovely family 
for all the weekends I spent with you, thank you for every delicious meal and your 
constant care and concern for me. Ant and Dan, Five Guys will never be the same 
without you and neither will my soft-drink habits; our cinema trips added some spice 
(or should I say salt) to my long weeks of work and looking back I was fortunate 
enough to have obtained enough salt to make it through the whole of this project, plus 
a few good scares to keep me awake during long working days. Slummers, those 
cheeky half pints kept me sane and despite being far away you made sure to actively 
keep checking up on me - sanity-check, check! Sophie, the support has not only been 
scientific, so here's one more thank you for all the non-scientific support you have 
provided along the way, to the glass always half full - cheers! Anke, not sure I need 
to say much, but the least I can say is thank you for the constant and much 
appreciated hugs. Sophie, Anke, Meike, Lisa, David, Jule, Jonas and Ellie, Hamburg 
would have definitely not been as fun without you all! Magda, don't forget what always 
keeps us going: at least we don't have to do a PhD in MEMS. Lieseke, thank you for 
being there from even before the start and for sharing all the frustrations along the 
way. Dulcinha, thank you for always believing in me and supporting me in the good 
and bad moments, taking so good care of me at some of the most difficult and 
frustrating times and being so happy and proud of me at all the good ones. Joao, 
akiro. To every single person included in this section, everyone that is not specifically 




A big thank you goes to Kyriakos Efthymiadis who shared my worries, was 
always the voice of logic, knows how to reason with me and helped me get through 
the most frustrating days; your support has been priceless. 
 
Finally, I would like to dedicate this thesis to my parents and my brother for 
their support through these years, when things were good but mainly when things 
were not. For understanding and being there for me even when I was stressed out 
and in the worst of moods and for never stopping to believe in me. To my dad who 
somehow completely by chance led me exactly where I was meant to be; your advice 
has always been so valuable. I have always admired your work ethics and love, the 
way you care for what you do and everything you are passionate about. It is inspiring 
and mesmerizing to listen to you explain any fact, scientific or not, and your 
knowledge for everything never stops to amaze me! Your goals, determination and 
views on life make us all stronger by the day. To my mum, who none of us understand 
how you manage to juggle everything or manage to deal with all of us, thank you for 
always listening and always being there when we need you the most. You always 
make every difficult moment easier and every storm calmer; I really don't know how 
we would manage without you and not just because you sort out our taxes. To my 
brother for entertaining me constantly with all the silly internet videos and for his 
unconventional sibling love; thank you for always accepting me just the way I am and 
definitely not said very often but I am very proud of you. It has been a tough year but 
if anything makes it better it's that we all have each other. 
 
It has been an absolutely amazing trip and I have loved every single moment. 
I complete this thesis with more knowledge as a scientist but more importantly as a 
better version of myself. If there is anything I could change I wouldn't change a thing, 
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Metagenomic next generation sequencing for 
viral pathogens: 
Application and validation of a deployable 
sequencer for virus identification 
 








Viral pathogen identification and discovery is of significant importance to 
clinical virology and public health. Rapid and unbiased diagnostic methods are vital 
when developing a strategy for treatment and eradication of an emerging pathogen. 
Advances in the field of sequencing over the last decade have facilitated pathogen 
identification without prior knowledge, introducing its potential and importance as a 
diagnostic support approach. More recently the development of the MinION, a 
portable palm-sized sequencing device run via a laptop computer has introduced 
sequencing in real time in remote settings and overcome many limitations of its 
predecessors. The objective of this project was to investigate the possibility of non-
targeted viral pathogen identification and full genome recovery from clinical samples 
utilising a metagenomic sequencing approach coupled with the MinION. The 
limitations and bottlenecks identified during initial experiments using a model system 
of Hazara virus spiked into human serum and preliminary clinical sample testing 
allowed for the development and optimisation of a pipeline for clinical sample 
processing. It was subsequently demonstrated that direct metagenomic sequencing 
of clinical serum samples in a laboratory setting can elucidate full viral genomes 
directly from clinical samples for Chikungunya, Dengue and Lassa virus across a 
range of clinically relevant viral titres. Finally, to evaluate metagenomic nanopore 
sequencing for the recovery of whole viral genome sequences from clinical samples 
of a divergent virus in a remote and resource-limited setting, metagenomic nanopore 
sequencing of Lassa virus was implemented in Nigeria during the 2018 endemic 
season, providing vital public health information in real-time. 
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1. Chapter 1. Introduction 
1.1 Viruses 
 
Viruses are classified into viral taxa and as defined by the International 
Committee on Taxonomy of Viruses (ICTV) (1), "a virus species is a polythetic class 
of viruses that constitute a replicating lineage and occupy a particular ecological 
niche". More specifically ICTV specifies that a "polythetic class" is defined by 
members, which have several properties in common, but not necessarily all or a single 
uniform one across all members, subsequently members of a viral species are 
defined by a consensus group of properties. The classification system includes, 
where possible, the assignment of viruses as members of appropriate species. Viral 
species are classified as members of recognised genera and some genera are 
members of recognised sub-families. Viral taxonomic classification is as follows: 
(Order), Family, (Sub-family), Genus, Species. The second widely used classification 
system for viruses is the Baltimore classification, first described in 1971 by David 
Baltimore (2). The Baltimore classification categorises viruses based on the type of 
their genome and their replication strategy. Seven classes of viruses exist in the 
Baltimore Classification system: (I) double stranded DNA viruses, (II) single stranded 
DNA viruses, (III) double stranded RNA viruses (dsRNA), (IV) positive-strand single-
stranded RNA viruses ((+)ssRNA), (V) negative-strand single-stranded RNA viruses 
((-)ssRNA), (VI) positive-sense single-stranded RNA reverse transcriptase viruses 
and (VII) double stranded DNA reverse transcriptase viruses (3).  
The majority of emerging and re-emerging infectious diseases are caused by 
RNA viruses, making RNA viruses a huge public health burden and prominent among 
the emerging viruses (4, 5). RNA viruses are subdivided into three groups based on 
the structure and coding of their genome: (a) (+) ssRNA (b) (-) ssRNA (c) dsRNA. 
Emerging and re-emerging viruses of major public health concern are in their vast 
majority (+) ssRNA and (-) ssRNA viruses. Genomes of (+) ssRNA viruses are single-
stranded molecules of RNA, function as mRNAs and are infectious. The viral genome 
serves both as the mRNA and as the template for synthesis of additional viral RNAs. 
Genomes of (-)ssRNA viruses contain a single stranded RNA genome that may be 
segmented (non-segments or segmented into 2-8 molecules) and the naked genomic 
RNA is not infectious (6). The primary event following genome release within a host 
cell is transcription, which is successfully accomplished in the presence of the viral 
proteins. Emerging and re-emerging viruses are extensively researched to 
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understand the way they infect and cause disease in humans, animals or plants. 
Additionally, non-pathogenic viruses are very commonly used as they can provide 
safe alternatives to study their related pathogenic-viruses. An overview is presented 
in this section for each virus studied in this thesis.  
1.1.1 Hazara virus 
 
Hazara virus (HAZV) was first isolated in 1964 from Ixodes redikorzevi ticks 
in Western Pakistan and identified to be a distinct virus but serologically related to 
Crimean-Congo Haemorrhagic fever virus (CCHFV) (7, 8). HAZV natural mammalian 
hosts are largely unknown, although antibody evidence has been found in wild rodent 
sera (9, 10). HAZV is not pathogenic to humans and can be handled in a low 
containment laboratory (CL2) making it a suitable model virus for molecular 
experiments to understand its related pathogenic nairovirus (11, 12).  
HAZV belongs to the family Nairoviridae, the genus Orthonairovirus and the 
order Bunyavirales (3, 10, 13). Orthonairovirus genomes are single-stranded, 
negative-sense RNA and are composed of three segments; the large (L) segment 
(~6.8-12 kb), the medium (M) segment (~3.2-4.9 kb) and the small (S) segment (~1-
3kb). The HAZV genome consists of an L segment of ~11.9kb, an M segment of 
~4.5kb and an S segment of ~2kb. All three segments have the same complementary 
sequence of nucleotides at their 3' and 5' end. These terminal nucleotide sequences 
are highly conserved within each viral genus.  
Orthonairovirus virions are enveloped and have a diameter of ~80-100nm. 
Glycoproteins are embedded within the lipid bilayer envelope, which has a thickness 
of 5-7nm, and display projections of 5-10nm (10). The virion contains individual 
complexes of each genomic RNA segment and nucleoprotein, termed 
ribonucleoprotein particles. Each genomic segment contains a single open reading 
frame, which is flanked between non-coding regions. The three segments combined 
encode for four structural proteins (Figure 1.1): the L segment encodes the RNA-
dependent RNA polymerase ( RdRp), the M segment the two glycoproteins (GN and 
GC) and the S segment the nucleoprotein (N) (3). The L protein functions as an RdRp 
but also has endonuclease activity and is responsible for generating the capped 
primers required for transcription. The M segment is translated into a single 
polyprotein precursor, which is co- and post-translationally cleaved into the two 
glycoproteins. The N protein is the most abundant viral protein and plays an important 
role in viral replication and protecting viral RNA from degradation.  
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Attachment of the virion to the host cell surface is mediated by an interaction 
between the viral glycoproteins and host receptors and leads to viral entry by 
endocytosis (3, 10). Acidification triggers conformational changes to the envelope 
glycoproteins, uncoating the virion and leading to fusion of the viral membranes with 
the endosomal membranes. The viral genome is released and primary transcription 
of the negative-sense RNA to mRNA is initiated. The virion-associated RdRp 
mediates transcription by interacting with the three ribonucleocapsids and the 
generated mRNA is translated to synthesise viral polypeptides. L and S mRNAs are 
translated by free ribosomes, whereas M mRNAs are translated by membrane-bound 
ribosomes. Once translated, the glycoprotein precursors undergo post-translational 
processing in the Golgi membrane. Genomic segments are replicated via the 
formation of complementary copies of the viral genomic RNA used as a template for 
the production of subsequent viral genomic RNA (3, 10). Virions assemble following 
the interaction of the newly synthesised viral ribonucleocapsids with the 
glycoproteins. The virions bud and are released from the cells through the secretory 
pathway. At least one of the three ribonucleocapsids needs to be contained within a 
virion for it to be infective.  
 
 
Figure 1.1 HAZV genome structure and protein products.  
Each segment contains a single long ORF and a subgenomic mRNA is expressed for each 
segment. A single polyprotein is produced for the M segment, which is co- and post-
translationally cleaved.  
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1.1.2 Dengue virus 
 
Dengue virus (DENV) is the most prevalent human arboviral pathogen globally 
(14). DENV fever occurs following infection with one of four serotypes (DENV1-4) and 
clinical presentation typically includes a high fever, arthralgia, myalgia, rash and 
headache (15). A minority of cases develop acute haemorrhagic manifestations and 
multi-organ failure. Despite DENV cases being underreported a 143.1% increased 
incidence was estimated between 2005 and 2015 (16). According to the World Health 
Organisation (WHO) approximately 500,000 DENV infected patients require 
hospitalisation annually with widely varied disease presentation and an unpredictable 
course of disease (17, 18).  
DENV belongs to the family Flaviviridae and the genus Flavivirus (3, 13, 19–
21). Flavivirus genomes are non-segmented, single-stranded, positive-sense RNA 
and range from 9.5-12.5 kb. The DENV genome is ~11kb in length and is non-
polyadenylated with a methyl-G-cap protecting its 5' end and a hairpin structure at the 
3'end, which stabilises the genome and is likely involved in genome replication (3, 19, 
20). The viral genome has three distinct roles during the lifecycle of the virus: (i) 
mRNA for translation (ii) template during RNA replication (iii) genetic material 
packaged within the new viral particles.  
The DENV virion is enveloped with a diameter of ~30nm and has a capsid (3, 
19). The glycoproteins lie flat on the surface of the mature virion and the structure is 
pH sensitive, at low pH the glycoproteins form spikes, which mediate the fusion 
process. The virions attach to host receptors on the surface of target cells through the 
viral envelope protein and are endocytosed. The low pH triggers the envelope protein 
rearrangement and leads to fusion of the viral envelope and cell membrane. 
Membrane fusion releases the viral RNA, which is efficiently translated utilising the 
host cell machinery. The positive-sense RNA genome is translated to produce viral 
proteins in the endoplasmic reticulum and a minus-strand RNA molecule is 
synthesized and used as a template for viral replication. Generated structural proteins 
and genomic positive-sense RNA molecules are packaged and assembled into 
virions. Progeny virion assembly occurs in the endoplasmic reticulum by budding and 
following maturation in the Golgi apparatus, virions are released by exocytosis via the 
host secretory pathway. 
The viral genome serves as the single mRNA and is translated from a single 
open reading frame (ORF) (Figure 1.2) (3, 19, 20). The genome organisation of 
Flaviviridae is conserved with the structural proteins (envelope, capsid) encoded at 
the 5' and the RdRp at the 3'end of the single ORF. Due to DENV lacking a poly(A) 
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tail at the 3'end, translation is cap-directed and viral proteins are synthesized as part 
of a large single polyprotein precursor. The polyprotein precursor is co- and post- 
translationally cleaved into ten proteins, three structural proteins (capsid, membrane 
and envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B, NSB5). A single capsid (C) protein is encoded and the two DENV envelope 
glycoproteins (prM and E). The non-structural proteins include a glycoprotein 
important for replication and flavivirus-specific humoral responses (NS1), a 
membrane-spanning protein involved in replication (NS2), a large multifunctional 
protein encoding enzymatic activities (the N-terminal domain is a serine protease and 
the C-terminal domain is an RNA nucleotide triphosphatase helicase (NS3)), proteins 
important for genome replication (NS4A, NS4B) and the RdRp (NS5B). Many DENV 
non-structural proteins interfere with the host immune response and have 
multifunctional roles in the virus's immune evasion. Replication takes place in the cell 
cytoplasm and involves the synthesis of a genome-length negative sense RNA using 
the viral genome as a template. The resulting dsRNA serves as a template for the 
synthesis of the viral genome copies.  
 
 
Figure 1.2 DENV genome structure and protein products.  
The viral genome contains a 5' methyl cap and lacks a 3' poly-A tail. The genome contains a 
single long ORF and no subgenomic mRNAs are expressed. A single polyprotein is produced, 
which is co- and post-translationally cleaved into 11 mature proteins.  
 
DENV can be distinguished in four serotypes, historically differentiated based 
on neutralisation assay data, DENV-1, DENV-2, DENV3 and DENV-4 (3, 19). The 
serotypes are related but genetically and antigenically distinct, with 30-40% variation 
in the viral envelope proteins. Within a given serotype the amino acid homology has 
a conservation level of ~90% and despite their differences all four serotypes cause 
similar disease and share epidemiological features. 
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1.1.3 Chikungunya virus  
 
 Chikungunya virus (CHIKV) causes the debilitating arthritic disease, 
chikungunya fever (22). The virus was originally restricted to limited regions of Africa 
and Asia but has recently spread globally and is designated a serious emerging 
disease by the WHO (23). The majority of people infected are symptomatic and 
contrary to other arboviral diseases CHIKV presents with less than 15% 
asymptomatic seroconversion (24). Symptoms include high grade fever with sudden 
onset, rash, headache, myalgia and often long persisting arthralgias (25). Over the 
last 15 years, outbreaks of CHIKV have been associated with increased morbidity 
and possibly mortality (26, 27).  
CHIKV belongs to the family Togaviridae and the genus Alphavirus (3, 13, 26, 
28, 29). Alphavirus genomes are non-segmented, single-stranded, positive-sense 
RNA and range from 11-12 kb. The CHIKV genome is ~12 kb in length and is 3’-
polyadenylated with a methyl-G-cap at the 5' end (3, 28). Non-structural proteins are 
translated from the genomic RNA and the structural proteins from the subgenomic 
RNA. Three types of RNAs are produced by virus-infected cells: (i) genome plus-
strand RNA, (ii) complementary minus-strand RNA and (iii) subgenomic mRNA (28).  
 The CHIKV virion is 70nm in diameter and has an envelope containing 80 
spikes, each composed of an E1 and E2 transmembrane glycoprotein trimer (3, 28). 
The protein spikes are contained within a lipid bilayer, which surrounds the capsid 
and the capsid has a T=4 icosahedron structure, with each subunit assembled from 
240 copies of a single capsid protein. Virions attach to host receptors and are 
endocytosed. Low pH triggers the fusion between the viral envelope and the 
endosomal membrane, releasing the viral RNA into the cytoplasm. Replication 
proteins are translated and processed enabling the replication of the viral genomic 
RNA and the translations of the subgenomic viral mRNA. The structural proteins are 
produced and cytoplasmic assembly of the genomic RNA and the capsid leads to the 
formation of the nucleocapsid. The nucleocapsids associate with the processed 
glycoproteins at the plasma membrane, resulting in budding of the mature progeny 
virions. 
The positive-sense RNA genome serves as an mRNA for the synthesis of the 
non-structural proteins (nsP1, nsP2, nsP3 and nsP4) and a subgenomic mRNA 
serves as template for the synthesis of the structural proteins (C, E1, E2, E3 and 6k) 
(Figure 1.3) (26, 29). Two polyproteins are produced directly from the viral genome: 
the smaller one (P123), which terminates at an opal codon and the second larger 
polyprotein (P1234), which includes the gene encoding for the RdRp, which is 
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produced at a lower frequency (~10-20%) when readthrough of the opal codon 
occurs. The polyproteins are subsequently processed to generate precursor and end-
product non-structural proteins. A short untranslated region located upstream of the 
structural polyprotein ORF encompasses a subgenomic promoter, which drives the 
synthesis of a subgenomic mRNA (26S RNA) (3, 28). A single polyprotein is produced 
from the subgenomic mRNA, which is co- and post- translationally cleaved. The non-
structural proteins include a protein encoding methyltransferase and 
guanylyltransferase activity (nsP1), a protein encoding multifunctional enzymatic 
activity: nucleotide triphosphatase helicase, RNA triphosphatase and protease 
(nsP2), a phosphoprotein important for the minus-strand RNA synthesis (nsP3) and 
the RdRp (nsP4). The structural proteins include a single capsid (C) protein, two 
envelope glycoproteins (E1 and E2), and two additional products whose functions are 
not fully understood, the E3 protein and a small peptide (6k). Genome replication 
occurs in the cell cytoplasm and is initiated with the synthesis of minus-strand RNA. 
Both minus-strand RNAs (detected at early stages of infection) and plus-strand RNAs 
are transcribed under the control of non-structural proteins. 
 
 
Figure 1.3 CHIKV genome structure and protein products.  
The viral genome contains a 5' methyl cap and a 3' poly-A tail. The genome encodes the non-
structural proteins at the 5' end, which are synthesized as two polyproteins, a small one and 
a larger one, which includes the RdRp, both are cleaved by viral proteases. Structural proteins 
are encoded at the 3' end and synthesized as a polyprotein precursor from a subgenomic 
mRNA.  
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CHIKV and DENV are arboviruses of particular interest as they are 
predominantly transmitted to humans via Aedes species mosquitoes, more 
specifically Aedes aegypti and Aedes albopictus (30, 31), and share clinical 
presentations of arthralgia, myalgia, high fever, headache and rash. Circulation of 
CHIKV, DENV (and other arboviruses) in overlapping locations leads to challenges in 
differential diagnosis, especially in endemic regions in which diagnosis is 
predominantly symptom-based (32). Additionally, reports of arboviral coinfections are 
increasingly common (33–36).  
1.1.4 Lassa virus  
 
Lassa virus (LASV) causes Lassa fever, an acute viral haemorrhagic illness 
estimated to affect between 300,000 and 500,000 people annually (37, 38) with a 
typical case fatality rate (CFR) of 18%, although significant increases of up to 31% 
have been reported during endemic seasons or among hospitalised patients (39). 
Lassa fever was first described in 1969 in the town of Lassa, Nigeria (40) and is 
endemic in parts of West Africa, particularly the countries of Nigeria, Benin, Côte 
d'Ivoire, Mali, Sierra Leone, Guinea and Liberia (39–44). Human to human 
transmission events have also been reported, through direct contact with bodily fluids 
of an infected patient, primarily as nosocomial infections (45–47). Laboratory 
diagnosis poses a significant challenge for LASV due to its high genomic diversity 
with strain nucleotide variation of up to 32% and 25% for the L and S segments 
respectively (48). 
LASV belongs to the family Arenaviridae and the genus Mammarenavirus (3, 
13, 49–53). Mammarenavirus genomes are segmented, single-stranded, negative-
sense RNA with two segments, a large (L) segment (~7.5 kb) and a small (S) segment 
(~3.5kb). Both segments are ambisense meaning that each segment contains two 
open reading frames. The two open reading frames contained within each segment 
are oppositely oriented and separated by an intergenic region. Viral mRNAs are 
capped at the 5' end, not polyadenylated and contain a hairpin structure at their 3' 
end. The capped 5' ends are followed by 4-5 nucleotides, which are not found in the 
viral genome, acquired through the cap-snatching mechanism involved in the priming 
of the viral mRNA synthesis (54–58). Sequences on the 3' end of both segments are 
highly conserved and base complementarity (19-33 nt) is present between the 5' and 
3' ends of each segment, able to form panhandle structures, which modulate 
replication and transcription (55, 59).  
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The LASV virion is round, pleomorphic and enveloped with a diameter 
reported to have a range between 40 and 300 nm (49, 55). The two glycoproteins 
(GP1 and GP2) and the stable signal peptide (SSP) form a trimer complex, which 
extends from the virion surface and forms spikes. Within the virion, the genome 
segments are encapsidated by nucleoprotein (NP) and associated with the L protein 
(RdRp) forming ribonucleoprotein particles (ribonucleocapsids) organised in circular 
structures. The virion attachment to the host cell is mediated by the GP1 glycoprotein 
extracellular spike and binding of the virion to the host cell surface activates 
endocytosis. Structural changes are triggered by the acidic pH leading to fusion 
between the viral envelope and the endosomal membrane. Subsequently, 
transcription and replication of the viral genome take place in the cytoplasm. 
Ribonucleocapsids associated with Z and glycoprotein complex at the plasma 
membrane where the progeny virions are released by budding, driven by the Z 
protein. 
The L genome segment encodes for the RdRp and the Z protein. The S 
genome segment encodes the nucleoprotein (NP) and the glycoprotein complex 
(GPC) (Figure 1.4) (3, 49). The intergenic regions present in both segments serve as 
a termination signal during transcription, likely through the formation of secondary 
structures (hairpin formation) which prompt the release of the polymerase from the 
substrate (60). Following the virion entry into the host cell, the RdRp initiates 
transcription to produce the NP and L mRNAs. Transcription is initiated at the 5′ 
untranslated region and terminates at the non-coding intergenic region found on both 
segments. The RdRp continues past the intergenic region as the concentration in NP 
increases, creating full length complementary segments (antigenome, (+) ssRNA). 
The complementary segments are templates for the transcription of GPC mRNA and 
Z mRNA and serve as a template for the replication of the viral genome. A 
glycoprotein precursor polyprotein is encoded on the S segment, which is post-
translationally modified by a signal peptidase and an ER protease. The signal 
peptidase cleaves the N-terminal signal sequence of the polypeptide to produce a 
stable signal peptide, which is required for the GP maturation. The remaining GP 
polypeptide is glycosylated and cleaved by an ER protease into the two glycoprotein 
subunits, GP1 and GP2.  
  




Figure 1.4 LASV genome structure and protein products.  
Both segments are ambisense. Each segment contains two open reading frames. The two 
open reading frames contained within each segment are oppositely oriented and separated 
by an intergenic region.  
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1.2 Emerging and re-emerging viruses 
 
Emerging pathogens are defined as the causative agents of an infectious 
disease that has newly appeared in a population (e.g. Dengue fever: global spread of 
all four DENV serotypes (61)) or has existed and is subsequently rapidly increasing 
in incidence, prevalence and geographic distribution (62, 63) (e.g. Ebola 
haemorrhagic fever: 2014-2016 West Africa Ebola virus (EBOV) outbreak (64)). Re-
emerging pathogens are characterised by resurgence, after a substantial decline, of 
a disease that previously caused major public health problems globally or in a 
particular country (65) (e.g. Yellow fever (YFV): West Africa resurgence since 2000 
(66)). According to the WHO, both emerging and re-emerging diseases as defined 
above, can be described as emerging, as it defines an emerging infectious disease 
as "one that has appeared in a population for the first time, or that may have existed 
previously but is rapidly increasing in incidence or geographic range" (67). 
The recent global emergence of zoonotic viruses has caused significant 
human disease. A combination of factors including globalisation, environmental 
changes, human intervention and their effect on disease spread and vector 
distribution have led to new opportunities for viral pathogens, leading to both the 
emergence of previously unknown viruses and the re-emergence of viruses 
previously not thought to be of public health significance (68–70). The majority of 
these infectious viral diseases are caused by RNA viruses (5, 71) which emerge either 
because they acquire the ability to infect new host populations that were previously 
non-susceptible (63, 72) or because of changes in their geographical spread 
introducing them to new, previously unaffected, populations (73). The vast majority of 
viral pathogens are zoonotic, originating in the animal world and following incidents 
of spillover to human hosts, they adapt and subsequently spread to cause an 
epidemic or in certain situations a pandemic (70). Viral pathogens that have 
developed the ability to cross species barriers can cause devastating infections 
leading to a high morbidity, mortality and disease burden (74). Many of these zoonotic 
viruses can cause little to no disease in their natural hosts, and interspecies 
transmission to humans may be asymptomatic, but can also lead to disease with 
symptoms ranging from mild to severe manifestations (75).  
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1.2.1 Zoonotic viruses  
 
 Over 70% of emerging infectious diseases affecting the human population are 
known to be zoonotic, infectious diseases transmitted from an animal host to humans 
(76). Human infection occurs through two routes (a) pathogens spread through direct 
or indirect contact with infected animals and (b) pathogens transmitted through 
vectors (77). 
Direct contact transmission requires physical contact between an infected 
animal and a susceptible human. Most commonly the transfer of the viral pathogen 
occurs through saliva (e.g. bites or scratches). Lyssavirus is the most prominent 
among the direct transmission zoonotic viruses, spanning across all continents except 
Antarctica (78, 79). It has been identified through historical documentation to date 
back at least 4000 years and is mainly transmitted through bites from rabid animals 
causing a lethal encephalitis; Rabies disease (79). Zoonotic indirect contact 
transmission occurs through consumption of contaminated food (e.g. human 
consumption of infected bush meat) and water or by close contact with faeces, 
organs, blood or other bodily fluids of infected animals. LASV is an example of indirect 
contact transmission as it is spread through human exposure to urine or faeces from 
the infected host rodents Mastomys natalensis, in which the virus causes persistent 
asymptomatic infection (80, 81).  
Finally, transmission can occur via intermediate species (vectors) which carry 
and transfer the virus, facilitating its spread. Climate and habitat changes have had a 
tremendous impact on vector-borne zoonotic viruses, introducing new geographical 
ranges to the vectors and expanding the population of susceptible animals and 
humans exposed to the virus (82). An example of a vector-borne zoonotic virus is 
West Nile virus (WNV), which originated in Africa and has spread to Asia, Europe and 
the Americas causing periodic large outbreaks (83). It is maintained in an enzootic 
cycle involving vertebrate hosts (reservoir) and mosquitoes (vector) (84). The vast 
majority of arthropod-borne viruses (arboviruses), such as WNV, are zoonotic and of 
major importance due to their increased frequency in recent years leading to a 
significant global health burden (85). The term “arboviruses” encompasses all viruses, 
which require hematophagous (blood-sucking) arthropods such as mosquitoes and 
other biting flies or ticks to maintain their transmission cycle (86). Transmission can 
occur through a sylvatic or enzootic cycle in which the pathogen circulates among 
wild animals and can cause disease in incidental or dead-end hosts such as humans, 
following events of spillover events (87). Epidemics caused by arboviruses have 
increased in prevalence over recent decades, with the spread of mosquito-borne 
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arboviruses such as YFV, DENV, WNV, CHIKV and Zika virus (ZIKV) across both 
hemispheres (88). The significance of arboviruses is highlighted by DENV, CHIKV 
and YVF, which are arboviruses of immense global health burden as they have lost 
the need for enzootic amplification, expanding their host range to include humans as 
an amplifying host and consequently be responsible for extensive epidemics (87, 89).  
1.2.2 Disease manifestation 
 
 Emerging viruses present an important challenge to public health as effective 
interventions are required to control outbreaks and eliminate global health and 
economic risks linked with such an extensive disease burden (90). Most emerging 
viral infections share common clinical features with mild/moderate disease 
presentation of fever and flu like symptoms, sometimes associated with rash (CHIKV, 
ZIKV), arthralgia (CHIKV, Mayaro virus) or jaundice (YFV, Rift Valley fever virus) and 
more severe disease manifestations with encephalitis or menencephalitis (Nipah 
virus, YFV, CHIKV, ZIKV) and haemorrhagic fever (LASV, Rift Valley fever virus, 
CCHF) (91).  
Viral encephalitis is a type of neuroinvasive disease caused by a viral infection 
and refers to an acute, commonly diffuse inflammatory process affecting the brain 
parenchyma (92, 93). Neurotropic viruses invade the central nervous system (CNS), 
causing neuroinvasive disease and come from a variety of different families, including 
Flaviviridae (e.g. WNV), Paramyxoviridae (e.g. Nipah virus), Togaviridae (e.g. 
Western equine encephalitis virus), Arenaviridae (e.g. Junin mammarenavirus) and 
Bunyaviridae (La crosse virus). Clinical presentation of encephalitis in patients may 
include change in consciousness level, fever, seizures, movement disorder or focal 
neurological defects, and the burden of the disease is big, as many patients with 
encephalitis face life-long residual physical or neurophysiological defects which 
require long-term management (94). An example is tick-borne encephalitis virus, 
which, as its name suggests, causes a human disease involving the CNS and 
occurring in parts of Asia and Europe. The virus is transmitted by infected ticks and 
the far eastern subtype is associated with the most severe disease presentation with 
mortality rates of up to 35% (95). 
Viral haemorrhagic fever (VHF) is a term used to refer to severe illness 
sometimes associated with bleeding (96). VHFs are caused by RNA viruses 
belonging to the families of Arenaviridae (e.g. LASV), Bunyaviridae (e.g. Rift Valley 
Fever), Filoviridae (e.g. EBOV) and Flaviviridae (e.g. DENV) (97). All haemorrhagic 
fever viruses are negative or positive-stranded RNA viruses of between one and three 
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genome segments. The initial presentation of VHFs in patients includes an acute 
febrile illness which is characterised by fever, musculoskeletal pain, nausea, vomiting 
and vascular permeability accompanied by conjunctival injection, flushing and 
petechial haemorrhages (98). In more severe cases of the disease bleeding 
manifestations may present accompanied with hypotension, circulatory collapse and 
shock. The case fatality rate for VHFs has been estimated to reach 80% of severe 
cases, with the severity of disease depending on the virus, its inoculum and route of 
exposure (98). An example of a VHF is Lassa fever (99).  
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1.3 Virus discovery, diagnosis and genomics 
  
The revolutionary developments of sequencing in the 1970s and of PCR in 
the 1980s, along with the advances in sequencing technologies over the past 20 
years (details in Section 2. History of sequencing) played a critical role in the field of 
virology and its progress. The technological developments witnessed in the first two 
decades of the 21st century have transformed viral research from lengthy protocols 
and retrospective investigations to near real-time pathogen investigation and 
genomics informed epidemiology. Whole genome sequencing has been instrumental 
in the effective management of viral pathogens, allowing for pathogen discovery, 
accurate diagnostic method development, and pathogen surveillance and molecular 
epidemiology. Sequencing has become a critical tool in clinical microbiology, where 
it is currently extensively used to facilitate the detection and monitoring of pathogen 
outbreak and epidemics using genomic precision which was not previously possibly 
using epidemiological data alone (100–103). Sequencing advances have had an 
immense effect on viral outbreaks both in human and animal populations allowing for 
efficient identification of the causative agent and for public health surveillance and 
epidemiological studies, which have in the past been hindered by lack of data.  
1.3.1 Virus discovery  
 
 The first viruses, described as filterable agents, were discovered as early as 
the 1890s. In 1886 Adolf Mayer was the first to describe tobacco mosaic disease and 
demonstrate its infectious nature. Mayer successfully infected healthy plants by 
inoculating them with fluid extracted from diseased plants. He attempted to identify 
the infectious agent but could not find any microorganisms accountable, leading to 
his observation that the soluble agent was enzyme-like. He concluded that the cause 
of the disease must be bacterial but the infectious forms had not yet been isolated 
(104). In 1892 Ivanofsky reported that tobacco mosaic infected leaf extracts were still 
infectious following filtration with filters known to retain bacteria, the first 
demonstration of a filterable pathogen. In 1898 Beijerinck observed that the filterable 
pathogen could diffuse through bacteria retaining agar and that it could only be 
cultured in living, growing plants. Beijerinck described the filterable pathogen as 
"contagium vivum fluidum" (Latin: "contagious living fluid") and was the first to use the 
term virus (105). The three aforementioned scientists contributed to the discovery and 
formation of a new concept: the virus, an infectious agent smaller than bacteria, not 
visible by light microscopy and which only multiplied in the presence of living cells (3). 
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Shortly after, Loeffler and Frosch identified a filterable agent as the cause of foot-and-
mouth disease, leading to the description of the first animal virus, foot-and-mouth 
disease virus (106).  
The first human virus discovered was YFV. Reports of the yellow fever 
disease date back to 1498 but it was not until the 18th century that its public health 
importance was realised and only at the start of the 20th century that the disease 
began to be understood (107). The disease is spread through a mosquito vector, 
Aedes aegypti, a hypothesis originally formed by Carlos Finely in 1881 and later 
confirmed by Walter Reed and his colleagues in 1901 (108). James Carroll, who was 
part of Reed’s team, showed that serum from a yellow fever patient was still infectious 
after filtering and therefore was caused by a filterable agent; a virus (109).  
Viral discovery has been primarily driven by the identification of diseases and 
the need to understand their causes. Multiple scientific developments over the years 
have provided essential tools for the investigation of viral pathogens, including: 
porcelain filters, light and electron microscopy, animal models, tissue and cell culture, 
immunoassays, PCR and microarrays (110). In recent years technological advances 
and progress in the field of molecular biology have played a vital role in the ability to 
identify and characterise viral pathogens, particularly sequencing technologies. 
Sequencing methods have enabled the detection and identification of viruses 
in clinical samples, and when used in combination with non-targeted methods, such 
as metagenomic sequencing make it possible to identify infectious diseases without 
prior knowledge of the causative agent (111). In recent years metagenomics has been 
used to identify the causative agents of several outbreaks, including Lujo virus in 
South Africa (21), a novel EBOV, Bundibugyo ebolavirus, in Uganda (22) and novel 
viruses such as the Rhabdovirus associated with haemorrhagic fever in central Africa 
(23). Applications of sequencing in virology not only provide information about the 
identity and the genome of the virus but can also allow for the study of virus/host 
interactions and host genetic responses in correlation to the infectious agent providing 
information on the mechanisms of infection and host genetics (112).  
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1.3.2 Virus diagnosis and detection 
 
The most common techniques currently used in diagnostic laboratories for 
identification of the causative agent of disease include both direct (PCR, antigen 
detection) and indirect (IgM and IgG serology) methods, but all require prior 
knowledge of the viral pathogen of interest for their design (113, 114).  
RNA viral pathogens are most commonly detected in diagnostic laboratories 
and acute-care settings by Reverse Transcriptase PCR (RT-PCR) based methods, 
primarily a major feature due to their timely and accurate nature (115). A significant 
advancement in PCR diagnostics was the development of real-time RT-PCR which 
enables reliable measurement and detection during amplification process, in addition 
to the components for the classical/end-point PCR, a fluorescent probe, that emits 
signal upon binding to target sequence DNA, is used and its signal strength is directly 
proportional to the number of amplified molecules (116, 117). The combination of the 
amplification and detection steps in one reaction eliminates the need for post-PCR 
processing, subsequently reducing the time to result (117). PCR methods have high 
specificity, reliability, reproducibility and can include multiple targets in one assay. 
Their wide dynamic range allows for analysis of samples with highly variable target 
abundance and methods are well established in clinical diagnostics with extensive 
validation, established analysis and reporting guidelines (117). The limitations of PCR 
based methods include their high sensitivity, which can lead to false-positive results 
from background contamination, particularly when handling high sample volumes, or 
false-negative results due to PCR inhibitory components present in samples. 
Additional limitations arise from PCR specificity, which leads to inadequate sensitivity 
when used for highly variable pathogens such as certain RNA viruses (eg. LASV) and 
it can only be used to identify the presence or absence of the target sequence against 
which the assay was designed, leading for example to difficulties in designing assays 
that can easily distinguish between serotypes (eg. DENV 1-4) (115). Reverse 
transcription of RNA and amplification of short fragments of DNA in vitro relies on a 
priori knowledge of the viral target sequence (115). 
Serological methods are routinely used in diagnostic laboratories and can 
identify if a patient has been exposed to a pathogen by detecting an antibody 
response. Serological assays can prove useful when detection of the viral antigen or 
nucleic acid is unsuccessful due to testing toward the end of or after viremia (114). 
The time frame relative to pathogen exposure is a limiting factor for serology testing 
early-on during infection if an antibody response has not been mounted (114, 118). 
Serology requires comparison of acute and convalescent antibody titers and has 
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issues of cross-reactivity of antibodies triggered by viruses within the same family or 
vaccination. This is the case with anti-flavivirus antibodies which are known to cross 
react with multiple flaviviruses leading to non-specific diagnosis and inability to 
distinguish between viral serotypes (118, 119). 
1.3.3 Genomic surveillance and epidemiology  
 
Viral disease surveillance involves the continuous monitoring and systematic 
collection, analysis and dissemination of information relating to the occurrence of a 
disease within a population (120, 121). The ultimate goal of viral disease surveillance 
is to facilitate the prevention of disease and effectively control outbreaks (120, 121). 
Genomic surveillance involves sequencing and analysis of viral genomes collected 
from patient and animal samples for the purpose of understanding viral spread and 
the changes occurring during the course of the disease spread within a population.  
Viral disease epidemiology is the study of disease events within a population 
(human or animal) and the detailed description of their incidence and rate at which 
they occur (120). The impact of viral transmission and spread is investigated through 
the study of different factors such as prevalence, mode or method of transmission, 
duration of infection, population density, patterns or associations, susceptibility and 
transmissibility. Viral genomic epidemiology is the study of viral epidemiological and 
emergence dynamics using sequencing data and genomics associated analysis 
(103). 
Evolutionary relationships between and among species were studied as early 
as the 18th century, although efforts at the time to categorise species were based 
solely on morphological characteristics (122, 123). Over the course of time, 
phylogenetic analysis has become a powerful tool in virus epidemiology research. By 
obtaining molecular/genomic data and applying statistical methods, it is now possible 
to understand viral emergence and transmission, as well as determine the key factors 
for successful epidemic spread. Phylogenetic trees are the visualisation of 
phylogenetic analysis and represent the patterns of shared mutations between 
genomic sequences as a function of their topological distance (124).  
The International Health Regulations (2005) as stated by the WHO "require 
the rapid detection of public health risks, as well as the prompt risk assessment, 
notification, and response to these risks'' (125). Genomic investigations have had a 
profound impact in our understanding of viral diseases and the dynamics of infection 
(126). The 21st century has witnessed a huge leap in sequencing technologies and 
has introduced molecular precision to the detection and monitoring of viral outbreaks. 
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Rapid, inexpensive sequencing has paved the way for viral genomics and created 
large and continuously growing databases (e.g. GenBank) of nucleotide sequences. 
The plethora of available viral genomes has permitted studies on pathogen diversity, 
evolution and transmission creating opportunities for genomic surveillance and 
epidemiology using molecular precision (103). Dudas and Bedford in 2019 (124) 
compared the ability of single genes versus full genomes to resolve phylogenetic, 
temporal and spatial inference. Their study importantly highlighted the ability of whole 
genome sequences to significantly enhance resolution and impact our understanding 
of emerging viral pathogens, which is increasingly evident with molecular surveillance 
and epidemiology shifting from retrospective studies to near real-time investigations 
(100–103). Particularly so for RNA viruses, whose polymerases have low replication 
fidelity leading to a rapid rate of mutations and subsequently a rapid differentiation of 
viral lineages at the whole genome molecular level (124, 127, 128). The high mutation 
and replication rates lead to genetic variations, which can be monitored during their 
spread (103). 
One of the first viral challenges of the 21st century was the 2002-2003 Severe 
acute respiratory syndrome (SARS) epidemic, which affected 23 countries (129). 
Within a time frame of six months the virus was isolated and sequenced allowing for 
the design of molecular assays, which confirmed that the new CoV was responsible 
for the SARS epidemic (130–132). 
In early April 2009 a new H1N1 influenza virus emerged and spread rapidly 
across the world. The first complete genome sequences were released to a publicly 
available influenza database by the Centre for Disease Control and Prevention (CDC) 
a few weeks later (133). Within a few months early assessments of transmissibility 
and severity were made using molecular epidemiology. Fraser et al. (134) identified 
the transmissibility to be substantially higher than that of the seasonal flu and 
estimated the basic reproductive number (R(0)) to be comparable to previous 
influenza pandemics. They also estimated the start of the outbreak to be a few months 
prior to the first documented case. Subsequent analysis by Rambaut and Holmes 
(135) used a larger data set to update the estimates of rate of evolutionary change 
and date of origin of the virus. They confirmed the date of origin of the outbreak to be 
a few months prior to the first documented case and obtained similar population 
growth rates and epidemic doubling times. In 2006 Mena et al. (136) conducted a 
retrospective study and identified H1N1 precursor viruses in central Mexican swine. 
The authors presented strong evidence that the first human outbreak of H1N1 
occurred in early 2009 in Mexico and highlighted the importance of surveillance as 
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the outbreak rose from a region, which was not previously considered a pandemic 
risk.  
Another viral outbreak that raised similar questions over its origin and 
transmission is Middle East Respiratory Syndrome coronavirus (MERS-CoV) which 
has been repeatedly reported since 2012. Preliminary data published by the WHO 
MERS-CoV Research Group (137) suggested the involvement of dromedary camels 
and concluded that sustained human-to-human transmission was not observed. 
Haagmans et al. (138) investigated the presence of the virus in dromedary camels 
linked to two human cases reported in 2013. Using PCR testing and sequencing they 
confirmed the presence of MERS-CoV in camels but could not conclusively prove that 
the camels were the source of infections in humans. Subsequent sequencing studies 
demonstrated multiple independent introductions into the human population from 
close contact with infected camels (139, 140). A retrospective study in 2018 by Dudas 
et al. provided a comprehensive genomic investigation of MERS-CoV phylodynamics 
in humans and camels. The authors confirmed that the viral population is maintained 
exclusively in camels and that humans are incidental hosts. Additionally, they 
estimated mean R (0) values of <0.90 suggesting that the virus was not likely to 
become endemic in humans, however they highlighted the need for continuous 
surveillance to monitor for the possible emergence of variants with increased 
transmissibility.  
The 2013-2016 EBOV epidemic in West Africa was of unprecedented scale 
with ~28,500 reported cases and ~11,000 reported deaths (141). The epidemic 
transformed the concept of viral epidemiology and marked the beginning of large-
scale phylodynamics analysis to inform ongoing outbreaks (141, 142). Genomic 
investigations enabled viral genomic surveillance during the unfolding outbreak and 
assisted in our understanding of the origin, transmission and evolution of the virus. 
The most recent common ancestor of all sequenced EBOV genomes was estimated 
to be at the beginning of 2014 which was consistent with classical epidemiological 
investigations that placed the first case in Guinea around late December 2013 (143–
146). Multiple introductions from the animal reservoir were excluded and it was 
demonstrated that the viral spread was maintained by human-to-human transmission 
(142–151). As the outbreak unravelled there was an apparent shift towards rapid in-
country sequencing which assisted in understanding viral transmission chains and 
community spread (142, 147, 152, 153). Most notably the set-up of portable MinION 
sequencing in Guinea by Quick et al. (147) to enhance local sequencing capacity and 
EBOV genomic surveillance.  
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In 2016, local transmission of ZIKV was identified in 33 countries and ZIKV 
infection during pregnancy was suspected to cause microcephaly and congenital 
abnormalities (154). Subsequently the 2016 ZIKV outbreak was declared by the WHO 
as a Public Health Emergency of International Concern. Efforts to gain insights into 
the origin, transmission and diversity of the virus were initiated and included 
sequencing of retrospective and ongoing cases (155, 156). Preliminary analysis by 
Faria et al. (157) of a small number of ZIKV sequences indicated a single introduction 
of ZIKV into the Americas. Using molecular clock analysis, they estimated the 
introduction to have occurred between May and December 2013, more than a year 
prior to the detection of ZIKV in Brazil. The spread of ZIKV was extensively 
documented in subsequent studies using genomic epidemiology (156, 158, 159). 
Grubaugh et al. (159) used genomic epidemiology to investigate ZIKV transmission 
in Florida and identified that multiple introductions of the virus contributed to the 
Florida outbreak and estimated that local transmission most likely started several 
months prior to initial detection, in spring 2016.  
The shift from retrospective studies to rapid near real-time investigations is 
apparent over the past 20 years. Continuous advances in genomic sequencing and 
phylogenetic analysis have expanded the key questions addressed by molecular 
epidemiology and increased the use of genomic epidemiology to inform public health 
response (103, 141, 160). 
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1.4. History of Sequencing 
 
The x-ray crystallography image of structure B of DNA (Photo 51, Rosalin 
Franklin and Raymond Gosling) (161), the description of the three dimensional 
structure of DNA (161, 162), the discovery of DNA polymerase (163) and RNA 
polymerase (164), and the cracking of the  genetic code are key scientific landmarks 
in DNA molecular biology that were precursors to the field of nucleic acid sequencing. 
Initial techniques were only able to measure nucleotide composition, rather than 
directly determine their order. Then in 1965 Holley et al. used pancreatic ribonuclease 
and takadiastase ribonuclease T1 to selectively cleave an alanine transfer RNA 
isolated from yeast (165, 166). The fully and partially degraded RNA fragments 
generated were identified via chromatography and electrophoresis and the order of 
the original nucleotide sequence was reconstructed to produce the first ever nucleic 
acid sequence (165, 167).  
Within the same year Fred Sanger and colleagues described the two-
dimensional (2D) fractionation of ribonuclease digested radiolabelled RNA. They 
used the unique pattern created, dictated by size and sequence composition, to 
determine ribosomal and transfer RNA sequences (168). The separation and 
visualization of the RNA fragments in 2D, 'fingerprinting' approach, was used in 1972 
by Jou et al. to determine the first complete sequence of a protein-coding gene (the 
bacteriophage MS2 coat protein) (169) and later in 1976 by Fiers et al. to sequence 
the last remaining MS2 gene (encoding the replicase) (170) marking the completion 
of the first ever whole genome sequence.  
The first DNA fragment sequencing was by Wu and Kaiser (171). The 
cohesive ends of bacteriophage lambda were used as a primer-template for DNA 
polymerase to incorporate radiolabelled nucleotides. By measuring the number and 
order of nucleotides incorporated, they identified the nucleotide length and sequence. 
This principle was soon expanded to include the use of defined oligonucleotides 
sequences as primers for DNA polymerase to initiate activity at selected regions of 
any DNA molecule (172–175). Despite these advances, attempts to determine the 
sequence of DNA were limited to short sequences and restricted by the lengthy and 
cumbersome nature of the methods used.  
The 'plus and minus' method described by Sanger and Coulson in 1975 was 
the first to promise accelerated DNA nucleotide sequence determination (176, 177). 
Oligonucleotide sequences were designed to match a target region of template DNA. 
These primers directed DNA polymerase synthesis of complimentary copies, of 
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assorted length, in the presence of the four nucleotides, one of which was 
radiolabelled. The DNA generated was purified and incubation with DNA polymerase 
was repeated under 'plus and minus' conditions. The 'minus' system consisted of four 
separate reactions in which synthesis occurred in the presence of only three 
nucleotides, leading to products terminating at the position of the missing nucleotide. 
The 'plus' system utilised the 3' exonuclease activity of T4 DNA polymerase in four 
separate reactions, with a single nucleotide present in each reaction. In each reaction, 
the enzyme degraded the DNA molecule until a position containing the reaction-
specific nucleotide is reached in the sequence; generating fragments, which have that 
nucleotide at their 3' end. The 'minus' and 'plus' mixtures were run in parallel on an 
acrylamide gel and the sequence was extrapolated from the bands present, with the 
two approaches confirming and complementing each other. The method was used to 
complete the first ever DNA whole genome sequence, that of bacteriophage ՓX174 
(PhiX), in 1977 (178).  
1.4.1 First sequencing methods 
 
Two key DNA sequencing method advancements were made in 1977: the 
Maxam and Gilbert chemical breakage method and the Sanger chain-termination 
method (179, 180). The Maxam and Gilbert (179) method involved radioisotope end-
labelling of DNA followed by nucleotide-specific chemical cleavage. The DNA 
molecule was preferentially damaged using conditions that targeted single 
nucleotides in each separate reaction (A>G, G>A, C, C+T) and the damaged base 
was subsequently removed from the sugar. Each reaction generated radiolabelled 
fragments extending from the radiolabelled end to the position of the base cleaved. 
The products of the four reactions were then separated by electrophoresis using an 
acrylamide gel and the sequence was deduced from the pattern of the radioactive 
bands.  
Later that year Sanger et al. (180) described the chain-termination method, 
which became the most widely used sequencing method for decades. The method is 
formally known as the chain-termination method or dideoxy sequencing but has 
become commonly known as 'Sanger sequencing'. Despite its similarity to its 
predecessor, the 'plus and minus' method, this approach was significantly faster and 
more accurate. The principle of Sanger sequencing was based on the observation of 
Atkinson et al. (181) that the absence of a 3' hydroxyl group in the dideoxy nucleotide 
analog results in the termination of extension at the location where it is incorporated 
during synthesis. In the original Sanger sequencing method, the DNA template was 
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incubated with primer, DNA polymerase, all four nucleotides (one of which was 
radiolabelled), and one dideoxy analog. The reaction resulted in a mixture of 
radiolabelled DNA molecules all of which started at the same 5' but resulted in various 
lengths, with the dideoxy nucleotide analog at the 3' end of each. A separate reaction 
for each nucleotide and its chain-terminating analog was set-up leading to a total of 
four reactions. The reaction products were run in adjacent lanes on an acrylamide gel 
and the sequence was read from the pattern of bands obtained. Sanger sequencing 
was a major breakthrough and became the most widely used DNA sequencing 
method for many years. A timeline including the key scientific advancements 
mentioned, from Photo 51 (1952) up until the official initiation of the Human Genome 
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1.4.2 Towards next generation sequencing 
 
The 1980s brought significant progress across the field of molecular biology 
and in the advancement of DNA sequencing. The launch of the Genbank public 
database (182) and the first use of microarrays in 1982 (183), the development of 
PCR in 1986 (184) along with the improved production of high-quality enzymes and 
primers were just some of the advancements made which proved instrumental for the 
sequencing field. The development of the first automated DNA sequencing machine 
and the switch to fluorescent chain-terminating nucleotide analogs in 1986 (185) 
transformed the accessibility of sequencing and enabled the creation of the Human 
Genome Project, which was initiated in 1990 and delivered the first human genome 
draft in 2001 (186, 187).  
The high demand for simple, rapid and automated sequencing methods led to 
the next major methodological advancement, which came in 1996 when Ronaghi et 
al. described pyrosequencing (188). Pyrosequencing is a sequencing by synthesis 
approach, which monitors the DNA polymerase activity through the detection of PPi 
released during each base addition of the synthesis. In the initial version of the 
method, a DNA molecule was immobilised on a solid surface and denatured to obtain 
single stranded DNA. A primer was added and in the presence of DNA polymerase 
repeated cycles of deoxynucleotide (dNTP) incubation and washing were performed. 
The second strand synthesis was accompanied by the release of PPi, which was 
converted to adenosine triphosphate (ATP) by ATP sulfurylase. The ATP acted as a 
substrate for firefly luciferase, which catalysed a light-emitting reaction, the 
conversion of luciferin to oxyluciferin, generating a light signal proportional to the 
number of nucleotides incorporated during the current round of addition. In contrast 
to Sanger sequencing, pyrosequencing overcame the need for electrophoresis by 
combining solid-phase technology with a sensitive luminometric assay and provided 
a method suitable for processing multiple samples in parallel. Improvements to the 
method over the following years included the use of paramagnetic beads for the DNA 
attachment and the use of a nucleotide-degrading enzyme (apyrase) to replace the 
intermediate washing steps (189).  
Biotechnology company 454 Life Sciences (later 454 Roche) bought the 
exclusive rights to pyrosequencing in 2003 (190, 191) and launched the first 
commercially available next generation sequencing (NGS) platform in 2005 (192). 
The 454 sequencer was a scalable, high capacity sequencing system that used an 
optimised pyrosequencing protocol. The device consisted of a fluidic assembly, a 
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chamber where the fibreoptic slide was located and a camera-based imaging system 
connected to a computer. DNA was randomly fragmented and sequencing specific 
adaptors added to the fragments. Using limiting dilution, single DNA molecules were 
obtained and each fragment was bound to individual beads. The fragment captured 
on each bead was clonally amplified within droplets of emulsion and the amplified 
template-bound beads were loaded into the individual wells of the fibreoptic slide.  
Sequencing occurred simultaneously in open wells of the fibreoptic slide and the light 
generated after every nucleotide addition was measured and signal-processed.  
In parallel, Solexa sequencing (later Illumina sequencing), was being 
developed. The method was conceptualised in 1997 by Shankar Balasubramanian 
and David Klenerman and in its early form included the immobilisation of discrete 
single stranded DNA molecules to a surface in order to monitor the incorporation of 
fluorescently labelled nucleotides by DNA polymerase (193, 194). An advancement 
that significantly increased throughput and accuracy was the inclusion of molecular 
cloning, an amplification step which created clonal copies of a DNA fragment within 
the same location of the sequencing chip, a technology acquired by Solexa in 2004. 
Molecular cloning was successfully achieved through solid phase bridge 
amplification, a method previously described by Adessi et al. in 2000 (195). Illumina 
sequencing in its current form entails clonal array formation and sequencing by 
synthesis using a cyclic reversible terminator method for the generation of short-read 
data (196, 197). Single stranded DNA molecules are immobilized sparsely on the 
sequencing flow cell prior to solid-phase amplification. Unlabelled nucleotides along 
with the enzyme are added to initiate bridge amplification, which generates up to 1000 
identical copies of each molecule creating a cluster of sequences originating from the 
same template. Sequencing begins with the addition of four fluorescently labelled 
reversible terminators, primers and DNA polymerase. A single terminator is 
incorporated per cluster and, following laser excitation, the fluorescence from each 
cluster is measured and the incorporated dNTP is identified. The sequencing cycles 
are repeated and the signal intensities measured are directly basecalled in each 
cycle. The first commercial sequencer released by Solexa was the Genome Analyzer 
in 2006 with the capacity to sequence 1 Gb in a single run. Illumina acquired Solexa 
soon after in 2007 and continued to introduce improvements leading to leaps in 
sequencing output, with their latest high-throughput sequencer (NovaSeq 6000) 
released in 2017 capable of producing up to 3000 Gb from a single flow cell. 
Pyrosequencing and clonal reversible terminator sequencing were both major 
methodological advances for the field of sequencing in the late 90s. In the coming 
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years, a variety of companies developed methods and platforms in parallel, with 
different sequencing chemistries, read lengths and throughput capabilities (198).  
Complete Genomics, founded in 2006 and acquired by BGI-Shenzhen in 
2013, is a sequencing service focused on whole human genome sequencing (199). 
The company uses sequencing technology that achieves DNA template enrichment 
in solution through rolling circle amplification leading to single stranded DNA 
palindrome-promoted coils known as DNA nanoballs (200). Single nanoballs are 
incorporated in each active site of the sequencing flow cell and sequencing is 
performed either using combinatorial probe-anchor ligation or combinatorial probe-
anchor synthesis (201).  
In 2007 Applied Biosystems commercialised the Sequencing by 
Oligonucleotide Ligation and Detection (SOLiD) system, which was discontinued in 
2016. SOLiD was a sequencing by ligation approach, which utilised emulsion PCR 
and bead enrichment to produce clonal bead populations of target DNA sequences. 
The clonal beads generated were deposited onto a glass slide and primer 
hybridization to the sequencing adapter initiated multiple cycles of ligation, detection 
and cleavage.  
A few years later in 2009, Helicos Biosciences released the first commercial 
sequencer using single molecule fluorescent technology (HeliScope). This single 
molecule technology was the first that did not require clonal DNA amplification, a 
feature shared by all its predecessors (166). DNA templates are attached to a surface 
prior to sequencing by synthesis, similarly to Illumina sequencing. Briefly, fluorescent 
reversible terminator nucleotides are added, washed and imaged prior to cleavage 
and repetition of the process with the next nucleotide. Despite the company going 
bankrupt in 2012 the technology was revived in 2015 with the launch of the GenoCare 
analyser for clinical applications from Direct Genomics (202).  
1.4.3 Sequencing developments of the last 20 years 
 
In 2010, the Ion Torrent PGM was released, which performed sequencing by 
synthesis using ion semiconductor sequencing technology. Sequencing adapted 
DNA fragments are attached to beads, known as Ion Sphere Particles, and clonally 
amplified by emulsion PCR. The beads are distributed over the sequencing chip 
within proton-sensing wells and sequencing is conducted with the introduction of each 
base sequentially. The protons released when a base is incorporated are detected 
and the signal generated is proportional to the number of bases incorporated.  
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Pacific BioSciences commercialised the first single molecule real-time 
technology (SMRT) in 2011, an approach originally described by Levene et al. in 
2003, further developed by Eid et al. and Pacific Biosciences in 2009 (203, 204). The 
method monitored DNA synthesis of single molecules in real-time with the use of 
small light detection volumes called zero-mode waveguides. A DNA template-
polymerase complex is immobilised at the bottom of the zero-mode waveguide and 
sequencing is initiated with the addition of phospholinked nucleotides into the 
chamber. Nucleotides are labelled with different fluorophores and each time a 
nucleotide is incorporated a light pulse is produced once the phosphate chain is 
cleaved and the attached fluorophore is released.   
A recent major innovation in the field of nucleic acid sequencing was the 
methodological advancement of nanopore sequencing introduced in 2012 (205). 
Nanopore sequencing was conceptualised in 1989 by David Deamer and first 
described in 1996 by Kasianowicz et al. (206). The authors showed that the 
measurement of transient current blockages caused by the translocation of a single-
stranded DNA or RNA molecule can be used to infer its length. Heptameric 
transmembrane channels of a-hemolysin with a diameter of 2.6 nm, sufficient to 
accommodate single stranded DNA or RNA, were embedded in a lipid bilayer 
membrane. In the absence of a nucleic acid molecule, the application of a potential 
across the membrane resulted in a continuous current, free of transients. However, 
in the presence of a polynucleotide, the potential applied presented transient current 
blockages, which were detected and identified to be proportional to the length of the 
polymer. The authors noted that with further improvements the method could identify 
the sequence of bases in a polynucleotide if the changes in ionic current reflected the 
molecular size and chemical properties of each nucleotide. In 1998, the 
"Characterisation of individual polymer molecules based on monomer-interface" 
patent (207) was filed. The patent described the rapid and reliable characterization of 
nucleic acid molecules, both in length and sequence, through the use of an ion-
conducting pore or channel and a detection mechanism to monitor the changes 
caused in the conductance of ions across the pore. The ionic current changes 
occurring when the polymer passes through the aperture of the channel embedded 
in an artificial membrane reflect the identities of the polymer monomers. For more 
than a decade the focus of the research groups involved and later of the company 
founded in 2005 (Oxford Nanopore Technologies), was the development of nanopore 
sequencing chemistry and technology for the delivery of commercial nanopore 
sequencers. In 2014, Oxford Nanopore Technologies launched the first nanopore 
sequencer to be made available to the scientific community, the MinION: a portable, 
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palm sized device that allows for real-time long-read DNA and RNA nanopore 
sequencing. Pore-forming proteins (nanopores) are embedded in an electrically 
resistant polymer membrane located within the MinION flow cell, which is equipped 
with 512 detection channels each connected to 4 nanopores. A current is applied 
through each nanopore by introducing a voltage along the membrane. Once a DNA 
molecule is close to the aperture of a nanopore it is captured and translocated 
through, creating a characteristic disruption in the current. For the successful capture 
and translocation of a DNA molecule, the presence of a motor protein is required, 
which allows for the separation of the two DNA strands and importantly limits the rate 
at which the DNA strand translocates through the pore. Each group of bases that 
goes through the nanopore creates a specific current drop/change, which is detected 
and measured by a sensor. The signal is then passed to the application-specific 
integrated circuit (ASIC) and finally to the MinKNOW software. The files generated 
encode the raw signal information, which is then basecalled by a variety of software 
that has changed over time. In 2017, Oxford Nanopore Technologies announced the 
release of the GridION X5, which is a desktop system composed of five MinION Flow 
cells and integrated computing power, scaling up throughput and analysis 
capabilities. A year later, the PromethION Early Access Programme was initiated and 
by April 2019, the platform was reported internally to generate more than 7Tb in a 
single sequencing run.  
The increasing demand for sequencing platforms that convey fast, 
inexpensive and accurate genome information has encouraged the development of 
sequencing technologies (197). An overview of the key sequencing developments 
mentioned from 1990 up until 2018 can be found in Figure 1.6. The constant 
development and improvement of sequencing platforms since 1977 has led to a 
decrease in cost of sequencing per base and the development of benchtop and 
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Sanger sequencing was one of the first sequencing methods described and 
grew to become the most widely used sequencing platform for years, with reads of a 
few hundred base-pairs initially and later following platform and technological 
advancements read lengths reaching ~1kb. The increase in data output that came in 
the decades that followed was majorly driven by short read technologies utilising 
clonal amplification such as Illumina and Ion Torrent. Ion torrent platforms reach read 
lengths up to 600 bp and produce data outputs of up to 50 Gb while Illumina platforms 
generate read lengths of 300bp (paired-end reads) and produce data outputs of up 
to 6 Tb. Single molecule fluorescent technology introduced by Helicos Biosciences 
was the first commercial sequencing technology that did not require clonal DNA 
amplification introducing however the platform produced significantly short read 
length (median read length ~35 nt). The true utility of single molecule sequencing was 
realised with the introduction of Pacific BioSciences, which allowed for long read 
length (~20 kb), high consensus accuracy, capability of epigenetic characterisation 
and a low degree of sequencing bias. The introduction of nanopore sequencing 
brought affordable, rapid and accessible single molecule sequencing and an apparent 
increase in sequencing read length and data output. To date the longest read reported 
using nanopore sequencing exceeds 2 Mb and the data output of the PromethION 
was reported to exceed 7 Tb from a single run, comparable in capacity with the 
equivalent short-read Illumina platform. An overview of the most commonly used 
platforms and their sequencing specifications can be found in Table 1.1. and an 
overview of their advantages and disadvantages can be found in Table 1.2.  
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Table 1.1 Overview of the most commonly used platforms and their sequencing specifications 
Technology Platform Read length 
(bp) 
Max output per 
run (reads) 





800 67 thousand - Min 30 min 
3500 Genetic 
Analyzer 
At least 850 138 - 403 thousand - Min 30 min 
Refreshed 3730 
Genetic Analyzer 
900 1.38 - 2.76 million - Min 20 min 
Illumina (210) 
 
iSeq 2 x 150 4 million  1.2 Gb 9.5 - 19 hrs 
MiniSeq 2 x 150  25 million 7.5 Gb 4 - 24 hrs 
MiSeq 2 x 300 26 million 15 Gb 4 - 55 hrs 
NextSeq 2 x 150 400 million 120 Gb 12 - 30 hrs 




Sequel Up to 20 kb 500 thousand Up to 20Gb Up to 20 hrs 
Sequel II Up to  20 kb ~ 8 x more data than Sequel Up to 30 hrs 
Ion Torrent 
(212) 
GeneStudio Up to 600 130 million 15 - 50 Gb 6.5 - 19 hrs 
Ion PGM 200 and 400 400 thousand - 5.5 
million 
60 Mb - 2 Gb 2 - 8 hrs 
Ion Proton 200 60 - 80 million 15 Gb 2.5 hrs 






so far > 2Mb 
Variable 
1 - 2 Gb 1 min - 16 hrs 
MinION 15 - 30 Gb 1 min - 48 hrs 
GrinION 75 - 150 Gb 1 min - 48 hrs 
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Table 1.2 Overview of the most commonly used platforms and advantages and disadvantages 
Technology Sequencing 
technology 







PCR ● Easy of sequencing 
● Widely accessible 
● Accuracy of sequencing 
● Low throughput 
● Labour, cost and time 









● High throughput 
● Low read error rate 
● Low cost per base 
● Long run time 
● High platform cost 
● Short read length 











● Long read length 
● No amplification required 
● Low degree of bias 
● High consensus accuracy 
● Identification of modified 
bases 
● High set-up and platform 
cost 
● Low throughput 
● Large instrument size 





Emulsion PCR ● Low platform and running 
cost 
● Short run time 
● Requires separate 
amplification of sequence 
libraries 
● Error rate related to 
homopolymers 
● Poor coverage at AT-rich 
regions or G-C rich regions 
Nanopore 
 
Nanopore NA (Single 
molecule) 
● Portable 
● No platform cost or 
maintenance 
● Long-reads 
● High accuracy consensus 
● No amplification required 
● Real-time data generation 
● Currently under continuous 
development, 
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1.5. MinION viral sequencing  
 
Virus diagnosis and surveillance has shifted towards rapid generation of 
complete viral genomes, which can provide clinically relevant information around 
pathogen identity, drug resistance genotypes and the presence of antigenic 
determinants. Similarly, the study of viral evolution and molecular epidemiology can 
be critical for informing public health interventions and infection control (214).  
Advancements in high throughput sequencing have created new opportunities 
for viral epidemiology; they allow for identification and characterisation of newly 
emerging viruses along with detection and monitoring of ongoing viral outbreaks (100, 
101). With the incidence of emerging viruses rising in remote and developing 
countries, the need for rapid diagnostic support in these settings is imperative, 
however conventional sequencing technologies are limited by their need for complex 
maintenance, continuous power supply and large equipment footprint. The MinION 
allows for long-read portable real time DNA and RNA sequencing and overcomes 
many limitations of conventional sequencing technologies, offering the prospect of 
combining diagnostics with complete viral genome generation, in real-time, in 
resource-limited settings. Direct nucleic acid sequencing of clinical samples requires 
detection of sufficient viral reads to assemble the genome confidently, which can be 
challenging due to the presence of high abundance host genetic material (102). Three 
main approaches for complete viral genome sequencing from clinical samples have 
been coupled with portable nanopore sequencing: (i) Target capture enrichment 
sequencing, (ii) PCR amplification sequencing and (iii) Metagenomic sequencing.  
1.5.1 Target capture enrichment sequencing  
 
Target capture enrichment protocols utilise virus-specific capture 
oligonucleotides, which allow for the enrichment of viral genomes present in a sample 
prior to sequencing. Target enrichment sequencing on conventional platforms has 
proven useful for sequencing of emerging viral pathogens in clinical samples (111, 
215) and a target enrichment protocol for selective enrichment of large fragments has 
been demonstrated successfully on the MinION for cultured influenza A virus (216) 
and DENV (217). These methods offer low limits of detection, but can suffer from 
coverage bias, are more expensive and require lengthy protocols (typically a 12-24hr 
hybridisation step) (216, 218). It is an approach that requires advanced design and a 
priori knowledge of the target pathogen, and is more costly and time-consuming 
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compared to PCR amplicon and metagenomic sequencing (102). Target enrichment 
can be extremely useful in a clinical setting but is challenging to establish for rapid 
sequencing during a virus epidemic or outbreak in less-equipped settings. 
1.5.2 PCR amplification sequencing  
 
PCR amplicon protocols allow for selective amplification of a viral genome of 
interest within a clinical sample prior to sequencing. PCR amplicon enrichment 
generates amplified viral genome fragments utilising primers complementary to a 
previously known viral nucleotide sequence (102). Sequencing PCR amplicons is a 
sensitive, cost efficient approach and is particularly useful for samples with low viral 
load, however, it is a laborious approach to scale up for a large amount of samples 
when a high number of amplicons are required per sample (156, 218). Its application 
in recovery of whole genome sequences of an emerging virus was highlighted in its 
use during the West Africa EBOV 2013-2016 epidemic. Quick et al. in 2016 used a 
tiling PCR approach, applying a combination of 11 (1.3 - 2.4 kb length) or 19 (0.9 - 
1.8 kb length) separate amplicon reactions coupled with nanopore sequencing to 
reliably recover more than 97% of the EBOV genome (18.959 kb) for 142 EBOV RT-
PCR positive samples (147). Furthermore, amplicon sequencing was used during the 
ZIKV epidemic in the Americas in 2015 (156, 218). 
These efforts resulted in the development of a novel multiplex PCR 
enrichment protocol which overcomes difficulties encountered with single-plex 
approaches, mainly the challenge of sequencing a high number of samples that 
require shorter fragment amplification, which is the case for viral clinical samples with 
high Ct values (>30), such as ZIKV positive samples (156, 218). The protocol 
described is an easily scalable approach, which allows for amplification of the whole 
virus genome using a multiplexed tilling PCR implemented in only two reactions; 
reducing reagent costs, manual pipetting steps, hands-on time and minimizing 
laboratory contamination and errors. PCR amplicon sequencing approaches have 
also been successfully used for YFV in Brazil (219) and WNV in the USA (219, 220). 
However, targeted methods are prone to amplicon contamination and are limited in 
coverage recovery of lower abundance regions and those regions which fall outside 
the primer pair coverage (both the 3' and 5' UTR regions) (218). The design of PCR 
amplicons offers many advantages but the need for previous knowledge of the 
sequence of the virus of interest leads to great challenges when encountered with 
highly diverse or recombinant viruses and specificity for the virus it has been designed 
against does not allow for viral discovery or unguided identification (102, 218). 
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1.5.3 Metagenomic sequencing 
 
Metagenomics was originally defined as the analysis of an environmental 
sample to determine the sequences of the collective microbial genomes contained in 
it (221). The use of the term has since been extended to refer to any culture-
independent analysis of microbial communities following the application of 
sequencing approaches in a variety of fields, including viral genomics (222). Clinical 
metagenomic protocols permit untargeted sequencing of total nucleic acid within a 
sample, including viral, host, bacterial and fungal genomic material that could be 
present (223). This approach is especially promising in clinical diagnosis, viral 
discovery and identification of viral co-infections (224). Diagnostic viral metagenomics 
has identified the causative agent of outbreaks and led to the discovery of novel 
viruses via a variety of metagenomic protocols (225–229). The success of a 
metagenomic approach is highly dependent on the method’s sensitivity when 
performed on a background-rich sample, both to detect and also to fully characterise 
the genome of the pathogen identified (230). This is one of the main limitations of the 
approach as it generally requires high sequencing depth to ensure sufficient viral 
reads are obtained, however, with advances in sequencing technologies and the 
decrease in sequencing cost the potential for pathogen discovery using metagenomic 
sequencing has greatly improved (231).  
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1.6 Sequence-independent single primer amplification 
 
Metagenomic protocols require no a priori knowledge of the pathogen of 
interest for their design, offering a hypothesis-free approach to target identification. 
Sequence-independent single primer amplification (SISPA) methods are commonly 
used metagenomic protocols for viral detection and discovery and can be grouped in 
two categories (a) SISPA by ligation (b) SISPA by random PCR. 
1.6.1 SISPA by ligation 
 
The ligation mediated SISPA method was originally developed by Reyes and 
Kim in 1991 for the amplification of heterogeneous DNA populations (232). Extracted 
RNA is reverse transcribed and converted to double stranded cDNA with the use of 
random or oligo-dT priming of the first strand. The method subsequently entails the 
directional ligation of an asymmetric adapter, called a linker/primer, onto the blunt 
ends of the resulting cDNA population using T4 DNA ligase. The primer sequence 
present on each end of the ligated DNA is used to enrich the cDNA population by 
PCR. The resulting amplified material can be used for downstream processing. In the 
original description of the ligation mediated SISPA method, restriction enzyme sites 
(EcoRI, NotI) were incorporated within the linker/primer. The resulting amplified 
material from the SISPA step could be incorporated into vectors by molecular cloning 
utilising the restriction endonuclease sites and sequenced. An overview of the SISPA 
by ligation method can be found in Figure 1.7. The protocol was initially evaluated on 
bacteriophage phi X174 and it was demonstrated that amplification was successful 
even at the lowest input amount tested. The method was used for cDNA preparation 
from low abundance sequences of Hepatitis C virus present in a positive serum 
sample. In 1991, Reyes et al. (233), used the SISPA method for the identification of 
the cause of a non-A and non-B hepatitis epidemic outbreak in humans, a new virus 
species: Hepatitis E virus. Later, Matsui et al. (234) coupled the SISPA method with 
conventional cloning and immunoscreening techniques for the identification of cDNA 
clones originating from a protein coding region of the Norwalk virus genome. 
Molecular characterisation of the virus had previously been difficult due to its low 
abundance in patient samples and its detection was limited to immunological assays. 
The use of non-selective cDNA amplification led to the identification of a portion of 
the viral genome and created opportunities for better characterisation of the virus. A 
variation of the method was introduced in 1992 by Lambden et al. (235) for dsRNA 
viruses. The linker/primer is directly ligated to the dsRNA, the dsRNA strands are 
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separated and reverse transcribed into cDNA. The resulting double stranded cDNA 
is amplified with the SISPA step in the same fashion as the original protocol.  
 
 
Figure 1.7 Overview of SISPA by ligation method. 
As originally described (232, 236), extracted RNA is reverse transcribed and converted to 
double stranded cDNA with the use of random or oligo-dT priming of the first strand. The 
method subsequently entails the directional ligation of an asymmetric adapter, called a 
linker/primer, onto the blunt ends of the resulting cDNA population using T4 DNA ligase. The 
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primer sequence present on each end of the ligated DNA is used to enrich the cDNA 
population by PCR.  
1.6.2 SISPA by random PCR 
 
SISPA by random PCR involves the use of a tagged random primer for the 
amplification of a cDNA population. The approach was first described in 1992 by 
Froussard (237), who tested it on MS2 phage RNA. In the first step of the protocol, 
RNA is reverse transcribed using a 26 nucleotide primer containing a random 
hexamer at its 3' end. The random hexamer leads to a mixture of 64 (4096) different 
primer combinations which anneals to different locations along the RNA sequence 
and a complementary DNA strand is synthesised. Following the first strand cDNA 
synthesis, DNA polymerase I Klenow fragment is added to the reaction for the second 
strand cDNA synthesis, also primed by the 26 nucleotide primer containing a random 
hexamer at its 3' end. The dsDNA generated therefore contains the tag sequence at 
both ends. SISPA of the randomly synthesised double stranded cDNA is performed 
in the presence of a single primer containing only the tag sequence. An overview of 
the SISPA by random PCR method can be found in Figure 1.8. Following SISPA the 
random amplified sequences could be visualised and size selected on an agarose 
gel, if a specific length range was desired. The resulting fragments, whether size 
selected or not, were purified, cloned and sequenced. Bohlander et al. (238) within 
the same year described the application of SISPA by PCR for direct amplification of 
microdissected chromosomal material. The approach included two rounds of DNA 
synthesis using DNA polymerase and a 21 nucleotide primer containing a random 
pentamer at its 3' end. Flanking of the target DNA population with tagged random 
primers allows for SISPA amplification of unknown sequences with the use of the 
known sequence (tag-primer) incorporated. The amplified product was biotinylated 





Chapter 1  Introduction 
 58 
 
Figure 1.8 Overview of SISPA by random PCR method. 
As originally described (236, 237), the random primer anneals to different locations along the 
RNA sequence and a complementary DNA strand is synthesised. Following the first strand 
cDNA synthesis, DNA polymerase I Klenow fragment is added to the reaction for the second 
strand cDNA synthesis, also primed by the 26 nucleotide primer containing a random hexamer 
at its 3' end. The dsDNA generated therefore contains the tag sequence at both ends. SISPA 
of the randomly synthesised double stranded cDNA is performed in the presence of a single 
primer containing only the tag sequence.  
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1.6.3 Recent applications for human viral pathogens 
 
Over the past two decades, the SISPA protocol has been widely used for viral 
metagenomic sequencing. Different 5' tag-primer sequences and various lengths of 
3' random sequence have been used. The tag-sequence commonly still contains 
restriction enzyme sites, which may facilitate downstream molecular cloning and 
sequencing, however recently the majority of methods proceed directly to sequencing 
following the SISPA. 
Wang et al. (239) in 2002 used a SISPA strategy in conjunction with 
microarray analysis for the detection of human viruses in respiratory samples. The 
approach utilised a tagged random octamer for the reverse transcription of the 
extracted RNA and Sequenase enzyme for the second strand DNA synthesis. The 
double stranded cDNA generated was amplified using a primer targeting the tag 
sequence and the products hybridized onto a custom designed DNA microarray. The 
DNA microarray included oligonucleotides representing more than 140 viruses, 
containing all available respiratory tract virus sequences available at the time, and 
was validated against respiratory virus culture extracts. Subsequent analysis of nine 
patient samples with respiratory infection symptoms led to clear indication of 
rhinovirus infection in four samples and of parainfluenza 1 in one sample, the 
presence of both viruses was confirmed by PCR. Ksiazek et al. (132) used an 
improved version of the DNA microarray coupled with the SISPA by PCR protocol 
during the 2003 outbreak of SARS, later described in detail by Wang et al. (240). The 
protocol was successfully used to identify the presence of a previously 
uncharacterized CoV in a viral culture isolate from a SARS patient. At the same time, 
Marra et al. (241) sequenced the complete genome of the SARS–associated CoV 
using a ligation-mediated SISPA approach coupled with molecular cloning and 
Sanger sequencing. In 2007, a novel Polyomavirus was identified from acute 
respiratory tract infection samples, using a SISPA by PCR protocol (242). Extracted 
RNA was reverse transcribed in the presence of a tagged random nonamer and cDNA 
was amplified by SISPA using the tag sequence. A year later, Towner et al. (243) 
used a SISPA by PCR protocol as described by Cox-Foster et al. (244) to investigate 
the cause of a haemorrhagic fever outbreak. The random-primed protocol approach 
was coupled with pyrosequencing to investigate reported cases of haemorrhagic 
fever in Western Uganda. Sequencing of total RNA extracted from a patient serum 
sample led to the identification of a novel ebolavirus species (Bundibugyo) and the 
recovery of approximately 70% of the virus genome. Similarly, a novel haemorrhagic 
fever–associated arenavirus, Lujo virus, was identified in 2008 using the same 
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unbiased high-throughput pyrosequencing approach (245–247). In 2009 Greninger 
et al. (248) demonstrated the utility of the SISPA by PCR protocol coupled with two 
different strategies, a pan-viral microarray assay and deep sequencing, for the 
identification and characterisation of H1N1 influenza A virus. The microarray 
approach successfully differentiated the seasonal H3N2 and H1N1 influenza from the 
newly emergent 2009 H1N1 pandemic strain. Deep sequencing of 17 clinical samples 
collected during the 2009 H1N1 pandemic enabled the detection of the virus in all 
samples and reached 97% virus genome coverage for one of the samples. Chen et 
al. (101) in 2011 described the detailed protocol involving SISPA by PCR prior to 
hybridization to the pan-viral microarray (Virochip) assay for clinical sample 
screening. The Virochip at the time consisted of approximately 36,000 probes derived 
from over 1,500 viruses available on Genbank. A SISPA by PCR protocol using a 
tagged random octamer (249) coupled with deep sequencing was for the 
retrospective investigation of three acute haemorrhagic fever cases presented in 
2009 in the Democratic Republic of Congo. The investigation led to the identification 
of a novel haemorrhagic fever associated Rhabdovirus, Bas-Congo virus, in 2012 
(250). Metagenomic sequencing using the SISPA by PCR protocol coupled with the 
Oxford Nanopore MinION for viral pathogens, was successfully demonstrated in 
principle in 2015. Greninger et al. (251) reported the unbiased detection of CHIKV, 
EBOV, and hepatitis C from human blood samples. Extracted RNA from all samples 
was reverse transcribed using a tagged random nonamer followed by second-strand 
synthesis and SISPA. The amplified cDNA was subjected to nanopore sequencing 
using the MinION. Within ~2hr of the sequencing run onset, a total of 6.7% of reads 
mapping to CHIKV and 90% of the genome was recovered. EBOV and hepatitis C 
samples both generated a smaller amount of reads mapping to the respective virus 
but nevertheless permitted the identification of the correct viral strain.   
The potential of metagenomic protocols has been evident for several years. 
Advancements in sequencing technology, such as increased data output and reduced 
and sample-to-results turnaround times make the coupling of metagenomic protocols 
with NGS more accessible and feasible in a variety of clinical environments.  
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1.7 Lassa virus: A closer look  
1.7.1 Background 
 
Lassa fever was first described in 1969 in the town of Lassa, Nigeria (40). A 
missionary nurse working in the village fell ill from a previously unknown 
haemorrhagic fever (252). She was transported to Bingham Hospital, Jos, Nigeria 
where a Bingham missionary nurse became infected as a result of human-to-human 
transmission whilst caring for her. Both missionary nurses became fatally ill. Both had 
been taken care of by a third missionary nurse, Lily Pinneo, who was also infected. 
Due to the fact that she was the third case to present similar symptoms, she was 
transported back to New York for diagnosis and treatment (40, 252). She eventually 
made a full recovery making her the first known patient to survive the new 
haemorrhagic fever disease. Blood samples taken from all three cases were sent to 
Yale Arbovirus Research Unit, Yale University to virologist Jordi Casals, who was the 
first to isolate the virus (253). The Yale Arbovirus Research Unit laboratory reported 
that all initial serum samples had a cytopathic effect on tissue culture and plaques 
were observed within 5-8 days. Electron microscopy identified spherical particles 
resembling those previously reported for lymphocytic choriomeningitis virus, a virus 
of the same genus (Mammarenavirus). Young adult mice were found to become sick 
after inoculation, similar to lymphocytic choriomeningitis virus (254). The virus was 
calculated by filtration to have a diameter of 70-150 nm and the viral genome 
appeared to be RNA. Casal and a laboratory technician, Juan Roman, both became 
infected, the latter fatally. Casal was treated with Lily Pinneo's convalescent serum 
and recovered. The novel arenavirus was isolated from the blood samples of the 
missionary nurses and that of Casal. The disease (Lassa fever) and virus (Lassa 
mammarenavirus) were assigned their name after the Nigerian town, Lassa, the 
location where the index case worked and most likely contracted the viral infection 
(40, 255).  
1.7.1.1 Symptoms 
  
Symptoms of Lassa fever are typically presented within 7-21 days of infection 
with LASV (55). The high population seroprevalence of LASV-specific antibodies in 
LASV endemic areas indicates that the majority (~80%) of infections are mild or 
possibly asymptomatic and in most cases do not lead to patient hospitalisation (55). 
However the acute viral haemorrhagic illness is estimated to affect between 300,000 
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and 500,000 people annually (256, 257) with a typical CFR of 18%, although 
significant increases of up to 31% have been reported during endemic seasons or 
among hospitalised patients (39).  
The onset of the disease is gradual with the early stages resembling other 
common diseases such as influenza or malaria (258). When symptomatic, the initial 
clinical presentation is characterised by fever, weakness and malaise. After a few 
days additional symptoms such as cough, red eyes, sore throat, severe headache, 
chest pain, muscle pain, abdominal pain, nausea, vomiting, diarrhoea may occur 
(259). Severe forms of the disease are commonly associated with multi-organ 
complications such as facial edema, fluid in the lungs, low blood pressure and 
bleeding from the mouth, nose, vagina or gastrointestinal tract (260). Additional 
symptoms that have been documented at later stages of the disease are shock, 
seizures, tremor, disorientation, coma and deafness. Deafness has been identified to 
occur in ~25% of patients that survive and in half of the cases, partial hearing recovery 
occurs after 1-3 months. In fatal cases, death commonly occurs within 14 days of 
onset. The disease is particularly severe during the third trimester of pregnancy, with 




Lassa fever diagnosis in endemic areas or in patients returning from endemic 
areas is based on clinical features and/or laboratory confirmation. Standard case 
definitions have been defined by the WHO/Regional Office for Africa (WHO/AFRO) 
and the CDC in the "Technical Guidelines for Integrated Disease Surveillance and 
Response in the African Region (IDSR)" document (262). It states that Lassa fever 
suspect cases are those, which present disease with a gradual onset of one or more 
of the following symptoms: malaise, fever, headache, sore throat, cough, nausea, 
vomiting, diarrhoea, myalgia, chest pain hearing loss combined with a history of 
contact with rodents, their excreta or with a known human case of Lassa fever. 
Confirmed cases are defined as those, which satisfy the suspect case definition and 
have been laboratory confirmed (positive IgM antibody, PCR or virus isolation) or 
epidemiologically linked to a Lassa fever confirmed case.  
 Clinical diagnosis is often hard due to the similarity of Lassa fever symptoms 
to those of other common diseases (263). This can often lead to misdiagnosis, 
especially early in the course of the disease. Additionally Lassa fever can be difficult 
to distinguish from other haemorrhagic fevers or diseases that cause fever such as 
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EBOV disease, malaria and typhoid fever (264, 265). Definitive diagnosis requires 
laboratory diagnosis, which can be achieved by a range of techniques such as RT-
PCR, antibody enzyme-linked immunosorbent assay (ELISA) and antigen detection. 
The current method of choice for the early detection of LASV in clinical samples is 
RT-PCR (39, 266, 267). The first RT-PCR assays used to detect LASV were 
developed using a limited number of genome sequences that were available at the 
time (268, 269). The technological advances in PCR and the increase in number of 
sequenced LASV samples has had a dramatic impact on diagnostic capabilities, 
however the diversity of the virus still continues to pose challenges for its detection 
(50, 51). The assay currently considered the gold standard is the commercially 
produced RT-PCR assay by Altona RealStar®, the first version of the assay targeted 
the S segment only, but the recently released updated version includes two assays, 
one targeting the L and the other the S segment (270).  
1.7.2 Zoonotic reservoir and transmission 
 
The primary animal reservoir of LASV is the multimammate rodent, Mastomys 
natalensis (M. natalensis), commonly known as the "multimammate rat", due to the 
female’s multiple and prominent mammary glands. M. natalensis is a dominant 
species in the ecosystem of Sub-Saharan Africa distributed across a variety of 
habitats, including savannahs, woodlands, forested areas and, importantly, houses 
and cultivated fields (271, 272). This varied habitat distribution demonstrates its 
capability to quickly adapt (273). Once infected, the rodents present persistent, 
asymptomatic infection and shed virus through their urine, faeces and saliva (274). 
Despite the presence of the Mastomys rodents across Sub-Saharan Africa, Lassa 
fever has not been identified outside West Africa (275). 
LASV was first identified in M. natalensis in 1972 and its role as a reservoir 
host confirmed by subsequent studies in Nigeria in 1975 (276). A study in 1983 
investigated the presence of M. natalensis rodents in Sierra Leone households where 
Lassa fever cases occurred (277). They reported that 79% of all rodents caught within 
the houses were M. natalensis and 39% of those were viremic compared to 3.7% in 
control houses. In 1987, McCormick et al. (278) surveyed populations in 15 different 
Sierra Leonean villages and found that human seroprevalence of anti-LASV 
antibodies ranged from 8% to 52%. They identified a high prevalence of infestation 
with M. natalensis in villages and that the rodents were found more frequently in 
houses than the surrounding areas. This finding suggested that humans are likely 
infected in their homes through primary exposure to the rodents or their excreta. In 
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endemic regions 50-100% of rodents caught in houses have been identified to the 
genus Mastomys, with a large fraction carrying LASV (277–280). Lecompte et al. 
(2006), screened 1,482 murid rodents caught across Guinea and identified LASV 
infections only in M. natalensis species (80). Additionally, Mastomys rodents are 
known to be a food source, thus infection may occur during catching or meal 
preparation. Recently additional rodent reservoirs of LASV have been identified, 
Mastomys erythroleucus (278, 281) and Hylomyscus pamfi (281) However, the role 
of M. natalensis as the primary reservoir continues to be strongly supported by the 
literature. 
Human to human LASV transmission events have also been reported, through 
contact with bodily fluids of an infected patient, primarily as nosocomial infections and 
less often as community infections (46, 47, 282). Nosocomial transmission occurs 
when health workers come into contact with infected blood or bodily fluids, with 
surgical procedures and births both particularly high risk sources of infection (283, 
284). Community transmission events can occur through exposure to infected blood 
or bodily fluids; this is commonly family members taking care of a Lassa fever positive 
relative (275). Secondary transmission during patient convalescence has not been 
documented, despite the delayed clearance of the virus. The only exception being 
rare reports of sexual transmission occurring months after patient recovery from acute 
disease (275, 285). Extensive human-to-human transmission has not been identified 
and its incidence is extremely low.  
 In 2016, Fichet-Calvet et al. (286) highlighted the importance of rodent control 
efforts to cover large geographical areas and the need to sustain them over time. 
Reduction in Lassa fever cases is currently primarily driven by rodent control, 
community hygiene and human awareness and behaviour (287).  
1.7.3 Molecular surveillance and epidemiology 
 
 Between 1969 (first case) and 1984, Lassa fever grew as a major public health 
concern after five epidemics in four West African countries: Nigeria (40, 288, 289), 
Liberia (290), Guinea (291) and Sierra Leone (292). The virus has now been identified 
in Benin, Togo, Côte d'Ivoire and Mali (39–44, 293–295). The virus is endemic in 
Nigeria, Liberia, Guinea, Sierra Leone, Mali and Côte d'Ivoire. Individual cases have 
been identified in Benin and Togo but additional evidence is required to confirm 
endemicity of the virus (296).  
LASV is genetically diverse with several different lineages in circulation in 
West Africa. The four first lineages were described in 2000 by Bowen et al. (41) using 
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a dataset of 49 unique partial nucleoprotein gene sequences. Sampling included 
samples from Guinea (human (n=4), rodent (n=1)), Liberia (human (n=9)), Nigeria 
(human (n=15)) and Sierra Leone (human (n=14), rodent (n=11)) taken between 1981 
and 1996. Three lineages were identified circulating in Nigeria. Lineage I includes the 
prototype Pinneo strain, isolated in 1970. Lineage II contained sequences from 
southern central Nigeria and lineage III, which contained sequences from sites in 
northern central Nigeria. The fourth lineage contained the largest group of LASV 
sequences used in the study, all of which originated from Guinea, Liberia and Sierra 
Leone. The authors noted that the interlineage genetic distances among the three 
Nigerian lineages (I, II, III) is greater than the distance between lineage III and lineage 
IV found in Guinea, Liberia and Sierra Leone. Overall variation in the partial 
nucleoprotein gene sequences used was found as high as 27% at the nucleotide level 
and up to 15% at the amino acid level. The genetic distance between LASV strains 
was strongly correlated with geographical distance suggesting that the reservoir 
(Mastomys sp.) had exhibited minimal regional movement since the first identification 
of the virus in 1970. Finally, the authors did not find evidence of a molecular clock, 
evolution occurring in a detectable constant rate. However, they highlight that it is 
likely a molecular clock is present in LASV evolution but was not evident due to the 
short time frame of data sampling (1969-1997).  
In 2000, Gunther et al. (44) isolated and characterised a novel LASV strain, 
imported into Germany by a traveller who had visited Ghana, Côte D’Ivoire, and 
Burkina Faso. The patient had visited all three countries during the 21 day incubation 
period, thus the exact origin of the sequence could not be identified. Evidence of 
LASV in this region of West Africa only existed historically from Burkina Faso, from a 
single imported non-fatal case in the Netherlands in 1980 (297). In 2009, Atkin et al. 
(43) reported the first case of LASV from Mali. The patient was medically evacuated 
from Mali to London for treatment but rapidly deteriorated with a fatal outcome. 
Phylogenetic analysis revealed that the Mali sequence was distinct from other Lassa 
strains but clustered most closely with the strain from the imported German case in 
2000 (43, 44). In 2010, Ehichioya et al (298) investigated the molecular epidemiology 
of LASV in Nigeria. Phylogenetic analysis of complete GP, NP and L gene sequences 
confirmed the existence of the previously described four LASV lineages, highlighted 
the predominance of lineage II and III sequences and postulated the existence of a 
previously undescribed lineage.  
In 2010, the presence of LASV infected rodents and epizootic viral 
transmission was confirmed in the village of Soromba, Côte D’Ivoire by Safronetz et 
al (294). The sequence obtained from the rodent Soromba LASV was 
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indistinguishable from the imported Mali case in the UK. In 2011 the first cases of 
LASV originating in Ghana were reported, the three geographical distinct cases had 
no travel history outside the area suggesting the infections were all acquired locally 
(299). In 2013, Kouadio et al.  (295), identified LASV positive Mastomys rodents in 
Côte D’Ivoire and subsequently in 2015, Mateo et al. (300) reported a LASV fatal 
human case in western Côte D’Ivoire. Ecologically, southern Mali, southern Burkina 
Faso, northern Côte D’Ivoire, Ghana, Togo and Benin share common characteristics 
with the known LASV endemic regions of Nigeria, Guinea, Sierra Leone and Liberia 
(301). All of the aforementioned countries and regions are part of the Tropical 
Wooded Savanna ecological zone and the environmental factors within these areas 
might favour the presence of M. natalensis and the circulation and spread of LASV 
(42, 301). In 2015, Andersen et al. sequenced ~200 LASV positive samples from 
rodents and humans from across West Africa. The existence of four LASV lineages 
was confirmed and samples from rodents and humans were found to cluster together, 
with no evidence for host-specific clades. High levels of nucleotide diversity were 
identified, up to 32% for at strain level and 25% for across individual segments. 
Evidence of segment reassortment was identified but no recombination events were 
found. Molecular dating identified that LASV most likely originated in Nigeria and 
subsequently spread into neighbouring countries. A molecular clock was estimated 
from plotting root-to-tip distances against sample collection dates across the entire 
LASV dataset. This allowed for the estimation of the time to the most recent common 
ancestor to be ~1000 years for the L segment and 650 years for the S segment. Whilst 
evidence of rodent-to-rodent transmission was identified by clustering of the 
sequences, only 5 of 169 LASV sequences originating from humans resulted in such 
clusters, leading to the conclusion that most human LASV infections are independent 
transmissions from the rodent reservoir rather than due to human-to-human 
transmission. Due to the high diversity identified within different LASV lineages, 
continuous surveillance and sampling of LASV positive rodents and humans is critical 
for the development of diagnostic tools, therapeutics and vaccines and for our 
understanding of LASV evolution and molecular epidemiology.   
Since the original four lineages described by Bowen et al (41), LASV lineages 
have been expanded to include an additional three as proposed currently in the 
literature. Strains from Mali and Côte D’Ivoire have been proposed to represent 
lineage V (302). A LASV from Nigeria found in a Hylomyscus pamfi rodent has been 
proposed to belong to a new lineage VI (281) and a LASV strain from a nosocomial 
outbreak in Togo has been proposed as lineage VII (293). An overview of the current 
LASV lineages and the region they have been identified in can be found in Figure 1.9.   





Figure 1.9 Graphical representation of known LASV lineages.  
The figure is adapted from the phylogenetic tree of the LASV L segment as reported in (303). 
The seven genotypes are indicated with different colours and roman numerals. The locations 
where each lineage has been identified is also included. The colour strip highlights the human 
LASV sequences obtained from previous years (light grey); sequences obtained from rodent 
samples (dark grey). The squares at the tips represent the host: empty square = human virus; 
black square = rodent virus; no square = laboratory virus. 
Chapter 1  Introduction 
 68 
1.8 Thesis scope 
 
This PhD research project set-out to evaluate metagenomic sequencing for 
the identification and complete genome recovery of pathogenic RNA viruses directly 
from clinical samples; to interrogate their feasibility and sensitivity when coupled with 
the Oxford Nanopore MinION and to evaluate its application in resource-limited 





Chapter 2  
Materials and methods 
  
Chapter 2                     Material and methods 
 70 
2. Chapter 2. Material and methods 
 
All chemicals were from Sigma unless stated otherwise, Diethyl 
pyrocarbonate (DEPC) treated nuclease free water (NFW) was from Thermo Fisher 
Scientific and oligos were from Integrated DNA Technologies (IDT) unless stated 
otherwise.  
2.1 Virus sample collection 
 
HAZV stock (Catalogue No. 0408084v) was obtained from the National 
Collection of Pathogenic Viruses (Public Health England, UK). Mock-clinical samples 
were produced by dilution of HAZV in human serum (S7023, Sigma-Aldrich). CHIKV 
and DENV positive clinical samples were obtained from the Rare and Important 
Pathogens Laboratory (RIPL, Public Health England, UK). Samples from RIPL tested 
in this study were residual diagnostic samples used for assay and method 
development thus required no further ethics approval. LASV samples were acquired 
through collaboration with the Bernhard Nocht Institute for Tropical Medicine 
(BNITM), Hamburg, Germany and originated from the Irrua Specialist Teaching 
Hospital (ISTH), Irrua, Nigeria. All diagnostic samples tested positive by real-time RT-
PCR for the virus of interest and were anonymised prior to any investigation. The use 
of LASV diagnostic leftover specimen and corresponding patient data was approved 
by the ISTH Research and Ethics Committee (approval ISTH/HREC/20171208/45) 
2.2 DNA quantification 
 
The Qubit® Fluorometer (Thermo Fisher Scientific) and dsDNA High 
Sensitivity (HS) assay kit (Q32854) were used, which has a quantitation range of 0.2-
100 ng. The Qubit® working solution is prepared by diluting the Qubit® dsDNA BR 
Reagent 1:200 in Qubit® dsDNA BR Buffer. For each standard, 190 µL of Qubit® 
working solution is mixed with 10 µL of Qubit® standard and for each sample, 199 µL 
of Qubit® working solution is mixed with 1 µL of sample. All tubes are incubated for 2 
minutes prior to measurement. Qubit™ Assay Tubes (Q32856, Thermo Fisher 
Scientific) were used for all Qubit® assay readings and the instrument was calibrated 
using the standards prior to every use.  
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2.3 Virus detection and quantification 
 
 All RIPL assays used were previously developed and clinically validated in 
certified diagnostic laboratories for ISO 15189 compliance, with the exception of the 
LASV Altona assay, which is commercially available (642013, Altona). Details on 
primer information along with the target and kit used can be found in Table 2.1. All 
assays were run on the LightCycler 480 (Roche Life Science), on LightCycler 480 
optical white reaction plates and sealing foil (Roche, UK). Bacteriophage MS2 was 
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Table 2.1 Overview of oligonucleotide sequences, kit information, target region and 
corresponding reference for each assay used 









CAA GGC AAG CAT TGC 












GCT TTC TCT CAC CCC 




TCG ACG CGC CCT CTT 









E1 gene (305) 
Reverse 
Primer 
ATC GAA TGC ACC GCA 
CAC T 
Probe 
6FAM ACC AGC CTG 





GGA TAG ACC AGA GAT 
















CAT TCC ATT TTC TGG 
CGT TC  
Reverse 
Primer 2 
CAA TCC ATC TTG CGG 
CGC TC  
Probe 6FAM CAG CAT CAT TCC AGG CAC AG BHQ1  
LASV Altona 
Commercial kit (LASV 
Probe labelled with 6FAM 
and Internal Control 












CCA CCA TYT TRT GCA 












GCA CAT GTN TCH TAY 
AGY ATG GAY CA 
Probe 
FAM-AAR TGG GGY 






TGG CAC TAC CCC TCT 
















GTA CGG GCG ACC 
CCA CGA TGA C 
Probe 
Cy5 CAC ATC GAT AGA 
TCA AGG TGC CTA CAA 
GC BBQ1 
aAbbreviation for reference and refers to publication associated with the equivalent assay. 
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2.3.1 HAZV assay 
 
HAZV was quantified using a semi-quantitative two-step RT-PCR (304). cDNA 
was synthesised from 6 µL of RNA using Superscript III First-Strand Synthesis 
Supermix (Thermo Fisher Scientific) as per manufacturer’s instructions and primers 
listed in Table 2.1. All HAZV PCR assays were run using the QuantiFast SYBR green 
PCR kit (Qiagen) and PCR conditions, as listed in Table 2.2 and Table 2.3. Standards 
with a range of 107 – 101 viral genome copies per ml were included in each run to 
allow for copy number approximation. Standards were 100 bp amplicon, generated 
using HAZV specific primers. The PCR product was quantified using the Qubit 
Fluorometer, the amplicon concentration was calculated and dilutions were made in 
NFW. 
 
Table 2.2 HAZV assay reaction mix composition 
Reagent Single Reaction Final Concentration 
Reverse Transcription Step 1. 
Primer (Forward) 1 µL 0.2 µM 
Annealing Buffer 1 µL NA 
Template 6 µL NA 
Water 2 µL NA 
Reverse Transcription Step 2. 
2X First-Strand Reaction Mix 10 µL 1x 
SuperScript™ III/RNaseOUT™ Enzyme Mix 2 µL NA 
PCR 
QuantiFast SYBR green 5 µL NA 
Forward Primer 1 µL 1µM 
Reverse Primer 1 µL 1µM 
Water 2 µL NA 
Template 1 µL - 
Total 10 µL - 
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Table 2.3 HAZV two step RT-PCR cycling parameters 
Step Name Analysis Mode Temp (oC) Time (M:S) Acquisition Mode Cycles 
Reverse Transcription 
Step 1.  NA 65 05:00 NA NA 
Step 2. NA 50 50:00 NA NA 
PCR 





95 00:12 None  
45 
60 00:30 Single 
2.3.2 CHIKV and DENV assays 
 
CHIKV and DENV were measured using the clinically validated real-time 
quantitative RT-PCR (qRT-PCR) protocols routinely used in the diagnostic 
laboratories (Rare and Important Pathogens Laboratory, PHE). All assays were 
performed on a LightCycler 480 using the Invitrogen SuperScript™ III One-Step RT-
PCR System with Platinum™ Taq DNA Polymerase (Invitrogen). The CHIKV assay 
targets the E1 gene generating a 127 bp amplicon (305) and the two DENV assays 
target the 3’ non-coding region generating a 79 bp amplicon (306). The DENV 1-3 
assay covers the three equivalent DENV serotypes and is a multiplex with the MS2 
PCR, the DENV4 assay covers the remaining DENV serotype. Details on each assay 
can be found in Table 2.4 and Table 2.5 and the cycling conditions in Table 2.6. The 
target regions amplified by real-time qRT-PCR were used for the design of custom 
RNA oligos (Table 2.7) as a standard to estimate copy numbers of detected virus for 
each sample.  
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Table 2.4 CHIKV assay reaction mix composition 
CHIKV 
Reagent Single Reaction Final Concentration 
2x Reaction Mix 10µL 1X 
Water 2.215 µL NA 
Forward Primer 0.18 µL 900 nM 
Reverse Primer 0.18 µL 900 nM 
Probe 0.125 µL 625 nM 
MgSO4 (50mM) 1.5 µL 3.75 mM 
Platinum Taq 0.8 µL NA 
Template 5 µL NA 
Total 15 µL NA 
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Table 2.5 DENV1-3 and DENV4 assay reaction mix composition 
Reagent Single Reaction Final Concentration 
DENV 1-3 
2x Reaction Mix 10 µL 1x 
Water 1.04 µL NA 
Forward Primer 0.06 µL 300 nM 
Reverse Primer 0.18 µL 900 nM 
Probe 0.1 µL 500 nM 
Forward Primer (MS2) 0.08 µL 40 nM 
Reverse Primer (MS2) 0.08 µL 40 nM 
Probe (MS2) 0.16 µL 80 nM 
MgSO4 (50mM) 2.5 µL 6.25 mM 
Platinum Taq 0.8 µL NA 
Template 5 µL NA 
Total 15 µL NA 
DENV 4 
2x Reaction Mix 10 µL 1x 
Water 1.41 µL NA 
Forward Primer 0.1 µL 50 nM 
Reverse Primer 0.09 µL 450 nM 
Probe 0.1 µL 500 nM 
MgSO4 (50mM) 2.5 µL 6.25 mM 
Platinum Taq 0.8 µL NA 
Template 5 µL NA 
Total 15 µL NA 
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Table 2.6 CHIKV, DENV1-3 and DENV4 RT-PCR cycling parameters 








None 45 10:00 None 1 20 





95 00:05 None  
45 
20 
57 00:35 Single 20 
Cooling None 40 00:30 None 1 20 
 
Table 2.7 CHIKV, DENV1-3 and DENV4 custom RNA oligos sequences 















2.3.3 LASV assay 
 
Suspected LASV samples are routinely screened at the Bernhard Nocht 
Institute for Tropical Medicine and the Institute of Lassa Fever Research and Control 
(ILFRC) using two real-time qRT-PCR approaches, the commercially available Altona 
kit (RealStar® Lassa Virus RT-PCR Kit 1.0 CE, Altona Diagnostics, Hamburg, 
Germany) targeting the S segment along with an in-house version of the previously 
described Nikisins RT-PCR targeting the L segment (307)pileup.  
The latter has been optimized by using the SuperScript™ III Platinum™ One-
Step qRT-PCR reagents (Invitrogen) according to manufacturer instructions (without 
magnesium sulfate; reaction volume of 25 µl). The temperature profile was identical 
to that of the Altona assay, while primer and probe sequences and concentrations 
were used as described (307). Both Altona and Nikisins real-time RT-PCR assays 
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have been implemented and extensively evaluated in terms of analytical and clinical 
characteristics by the BNITM, and were found to have good performance when used 
in combination for detection of the virus in acute Lassa fever cases. Reaction setup 
can be found in Table 2.8. Both assays are run on the Rotor-Gene Q (Qiagen) and 
share the same cycling conditions (Table 2.9). 
 
Table 2.8 LASV Altona and Nikisins assay reaction mix composition 
Altona 
Reagent Single Reaction 
Master Mix A 5 µL 
Master Mix B 15 µL 
Template 10 µL 
Total 30 µL 
Additional: 1µL Internal Control is added to the positive and negative control 
Nikisins 
Reagent Single Reaction Final Concentration 
2x Superscript Mix 12.50 µL 1X 
Water 3.95 µL NA 
Forward Primer  1.25 µL 500 nM 
Reverse Primer 1.30 µL 520 nM 
Probe  0.5 µL 200 nM 
Superscript III 0.5 µL NA 
Template 5 µL NA 
Total 25 µL NA 
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Table 2.9 LASV Altona and Nikisins RT-PCR cycling parameters 




Acquisition Mode Cycles 
Reverse Transcription None 55 20:00 None 1 







95 00:15 None  
 
45 
55 00:45 Single 
72 00:15 None 
2.3.5 MS2 
 
 MS2 is used as an internal extraction control specifically used in the diagnostic 
laboratories as an inhibition control for RT-PCR reactions. We utilise MS2 as an 
internal control for our sequencing runs to validate that the extraction, reverse 
transcriptase and library preparation has been successful. The MS2 assay targets a 
99 bp amplicon using the SuperScript™ III One-Step RT-PCR System with 
Platinum™ Taq DNA Polymerase (Invitrogen). Reaction setup can be found in Table 
2.10 and cycling conditions in Table 2.11. 
 
Table 2.10 MS2 assay reaction mix composition 
Reagent Single Reaction Final Concentration 
2x Reaction Mix 10µL 1X 
Water 1.38 µL NA 
Forward Primer 0.08 µL 40 nM 
Reverse Primer 0.08 µL 40 nM 
Probe 0.16 µL 80 nM 
MgSO4 (50mM) 2.5 µL 3.75 mM 
Platinum Taq 0.8 µL NA 
Template 5 µL NA 
Total 15 µL NA 
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Table 2.11 MS2 RT-PCR cycling parameters 








None 45 10:00 None 1 20 





95 00:05 None  
45 
20 
57 00:35 Single 20 
Cooling None 40 00:30 None 1 20 
2.4 Nucleic acid extraction 
 
Total nucleic acid was extracted from 140 μl of each sample using the QIAamp 
viral RNA kit (Qiagen) with the addition of linear acrylamide instead of carrier RNA 
and eluted in 60 μl. All patient samples were inactivated in a biosafety level 3 or 4 
laboratory depending on the pathogen classification by addition of AVL buffer 
(Qiagen) and disinfected with 5,000ppm chlorine solution (HazTabs, Appleton Woods 
LTD) for 10 min prior to removal and downstream processing in a Biosafety level 2 
laboratory. 
2.5 DNase treatment and purification 
 
As the extraction kit is not designed to separate viral RNA from host DNA and 
both nucleic acids will be recovered, thus 30 μl of elute were subjected to DNase 
treatment with TURBO DNase (Thermo Fisher Scientific) at 37oC for 30 min to remove 
any host DNA present. Finally, RNA was purified and concentrated to 8 μl using the 
RNA Clean & Concentrator™-5 kit (Zymo Research) as per manufacturer's 
guidelines. 
2.6 Agencourt AMPure XP PCR Bead Clean-Up 
 
 Agencourt AMPure XP PCR beads (Beckman Coulter Life Sciences) (from 
herein referred to as AMPure beads) allow for purification and clean-up with no salt 
carryover. Excess oligos, nucleotides, enzymes and salts are removed resulting in 
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purified products through selective binding of dsDNA to paramagnetic beads. DNA of 
100 bp and larger binds to the beads and is followed by separation of the beads from 
the solution using a magnetic field. The beads are then washed to remove 
contaminants and DNA is eluted in the final step from the magnetic beads.  
 Sample purification is done as per manufacturer's guidelines. Briefly, AMPure 
beads are stored at 4oC and allowed to come to room temperature prior to use. Beads 
are mixed well before use until homogenous and 70% Ethanol (EtOH) is freshly 
prepared. Beads are added to the sample at desired ratio (1:1) and incubated at room 
temperature for 5 min. The reaction tube is then placed on a DynaMag™-2 Magnet 
(12321D, Thermo Fisher Scientific) and allowed for beads to separate. Cleared 
solution is then aspirated and beads are washed 2x with 200 μl of the freshly prepared 
70% EtOH. Once the last EtOH wash is removed beads are allowed to air dry before 
eluting in desired volume.  
2.7 Single Primer Isothermal Amplification 
 
The Ovation RNA-Seq System V2 kit (Nugen) - mentioned throughout the 
thesis as Ribo-SPIA® protocol - was used per manufacturer's instructions for Single 
Primer Isothermal Amplification (SPIA) of RNA. Briefly, the first step is the generation 
of the first strand cDNA which is prepared using a first strand DNA/RNA chimeric 
primer mix and reverse transcriptase. The primers have a DNA portion, comprised of 
either a random k-mer sequence or polyT, which hybridizer to the 5’ end or randomly 
across the RNA length to initiate amplification. The reverse transcriptase extends the 
3’ DNA end of the primer generating the first strand and the resulting hybrid contains 
a unique RNA sequence at the 5’ end of the cDNA strand. The final step is the SPIA 
which uses the DNA/RNA chimeric primer, DNA polymerase and RNase H in a 
homogeneous isothermal assay which amplifies the cDNA. RNase H allows for the 
degradation of the RNA in the DNA/RNA duplex which results in exposure of the 
unique DNA sequence. This provides a binding site for a new DNA/RNA primer and 
the initiation of replication by DNA polymerase at the 3’ end of the primer displacing 
the existing forward strand. The RNase H removes the RNA portion at the 5’ end of 
the newly synthesised cDNA allowing for the next round of cDNA synthesis. The 
process is repeated resulting in amplification of cDNA. 
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2.8 Sequence Independent Single Primer Amplification 
 
The SISPA approach was adapted from Greninger et al (308). For the reverse 
transcription step, 104 copies/ml of purified MS2 RNA was included as a control at 
this step and samples were incubated at 65oC for 5 min with 1 μl (40 pmol/μl) Primer 
A (5’- GTTTCCCACTGGAGGATA-N9 -3’), followed by the addition of 5 μl 
SuperScript™ III Reverse Transcriptase (Thermo Fisher) reaction mix (2 μl 5x First-
Strand Buffer, 1 μl water, 1 μl 10 mM dNTP mix, 0.5 μl 0.1M DTT, 0.5 μL SSIII RT) 
and incubation at 42oC for 60 min. Second strand DNA synthesis followed using 
Sequenase Version 2.0 DNA Polymerase (Thermo Fisher), 5 μl of Sequenase mix #1 
(1 μl 5x Sequenase Buffer, 3.85 μl H2O, 0.15 μl Sequenase enzyme) is added to the 
reaction and incubated at 37oC for 8 min followed by the addition of Sequenase mix 
#2 (0.45 μl Sequenase Dilution Buffer, 0.15 μl Sequenase Enzyme) and a second 
incubation at 37oC for 8 min. This concludes the reverse transcription and second 
strand cDNA synthesis. The final step in the SISPA protocol is the DNA amplification 
which was performed with AccuTaq™ LA DNA Polymerase (Sigma), in which 5 μl of 
cDNA synthesised material is added to 45 μl of AccuTaq LA reaction mix (35 μl H2O, 
5 μl 10x AccuTaq Buffer, 2.5 μl 12.5 mM dNTP, 1 μl DMSO, 1 μl (100 pmol/μl) Primer 
B (5′-GTTTCCCACTGGAGGATA-3′), 0.5 μl AccuTaq enzyme) per sample with the 
following PCR conditions: 98°C for 30s; 30 cycles of 94°C for 15s, 50°C for 20s, and 
68°C for 5 min, followed by 68°C for 10 min. Amplified cDNA was purified using a 1:1 
ratio of AMPure XP beads (Beckman Coulter, Brea, CA) and stored at -20oC. All 
samples were quantified when defrosted for the preparation of a sequencing library. 
2.9 MiSeq library preparation 
 
MiSeq sequencing libraries were prepared using 1.5 ng of amplified cDNA as 
input template into the Nextera XT V2 kit (MiSeq, Illumina) and library preparation 
was conducted as per manufacturer's instructions. Briefly input DNA is tagmented 
using the Nextera transposome, a process that allows from the simultaneous 
fragmentation of the DNA and addition of adapter sequences to tag the DNA. The 
tagmented DNA is then amplified using a limited-cycle PCR which also allows for the 
addition of index sequences and full adapter sequences to the tagmented DNA. 
Indexes were selected using the MiSeq experimental manager software and samples 
were multiplexed in batches (maximum 16 samples per run). Once the amplification 
step is finished the libraries are cleaned-up using AMPure XP beads (Beckman 
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Coulter) to purify the DNA and remove short fragments. Quantity of each library is 
normalised to ensure equal library representation in the pooled library which 
combines equal volumes of the normalised libraries in a single tube. The pooled 
library is finally diluted and heat-denatured prior to loading for the sequencing run. 
Pooled libraries were sequenced on a 2x150 bp paired end Illumina MiSeq run, by 
the Genomics Services Development Unit, Public Health England, Colindale, London, 
UK. 
2.10 MinION sequencing and library preparation 
 
MinION sequencing libraries were prepared using the latest available 
consumables and protocols from Oxford Nanopore Technologies at the time of the 
experiments. Protocols evolved along the three year period of this project. Details on 
which protocols were used are included in the results chapters but information on all 
protocols used and a description of the protocol chemistry is included in this section. 
Whilst all protocols include an optional DNA fragmentation and DNA repair step prior 
to the main protocol, neither of these steps were included in any of the library 
preparations used. The MinION device is connected to a computer through a USB 
port and configured through the MinKNOW™ Software Agent, which was updated 
prior to each experiment to ensure the most recent version of the software was used. 
MinION sequencing libraries were prepared using the total available amplified 
cDNA of each sample with a maximum input of 1000 ng, in the majority of samples 
processed this level was not reached, thus input was less than recommended, details 
are specified in each results chapter. All steps of the MinION protocol were performed 
in DNA LoBind tube (Eppendorf). Prior to any sequencing run, the flow cell used was 
quality controlled by running the Platform QC script on MinKNOW, assessing the 
number of active pores in the flow cell, generally a total of 450 or more active pores 
in Group 1 was considered acceptable to continue with the experiment. Once quality 
checked the flow cell was primed using the Flow Cell priming mix prior to loading the 
prepared library, which was sequenced using the 48hr script for all samples. Copies 
of the MinION library preparation protocols, which are briefly described below, can be 
found in the Supplementary material section (Protocols S1-S4).  
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2.10.1 2D DNA by ligation (SQK-NSK007 and SQK-LSK208) 
 
The 2D DNA by ligation protocol (SQK-NSK007 and SQK-LSK208, Oxford 
Nanopore Technologies) has now been discontinued but was used for experiments 
in Chapter 4. The protocol allowed sequencing of both strands within a dsDNA 
molecule using a leader adaptor and a hairpin adaptor, which allowed for both the 
template and complement strands of a dsDNA to pass through a pore leading to a 2D 
read. An overview of the protocols is shown in Figure 2.1.  
 
 
Figure 2.1 2D DNA by ligation protocol overview  
(Figure adapted from https://community.nanoporetech.com/) 
 
Briefly, input DNA was end-repaired and dA-tailed using the NEBNext® 
Ultra™ II End Repair/dA-Tailing Module (New England Biolabs) and incubated for 5 
min at 20oC and 5 min at 65oC using a heat block. DNA was purified using 60 μl 
AMPure beads and eluted in 31 μl nuclease free water. End-prepped/dA-tailed DNA 
was quantified with an expected recovery of ~700ng and 30 μl was taken forward for 
adapter ligation. The adaptor and the hair pin adaptor were added using Blunt/TA 
Ligase Master Mix (New England Biolabs) followed by the addition of the tether. 
Dynabeads™ MyOne™ Streptavidin C1 (Thermo fisher Scientific) were used to purify 
the adapted and tethered DNA library, which was then eluted in 15 μl of elution buffer 
and quantified. The final library was prepared, loaded and the sequencing run was 
initiated. At the time of these experiments, the Metrichor™ Desktop Agent managed 
the connection to the base-calling service in the cloud hosted by Metrichor, which 
was run in parallel to the sequencing run generating basecalled fast5 files. 
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2.10.2 1D2 kit (SQK-LSK308)  
 
The 1D2 kit (SQK-LSK308, Oxford Nanopore Technologies) chemistry utilises 
the same principles as the 1D kit with the main difference being the sequencing 
adaptors, which in this case are designed to encourage the complementary strand to 
immediately be sequenced after the template. This protocol in combination with 
appropriate 1D2 data analysis produces reads with higher accuracy than the 1D 
protocol. The protocol incorporates ligation of the 1D2 adapters onto the end-
repaired/dA-tailed DNA fragments prior to the ligation of the sequencing adaptors and 
the tether. An overview of the protocol is shown in Figure 2.2.  
 
 
Figure 2.2 1D2 DNA by ligation protocol overview  
(Figure adapted from https://community.nanoporetech.com/) 
 
Briefly, input DNA was end-repaired and dA-tailed using the NEBNext® 
Ultra™ II End Repair/dA-Tailing Module (New England Biolabs) and incubated for 5 
min at 20oC and 5 min at 65oC using a heat block. The reaction was then cleaned-up 
using 60 μl AMPure beads, eluted in 23 μl nuclease free water and quantified. 
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Sequencing 1D2 adaptors were added using the Blunt/TA Ligase Master Mix (New 
England Biolabs) and 20 μl AMPure beads were added to purify the adapter ligated 
DNA, which was eluted in 46 μl of elution buffer and quantified. Sequencing adaptors 
were then added using the Blunt/TA Ligase Master Mix (New England Biolabs) and 
40 μl AMPure beads were added to purify the adapter ligated DNA, which was 
washed using the Adapter Bead Binding Buffer, eluted in 15 μl of elution buffer and 
quantified. Library was prepared, loaded using Library Loading Beads (EXP-LLB001) 
and the sequencing run was initiated.  
2.10.3 Rapid kit (SQK-RAD003) 
 
The Rapid kit (SQK-RAD003, Oxford Nanopore Technologies) utilises a 
transposase-method for the sequencing library preparation during which a 
transposome complexes (transposase in combination with two adapters) are used to 
fragment DNA molecules and simultaneously add adaptors to the fragmented DNA 
(used in Chapter 4). The approach is characterised by its 10min library preparation. 
An overview of the protocols is shown in Figure 2.3.  
 
 
Figure 2.3 Rapid Sequencing protocol overview  
(Figure adapted from https://community.nanoporetech.com/) 
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Briefly, input DNA of approx. 400 ng, in a volume of 7.5 μl, was mixed with 2.5 
μl Fragmentation Mix (FRA) and incubated for 1 min at 30oC and 1 min at 80oC. 
Following the fragmentation step, 1 μl of Rapid adaptor (RPD) was added and 
incubated for 5 min at room temperature. Library was prepared, loaded using Library 
Loading Beads (EXP-LLB001) and the sequencing run was initiated.  
2.10.4 1D DNA by ligation (SQK-LSK108) 
 
The 1D protocol (Oxford Nanopore Technologies) allows for sequencing of 
DNA by the addition of a leader adaptor ligated onto each end of a dsDNA and is 
currently one of the most widely used kits (used in Chapter 5). The leader adaptor 
consists of two partially complementary oligos that form a Y-shaped structure when 
annealed. A tether is added to the adaptors during library preparation, which anchors 
the DNA fragments to the membrane, in close proximity to the nanopore facilitating 
binding and sequencing initiation. The leader adaptor with the motor protein binds to 
the nanopore and the single strand of that leader adapter is fed through the nanopore. 
Once the strand, referred to as the template, is sequenced the complement strand 
dissociates and possibly gets sequenced as a separate event.  
An overview of the protocol is shown in Figure 2.4. Input DNA was end-
repaired and dA-tailed using the NEBNext® Ultra™ II End Repair/dA-Tailing Module 
(New England Biolabs) and incubated for 5 min at 20oC and 5 min at 65oC using a 
heat block. The reaction was then cleaned-up using 60 μl AMPure beads and eluted 
in 31 μl nuclease free water. End-prepped/dA-tailed DNA was quantified and 30 μl 
was taken forward for adapter ligation. Adaptor ligation used Blunt/TA Ligase Master 
Mix (New England Biolabs) with a 10min incubation and 40 μl AMPure beads were 
added to purify the adapter ligated DNA, which was washed using the Adapter Bead 
Binding Buffer, eluted in 15 μl of elution buffer and quantified. Library was prepared, 
loaded using Library Loading Beads (EXP-LLB001) and the sequencing run was 
initiated.  
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Figure 2.4 1D DNA by ligation protocol overview  
(Figure adapted from https://community.nanoporetech.com/) 
2.10.5 Barcoding Kit (EXP-NBD103) 
 
Barcoded MinION sequencing libraries were prepared using the Ligation 
sequencing kit 1D (SQK-LSK108, Oxford Nanopore Technologies) and the Native 
Barcoding Kit (EXP-NBD103, Oxford Nanopore Technologies) (Used in Chapter 5). 
PCR-free multiplexing of samples is achieved using 12 unique barcodes. The 
barcodes are added at each end of the dsDNA by ligation prior to the addition of the 
leader adaptors and the tether.  
An overview of the protocol is shown in Figure 2.5. Briefly, input DNA was 
end-repaired and dA-tailed using the NEBNext® Ultra™ II End Repair/dA-Tailing 
Module (New England Biolabs) and incubated for 5 min at 20oC and 5 min at 65oC 
using a heat block. The reaction was then cleaned-up using 60 μl AMPure beads and 
eluted in 23 μl nuclease free water. A unique barcode was selected per sample, end-
prepped/dA-tailed DNA was quantified and 500 ng of each sample were taken 
forward for barcode ligation. Each reaction was then cleaned-up using 50 μl AMPure 
beads and eluted in 26 μl nuclease free water. Each barcoded DNA sample was 
quantified and equimolar amounts of each were pooled together producing a pooled 
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sample of 700 ng in total in 50 μl. Sequencing adaptors were added to the pooled 
barcoded sample using the Quick Ligation™ Kit (New England Biolabs) and 40 μl 
AMPure beads were added to purify the adapter ligated DNA, which was washed 
using the Adapter Bead Binding Buffer, eluted in 15 μl of elution buffer and quantified. 
Library was prepared, loaded using Library Loading Beads (EXP-LLB001) and the 
sequencing run was initiated.  
 
 
Figure 2.5 Barcoding Kit coupled with 1D DNA by ligation protocol overview  
(Figure adapted from https://community.nanoporetech.com/ ) 
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2.11 Data analysis 
 
Two main routes were used to analyse sequencing data. The first one is 
reference mapping using an existing sequence, to which the reads are aligned. The 
second is de novo assembly, which is the reference free assembly of contiguous 
sequences from the reads. 
2.12 Reference assisted alignment consensus  
2.12.1 Mapping and alignment statistics 
 
The Burrows-Wheeler Alignment tool (BWA) (309) was used to align reads to 
a reference sequence, details on specific version and reference sequences used are 
included in the results chapters. BWA allows for mapping of low-divergence 
sequences against a reference genome and consists of three algorithms: BWA-
backtrack, BWA-SW and BWA-MEM. We utilise BWA-MEM, which is designed to run 
with longer sequences (70 bp to 1 Mbp), is faster, more accurate and recommended 
for high-quality queries (310). BWA-MEM is based on an algorithm that identifies 
super-maximal exact matches originally published in 2012 (311) and later extended 
into its current form in 2013 to allow for BWA-MEM to be a fully featured mapper (309, 
312). Samtools, is a suite of utilities for manipulating sequencing alignments. 
Bedtools, is a suite of programs for working with SAM/BAM, BED and VCF files. 
Available online resources were utilised for all tools (313–317). 
 
The first step is for BWA to construct the FM-index for the reference genome used. 
Sub-command to index the reference is: 
 
bwa index ref.fasta 
 
Once the reference is indexed BWA-MEM is used to align the query 
sequences to the reference. BWA-MEM is also able to process MinION long reads 
and account for their accuracy using the -x option and specifying ont2d. Command 
for alignment of MiSeq paired-end reads to a reference and for alignment of MinION 
reads to a reference: 
MiSeq: 
bwa mem -t 8 ref.fasta sample.R1.fastq sample.R2.fastq > sample.sam 




bwa mem -x ont2d -t 8 ref.fasta sample.fastq > sample.sam 
 
BWA output file format is a Sequence Alignment/Map format (SAM). SAM is 
a TAB-delimited format consisting of an optional header and an alignment section. A 
SAM file needs to be transformed to its binary counterpart the BAM format, for further 
analysis. This is done using samtools with the options -S (specifies that the input file 
is a SAM file) and -b (indicates that the output file will be in BAM format), the two 
requirements can be merged and represented as -Sb in the command. The alignment 
produced is in a random order with respect to their position in the reference genome, 
leading to a BAM file, which includes the information in the order the sequences occur 
in the input fastq files.  
 
samtools view -Sb sample.sam > sample.bam 
 
Certain analysis tools require that the BAM file is sorted so that the alignment 
information is present in the reference genome order, i.e. the information needs to be 
ordered based on their alignment coordinates to the reference genome. 
 
samtools sort sample.bam -o sample.sort.bam 
 
Samtools is designed to run as part of a stream thus takes into account the 
input file as stdin and the output file as stdout allowing for several commands to be 
combined using UNIX pipes. An example of this functionality is included below for a 
piped analysis of MiSeq data. 
 
bwa mem -t 8 ref.fasta sample.R1.fastq sample.R2.fastq | samtools view -Sb - | samtools sort -o 
sample.ref.illumina.bam 
 
Next step is to index the sorted BAM file which allows for quick extraction of 
alignment information and is required by genome viewers (e.g. Tablet (318), The 
James Hutton University) to quickly display alignment when navigating to different 
regions of the genome. The Samtools command to index the sorted bam file will 
create an additional index file in the current directory where the command is run. 
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samtools index sample.sort.bam 
 
Samtools and bedtools were used to generate additional information. 
Samtools was used to generate Samtools flagstat that goes through the input file to 
calculate and print statistics to stdout and this is then passed and written in a text file 
to store the information. 
 
samtools flagstat sample.sort.bam > sample.flagstat.txt 
 
Samtools depth computes the depth at each location. To output all positions 
including positions with depth zero the -a option needs to be included in the 
command. 
 
Samtools depth -a  –d 100000000 sample.bam > sample.depth.txt  
 
Bedtools genomecov computes histograms and can take a BAM file as input 
(-ibam). The histogram’s maximum can be controlled using the -max option.  
 
bedtools genomecov -ibam sample.sort.bam -max 20 -g > sample.cov20.txt 
 
Commands were put together in a shell script. All required files (sample.fastq 
and reference.fasta) were always located in the parent directory and all generated 
files were saved in the current directory where the script was run from. Commands 
were included in a text file and saved as a .sh file. An example of the MiSeq script 
and how to run using the command line: 
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bwa index ../$ref.fasta 
 
bwa mem -t 8 ../$ref.fasta ../$prefix.R1.fastq.gz ../$prefix.R2.fastq.gz | samtools view -Sb - | 
samtools sort -o $prefix.to.$ref.illumina.bam 
 
samtools index $prefix.to.$ref.illumina.bam 
 
samtools flagstat $prefix.to.$ref.illumina.bam > $prefix.to.$ref.illumina.flagstat.txt 
 
Samtools depth -a  –d 100000000 $prefix.to.$ref.illumina.bam > $prefix.to.$ref.illumina.depth.txt 
 
bedtools genomecov -ibam $prefix.to.$ref.illumina.bam -max 20 -g > 
$prefix.to.$ref.illumina.cov20.txt 
2.12.2 Variant calling and consensus generation 
 
For MiSeq sequencing data, quasibam (319), an in house developed C++ 
program, was used to process the BAM file and generate the consensus sequence. 
Quasibam uses a pileup based method and generates a majority consensus along 
with a table of nucleotide frequency, depth and quality metrics for each nucleotide 
position in the mapping process. Minimum variation for inclusion in consensus was 
set at 20, inferring any mixture greater than 20% to be coded as IUPAC ambiguities. 
Minimum number of reads required to report consensus position was set at 20. All 
other parameters were run as default, setting options listed in Table 2.12. 
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Table 2.12 Quasibam parameters and options used 
Parameter Option 
mapq minimum 30 
Minimum percentage of variants reported 1 
Minimum variation for inclusion in consensus sequence 20 
ASCI string cutoff for fastq 33 
Minimum number of reads required to report a consensus position 20 
Insert optimisation? Yes please 
Remove PCR duplicates? Yes please 
Perform error checking based on position of minority variants in a read? Yes please 
Fraction at each end of a read where errors are expected. 0.1 
Fraction of reads containing a variant that are within the read region above. 0.9 
Report fasta header as key value pairs? No thanks 
 
For MinION data, Nanopolish and margin_cons script were used in 
combination. Nanopolish (320) allows for the calculation of an improved consensus 
sequence for a draft genome assembly, detects base modifications, calls SNPs and 
indels with respect to a reference genome. Nanopolish was utilised as previously 
described by Quick et. al. (147). Briefly, this reference mapping approach utilises 
nanopolish variants to align signal-level events and detect variants in regards to the 
most closely related reference genome; insertions and deletions were not called due 
to the nature of the sequencing data. Nanopolish required access to the signal-level 
data (fast5) output from the nanopore sequencer. Nanopolish options used can be 
found in Table 2.13. This leads to the first step of the nanopolish workflow, which is 
the indexing of the fast5 files by telling nanopolish where to locate the files. Providing 
the sequencing_summary.txt file speeds up the indexing process. 
 
nanopolish index -d /fast5_files -s sequencing_summary.txt albacore_output.fastq 
 
Once the fast5 files are indexed using nanopolish, bwa is used to index the 
reference genome and to align the basecalled reads to the reference sequence. 
Samtools is used to sort the resulting bam file and the consensus algorithm is run 
using nanopolish variants, which computes the vcf file with the variants information. 
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Finally margin_cons.py script (218), which is integrated in the zika pipeline of the 
ZIBRA project (321), was used to generate the consensus from the vcf file generated 
from nanopolish and the reference used as input in nanopolish. The commands were 
put together in a script: 
 







bwa index ../References/$1.fasta 
 
bwa mem -x ont2d -t 10 ../References/$1.fasta ../seqtk/$2.fastq | samtools sort -o 
Sorted.$3.$1.$4.bam -T readsmap.$1.$4.tmp - 
 
samtools index Sorted.$3.$1.$4.bam 
 
nanopolish variants -t 10 --ploidy 1 --snps -r ../seqtk/$2.fastq -b Sorted.$3.$1.$4.bam -g 
../References/$1.fasta -o $3.$4.$1.NPSNPS.vcf --min-candidate-frequency 0.1 2>&1 | tee -a 
logfile.$2.$1.$4.log 
 
python /zika-seq-master/pipeline/scripts/margin_cons.py ../References/$1.fasta 
$3.$4.$1.NPSNPS.vcf Sorted.$3.$1.$4.bam > $3.$4.NpSnpsMrgCons.Consensus.fasta 2> 
logfileMarginCons.$2.$1.$4.log 
 
Table 2.13 Nanopolish parameters and options used 
Parameter Option 
variants Find SNPs using a signal-level HMM 
-t Number of threads used 
--ploidy Ploidy level of the sequenced genome 
--snps Only call SNPs 
-r  Reads in fasta format 
-g Reference genome (fasta) 
-o Output file  
--min-candidate-frequency Extract candidate variants from the aligned reads when the variant 
frequency is at least F (default 0.2) 
 
Additionally, for MinION data, a simple pileup script (Figure S1) with bases 
called at a minimum depth of 20x and 70% support fraction was used, either 
independently or in succession to Nanopolish and margin_cons script. The pileup 
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script generates a majority consensus along with a table of nucleotide frequency and 
depth metrics for each nucleotide position in the mapping process. Any base location 
that does not fulfil the depth and support fraction is assigned an N IUPAC ambiguity 
code.  
2.13 De novo assembly 
 
MiSeq generated sequences were assembled de novo using Spades 3.8.2 (322) in 
combination with SSPACE Standard v3.0 (323). Spades is a short-read genome 
assembly module and SSPACE Standard is a script based on SSAKE that allows for 
scaffolding of pre-assembled contigs. Both have been designed to run with paired-
end libraries. The Spades command and the parameters (Table 2.14) used are as 
follows: 
 
python ../../spades.py --pe1-1 sample.R1.fastq.gz --pe1-2 sample.R2.fastq.gz --cov-cutoff 5 --
careful -t 6 -k 21,33,55,77,99,127 -o Sample_Spades_OutputFolder 
 
Table 2.14  Spades parameters and options used 
Parameter Option 
--pe1-1 File with left reads for paired-end library 
--pe1-2 Files with right reads for paired-end library 
--cov-cutoff Read coverage cut-off value.  
--careful Minimises number of mismatches in the final contigs 
--only-assembler 
 
Option not included, this is for reads that have been corrected prior to 
running assembler 
-t  Number of threads 
-k K-mer lengths, increased in increments of 22 until k-mer length reaches 
127 
-o Output directory 
 
The contig.fasta output from SPades is then used as input for SSPACE, which 
is able to order, distance and orientate the contigs and combine them into scaffolds. 
SSPACE requires a library file, which contains the paired read files and information 
on the insert size, error and orientation. The library file provides information on the 
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appropriate format for the reads to be stored (e.g. paired reads are stored in a new 
file with similar read names for easy identification of the paired reads) and once the 
reads are formatted provides information on mapping the filtered paired reads. The 
format of the information included in the library.txt file is as follows and the information 
included in each column of the file is in Table 2.15.  
 
Lib1 bwa ./Sample.R1.fastq.gz ./Sample.R2.fastq.gz 250 0.25 FR 
 
Table 2.15  SSPACE column information 
Column Option 
1 Name of library 
2 Name of aligner to be used for library 
3 and 4 Fasta or fastq files - paired end reads 
5 Expected insert size 
6 Maximum allowed error 
7 Orientation of the paired- reads 
 
 Once the library file is ready and is located in the directory where SSPACE 
will be run, SSPACE is run with the following command: 
 
perl ./SSPACE_Standard_v3.0.pl -l libraries.txt -s ./Sample_Spades_OutputFolder/scaffolds.fasta 
 
MinION sequencing data was assembled de novo using CANU (324), a fork 
of the Celera Assembler designed to work with high-noise long-read sequences such 
as the Oxford Nanopore MinION output. Canu has three functions which can run 
independently or combined: correction, trimming and assembly. Canu has novel 
features allowing for improved performance with high noise long read data such as 
auto-detection of computational resources to scale itself to the available resources, 
adaptive k-mer weighting and automated error rate estimation. Canu was run with the 
following command, all functions combined and parameters as mentioned in Table 
2.16. 
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canu -d Sample_Parameters -p Sample_Parameters -nanopore-raw sample.fastq 
genomeSize=10000 minReadLength=400 minOverlapLength=200 corOutCoverage=10000 
gnuplotTested=true 
 
Table 2.16 CANU parameter information 
Parameter Option 
-d  Allows canu to create an assembly-directory and run in that directory 
-p Set the file name of intermediate and output files 
-nanopore-raw Reads option to describe how reads were generated 
genomeSize Estimate of the size of the target genome. Is used to decide how many 
reads will be corrected and how sensitive the mhap overlapper should be. 
Also impacts some logging, in particular reports the NG50 sizes. 
minReadLength Reads shorter that the input value will not be loaded in the assembler. 
Reads output by correction and trimming that are shorter than this will also 
be discarded. 
minOverlapLength Overlaps shorter than this will not be taken into account. Smaller values 
are used to overcome lack of read coverage, but also lead to false overlaps 
and potential assemblies. The higher the value the more accurate 
assemblies but more fragmented too.  
corOutCoverage Only correct the longest reads up to this coverage, defaults to 40 
2.14 Metagenomic data analysis 
 
Metagenomic laboratory preparation of samples is important to allow for 
identification of pathogens that are not previously known to be present. To allow for 
this it is important to utilise the correct tools to analyse this data thus to allow for non-
targeted screening of the data. Samples often contain multiple pathogens, pathogens 
that cross react in the diagnostic assays used, or new pathogens that were not 
considered previously to have caused human disease leading to difficulty in 
identifying all these scenarios unless the right tools are used.  
Bioinformatics tools for metagenomic analysis are designed to methodically 
screen sequencing data and return classified reads within a list of species. 
Metagenomic classification tools have been used to characterise the composition of 
a variety of samples including clinical patient samples.  
Metagenomic analysis was conducted using the taxonomic classifier Kraken 
v0.10.4-beta (325) and Centrifuge v1.0.4-beta (326). For Kraken Taxonomic labels 
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were assigned against a locally built database populated with bacterial, viral, archaeal 
genomes and a representative yeast genome. The majority of sequences included in 
the database are complete genomes from the RefSeq database (v.66) with an 
addition of 141 viral GenBank sequences including several Hepatitis E viruses, 
Parechovirus and HAZV. For Centrifuge taxonomic classification was performed 
against the provided Bacterial, Archaea, Viruses, Human (compressed) indexes (last 
updated: 12/06/2016).  
2.15 Basecalling 
 
Basecalling was performed in the first sequencing runs using Metrichor (Oxford 
Nanopore Technologies) and Albacore v1.2 (Oxford Nanopore Technologies) and 
later only using Albacore v2.2.7 (Oxford Nanopore Technologies). Metrichor was a 
cloud-based basecalling approach that is no longer available, as it was replaced with 
Albacore which performed local basecalling. Albacore is a data processing pipeline 
that provides the basecalling algorithms and post-processing options for the fast5 files 
generated by the MinION. As of Albacore v1.1 and later the algorithm could basecall 
directly to fastq files using the option -o fastq. The command used to basecall a run 
using the latest Albacore version used was: 
 




Porechop (327) is a tool for identifying and removing barcodes and sequencing 
adaptors from Oxford Nanopore reads. Sequencing barcodes and adapters are 
identified at the ends of reads and trimmed, additionally reads that were barcoded 
are demultiplexed. Porechop is able to identify reads with adapters in the middle, 
which are considered chimeric and separated to two reads. Porechop v0.2.3 was 
used to trimm and demultiplex reads directly from the Albacore output directory using 
the command: 
 
porechop -i input_reads.fastq -b output_dir 




SeqTK (328) is a fast tool for processing FASTA and FASTQ files. It allows 
for fast manipulation of both files. Command used to convert fastq files to fasta: 
 
seqtk seq -a in.fq.gz > out.fa 
 
Command used to trim 30bp from the left and 30bp from the right end of each read:  
 
seqtk trimfq -b 30 -e 30 input.fastq > output.fastq 
2.18 Samtools fastq 
 
Samtools fastq allows for the conversion of a BAM file into a fastq. The -f 
option is used to only output alignments with all bits set in INT present in the FLAG 
field. In this case -f 4 is used which outputs all unmapped reads. This command was 
used to generate fastq files that excluded any reads mapping to human. An other 
example of using samtools fastq is to extract all reads that mapped, in which case we 
would use -F 4. The -F option does not output alignments with any bits set in INT 
present in the FLAG field, so it would not include any unmapped reads.  
 
samtools fastq -f 4 sample.bam > sample_unmapped.fastq 
2.19 Awk and Bioawk 
 
The awk (329) language allows users to select records within a file and 
perform operations on them. Bioawk (330) is an extension to awk adding specific 
support for multiple sequencing and biological data formats including SAM, FASTA 
and FASTQ. Commands sourced online have been used to manipulate fastq files. 
Read length and frequency of identified read length was extrapolated using: 
 
awk 'NR%4 ==  2 {lengths[length($0)]++} END {for (l in lengths) {print l, lengths[l]}}'  file.fastq 
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Commands using bioawk to count the number of total sequences in a fastq file and 
creation of a tab delimited table with names and sequence length: 
 
bioawk -cfastx 'END{print NR}' test.fastq 
 
bioawk -c fastx '{ print $name, length($seq) }' < Sample.fasta > Sample_ReadNames&Length.txt 
2.20 Chapter 3 specific material and methods 
2.20.1 Sample selection 
 
 The HAZV mock-sample was prepared at a concentration of 106 viral 
copies/ml using a stock of culture grown HAZV and sterile-filtered human serum 
(S7023, Sigma-Aldrich). Subsequently four positive routine diagnostic samples, two 
plasma and two serum, were obtained from RIPL, Public Health England (PHE), 
Porton Down. All had previously tested positive by real-time qRT-PCR for DENV with 
different cycle threshold (Ct) values, one low (Ct: 17.67), two medium (Ct: 24. and 
25.28) and one high (Ct: 28.69). RT-PCR assays were used for confirmation and 
quantitation of DENV (Chapter 2, section 2.3.2). 
2.20.2 Sample preparation and sequencing 
 
Samples were extracted (Section 2.4), DNase treated and purified (Section 2.5) and 
AMPure XP beads were used for clean-up (Section 2.6). The Ovation RNA-Seq 
System V2 kit (Nugen) - referred to throughout the thesis as Ribo-SPIA® protocol - 
was used as per manufacturer's instructions for SPIA of RNA (Section 2.7). SISPA 
protocol was carried out as described in Section 2.8. Illumina libraries of all samples 
were prepared as per Section 2.9. 
2.20.3 Data handling 
 
References used for alignments in this chapter were (Genbank ID): HAZV L segment 
(NC_038709.1), HAZV M segment (NC_038710.1), HAZV S segment 
(NC_038711.1), DENV Serotype 1 (NC_001477.1), DENV Serotype 2 
(NC_001474.2), DENV Serotype 3 (NC_001475.2), DENV Serotype 4 
(NC_002640.1). Reads were randomly normalised using fastq_pair (331) and the -n 
option (number of read subselection) was set based on the total number of Ribo-
Chapter 2                     Material and methods 
 102 
SPIA® reads generated per sample. Further details on the data analysis and the tools 
used can be found in Chapter 2.  
2.21 Chapter 4 specific material and methods 
2.21.1 Sample selection 
 
Twenty-six positive routine diagnostic samples, nine plasma and 17 serum, were 
obtained from the RIPL, PHE, Porton Down. All had previously tested positive by real-
time qRT-PCR for CHIKV or DENV, with a maximum cut-off value of Ct 35. Drosten 
et al. (306) and Edwards et al (305).  RT-PCR assays were used for confirmation and 
quantitation of DENV and CHIKV respectively, as described in Section 2.3. Samples 
were selected based on their Ct values, among a larger set of 441 samples, so as to 
represent a Ct clinical range.  
2.21.2 MinION library preparation and sequencing 
 
MinION sequencing libraries were prepared using total amplified cDNA of each 
sample to a maximum of 1 µg. Oxford Nanopore kits SQK-NSK007 or SQK-LSK208 
(2D), SQK-LSK308 (1D2) and SQK-RBK001 (Rapid) were used and each sample was 
run individually on the appropriate flow cell (FLO-MIN105, FLO-MIN106 or FLO-
MIN107) using the 48hr run script. Base calling was performed using Metrichor 
(Oxford Nanopore Technologies) for SQK-NSK007 and SQK-LSK208 or Albacore 
v1.2 for SQK-LSK308 and SQK-RBK001. Poretools (332) was used to extract FASTQ 
files from Metrichor FAST5 files. 
2.21.3 Data handling 
 
BWA-MEM v0.7.15 (309) was used to align reads to the following references 
(Genbank ID): DENV Serotype 1 (NC_001477.1), DENV Serotype 2 (NC_001474.2), 
DENV Serotype 3 (NC_001475.2), DENV Serotype 4 (NC_002640.1) and CHIKV 
(NC_004162.2). Mapping consensuses for MiSeq were generated using in-house 
software QuasiBam (319) and for MinION using a simple pileup. Nanopolish variants  
(147, 320) was used in consensus mode to compute error-corrected consensus 
sequence for the Rapid kit. De novo assemblies for MinION sequences were run 
using CANU v1.6 (333, 334) with the following settings: corOutCoverage=1000, 
genomeSize=12000, minReadLength=300, minOverlapLength=50. 
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2.22 Chapter 5 specific material and methods 
2.22.1 Sample Collection 
 
Samples from suspected Lassa fever patients were routinely tested for 
presence of LASV RNA at the ILFRC, Irrua Specialist Teaching Hospital (ISTH), Irrua, 
Edo State, Nigeria, using two real-time reverse transcription PCR assays (Section 
2.2.3); the commercially available Altona kit (RealStar® Lassa Virus RT-PCR Kit 1.0 
CE, Altona Diagnostics, Hamburg, Germany) targeting the S segment and the 
Nikisins RT-PCR targeting the L segment (307). A total of 120 plasma, breast milk, 
or cerebrospinal fluid samples identified as LASV-positive by one or both real-time 
PCRs were selected based on temporal and geographical spread across the 
outbreak.  
2.22.2 MinION Library Preparation and Sequencing 
 
Barcoded MinION sequencing libraries were prepared using the Ligation 
sequencing kit 1D (SQK-LSK108) and Native Barcoding Kit (EXP-NBD103) (Section 
2.10.4 and 2.10.5). Up to 6 samples plus one negative control (consisting of a water 
blank sample included in each batch of extractions) were included per multiplex 
library. Reads generated from the negative controls were taken through the analysis 
pipeline with no significant viral assemblies generated and no viral sequence 
produced. If the negative controls were identified positive for LASV with a viable viral 
sequence of more than 50% consensus sequence of a segment, the complete run 
would be dismissed and repeated. Libraries were sequenced for 48hr on FLO-
MIN106 flow cells using a Mark 1B MinION device.  
2.22.3 Data Handling 
 
Reads generated were basecalled using Oxford Nanopore Technologies 
Albacore software v2.2.7 (Section 2.15) and basecalled fastq files were concatenated 
and demultiplexed using Porechop (Section 2.16). SeqTK was used to trim from both 
ends (Section 2.17) to eliminate primer sequences and resulting fastq files were 
mapped to the human genome, human_g1k_v37 (1000 Genomes) and mapped 
reads were excluded from the subsequent de novo assembly. Owing to the diversity 
of LASV, selection of an individual reference genome for read alignment was required 
for each sample. CANU v1.6 (Section 2.13) was used for de novo assembly, which 
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allowed for LASV reference identification. CANU genomeSize and minReadLength 
parameters were lowered for samples that did not assemble any LASV contigs with 
the specified values. Assemblies were used in a blastn search against the NCBI 
database to identify the closest LASV reference genome available and BWA was 
used for read alignment (Section 2.12) to the reference genome identified. 
Nanopolish variants and margin_cons.py script (321) were used to filter out low-
quality or low-coverage candidate SNPS and compute the final consensus 
respectively (Section 2.12.2). Samtools was used to compute percentage reads 
mapped along with coverage depth and bedtools was used to calculate genome 
coverage at 20x (Section 2.12). Taxonomic classification of the data was performed 
using Centrifuge (Section 2.14).  
2.22.4 Hardware equipment  
 
 Four nanopore MinION devices, and the computer hardware necessary were 
put together. The hardware used (Figure 2.6) included 3x MacBook Pro laptop, along 
with a custom-build computer (Table 2.17) built in a light and compact (260 x 208 x 
280 mm) Cool Master case, running Ubuntu 14.4. The devices were set-up with all 
expected requirements for software. Additionally four Samsung T5 2TB USB 3.0 & 
USB-C (Samsung) external solid state drives and two WD Elements USB 3.0 4TB 
(Western Digital) portable external drives were used to allow for fast data 
manipulation and back-ups, subset of each were formatted for use with the MacBook 
(Mac OS Extended) and the remaining formatted for use with Linux computer (EXT4).  
 
 
Figure 2.6 Hardware equipment  
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Table 2.17 Computer Specifications of custom build desktop computer. 
iItem Catalog Number Manufact
urer 
Cooler Master Elite 110A   RC-110A-KKN1 Cool 
Master 
Intel - Core i9 - 7980XE 2.6GHz 18-Core 
Processor   
i9-7980XE Intel  
Cooler Master - MasterLiquid Lite 120 66.7 





ASRock - X299E-ITX/ac Mini ITX LGA2066 
Motherboard   
X299E-ITX/ac ASRock
  
SanDisk - X400 1TB M.2-2280 Solid State 





Corsair - HX Platinum 750W 80+ Platinum 
Certified Fully-Modular ATX Power Supply 
HX750 Platinum Corsair 
Corsair - Vengeance 32GB (2 x 16GB) DDR4-




Western Digital - Black 1TB 2.5" 7200RPM 
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3. Chapter 3. Method evaluation for metagenomic 
sequencing of RNA viruses 
3.1 Overview 
 
Two methods of unbiased cDNA amplification for viral metagenomic 
sequencing were compared: The Ribo-SPIA® approach, used with Illumina 
sequencing for viral metagenomic sequencing in the 2014 EBOV outbreak (144) and 
a SISPA protocol, which had been previously successfully coupled with the MinION 
for detection of viral pathogens in clinical samples (308). Samples, including a mock 
sample spiked with HAZV and four DENV clinical samples, were prepared using both 
protocols, sequenced on an Illumina MiSeq and assessed based on percentage of 
reads mapping to the viral genome and consensus sequence recovery at 10x and 
20x depth. The SISPA protocol outperformed the Ribo-SPIA® particularly for the 
DENV clinical samples, leading to higher percentages of total reads mapping to the 
virus and near-complete genomes for all four DENV samples.  
3.2 Introduction  
   
Metagenomic protocols require no a priori knowledge of the pathogen of 
interest for their design, offering a hypothesis-free approach to target identification. 
The aim of this chapter was to identify possible methods for metagenomic sequencing 
of RNA viruses on the MinION platform. From the pre-existing literature, two leading 
methods were identified for further evaluation, Ribo-SPIA®  and SISPA. 
Ribo-SPIA® had been extensively used on clinical samples during the 2014 
EBOV outbreak (144, 336) and was a well established method available, but had not 
been tested coupled with nanopore sequencing. Ribo-SPIA® uses a single-primer 
isothermal linear amplification and has been shown to generate full genomes of 
EBOV, human immunodeficiency virus, respiratory syncytial virus and WNV from 
ultra-low copy viral samples, as low as 100 copies of viral RNA (335). SISPA had 
been demonstrated to work with nanopore sequencing, however the number of 
clinical samples tested was low. SISPA uses tagged random primers for the 
amplification of cDNA and has been extensively used for virus detection and full 
genome sequencing of viruses (see Section 1.6 Sequence-independent single primer 
amplification). 
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Sequence-independent sequencing using RNA single primer isothermal 
amplification (Ribo-SPIA®, Ovation® RNA-Seq System V2, NuGEN), previously 
mainly used for transcriptome analysis, was successfully applied by Gire et al. (144), 
Malboeuf et al. (335) and Lewandowski et al. (336) for the identification of RNA 
viruses in clinical samples. Ribo-SPIA® utilises a mixture of random and oligo (dT) 
DNA/RNA chimeric primers for the reverse transcription step, generating the first 
strand cDNA which serves as a template for the second strand synthesis. For the 
second strand synthesis, the RNA strand within the DNA/RNA duplex is fragmented 
creating a priming site for the DNA polymerase to synthesize the second strand 
resulting in a double stranded cDNA with a unique DNA/RNA heteroduplex at one 
end. The final step is the single-primer isothermal amplification which uses the 
DNA/RNA chimeric primer, DNA polymerase and RNase H in a homogeneous 
isothermal assay which amplifies the cDNA (Figure 3.1B).  
Metagenomic sequencing of CHIKV, EBOV and Hepatitis C was 
demonstrated in principle using a SISPA protocol coupled with the MinION by 
Greninger et al. in 2015 reporting their detection from a small number of human blood 
samples (308). The SISPA approach utilizes a primer consisting of a random 3' end 
sequence, more specifically nine random N (each N position can be an A, C, T or G 
nucleotide) in the protocol used by Greninger et al. (308), and a defined sequence 
tag at the 5' end. The tagged nonamer is used for the reverse transcription of the 
extracted RNA, followed by the second strand synthesis to generate dsDNA which is 
subsequently amplified using the defined sequence as a primer-binding extension 
sequence (Figure 3.1A).  
To compare the two protocols and assess their feasibility and sensitivity, both 
methods were used for the non-specific RNA amplification of a mock sample spiked 
with HAZV and of four DENV positive clinical samples with a variety of Ct values. 
Both protocols were evaluated based on the proportion of viral nucleic acid recovered 
from each sample and on the percentage recovery of complete genome sequences 
for each virus.  
  


















Figure 3.1 Schematic diagram of SISPA and Ribo-SPIA® amplification processes.  
(A) SISPA protocol outline. SISPA primer A consisting of a random 3' end sequence (nine 
random N and a defined sequence tag at the 5' end) is used for the reverse transcription of 
the extracted RNA, followed by the second strand synthesis to generate dsDNA which is 
subsequently amplified using a long amplification DNA polymerase and SISPA primer B (the 
tag sequence of SISPA primer A) as a primer-binding extension sequence. (B) Ribo-SPIA® 
protocol outline. A mixture of random and oligo(dT) DNA/RNA chimeric primers are used for 
the reverse transcription step. For the second strand synthesis, the RNA strand within the 
DNA/RNA duplex is fragmented creating a priming site for the DNA polymerase. A single-
primer isothermal amplification using the DNA/RNA chimeric primer, DNA polymerase and 
RNase H in a homogeneous isothermal assay allows for cDNA amplification. (Section B of the 
figure was adapted from: Ovation RNA Amplification System V2 User guide PART NO. 3100-
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3.3 Results 
3.3.1 HAZV spiked sample assessment 
  
A serum sample spiked with HAZV at a titre of 106 genome copies per ml was 
sequenced using both SISPA and Ribo-SPIA® approaches. The proportion of viral 
nucleic acid present relative to host/background and the genome coverage achieved 
can be seen in Table 3.1. The proportion of total reads mapping to each segment (L: 
large segment, M: medium segment, S: small segment) of the virus was substantial 
using either metagenomic protocol. The percentage of total reads mapping to the 
complete HAZV genome was 59% for the Ribo-SPIA® protocol and 78% for the 
SISPA protocol. Using the Ribo-SPIA® protocol 35%, 11% and 3.7% mapped to 
HAZV segments L, M and S respectively and for SISPA protocol the equivalent 
percentages were 56%, 14% and 9% (Figure 3.2). Irrespective of lower mapping 
percentages observed with the Ribo-SPIA® protocol both approaches produced 
sufficient viral reads to achieve genome coverage of >98% for each of the three 
segments (Figure 3.2). The SISPA approach produced a slightly lower percentage of 
genome coverage both at 10x and 20x, with 70 bp less coverage at 10x (SISPA: 
99.16%, Ribo-SPIA®: 99.96%) and 85 bp less at 20x, a negligible difference in 
coverage of the complete genome (18232 bp) of HAZV (Table 3.1).  
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Figure 3.2 Proportion of reads mapping to the appropriate viral reference sequence and 
proportion of reference genome sequenced at minimum 20-fold coverage in the HAZV 
mock sample.  
The percentage of total reads mapping to each segment reference sequence and the 
complete genome is plotted in the upper panel. Lower panels display the percentage of the 
reference genome sequenced to a minimum depth of 20-fold in the Illumina data. 
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Table 3.1 Description of sequencing mapping data to HAZV for the SISPA and Ribo-SPIA® 






















SISPA 2288576 1794072 78,39 % 99.40 % 99.16 % NC_038709.1-NC_038711.1 18232 
Ribo-SPIA 1260234 626222 49,69 % 100% 99.96 % NC_038709.1-NC_038711.1 18232 
L Segment 
SISPA 2288576 1276899 55,79 % 99.74 % 99.73 % NC_038711.1 11980 
Ribo-SPIA 1260234 436671 34,64 % 100% 100% NC_038711.1 11980 
M Segment 
SISPA 2288576 312268 13,64 % 99.54 % 99.41 % NC_038710.1 4575 
Ribo-SPIA 1260234 143252 11,36 % 100% 100% NC_038710.1 4575 
S Segment 
SISPA 2288576 204905 8,95 % 98.92 % 98.33 % NC_038709.1 1677 
Ribo-SPIA 1260234 46299 3,67 % 100% 99.88 % NC_038709.1 1677 
a 'R1+R2' indicates paired end sequencing 
 
Figure 3.3 shows the percentage of reads mapping to the human genome 
reference and specifically to human ribosomal sequences. The Ribo-SPIA® protocol 
yielded a higher percentage of reads mapping to both with 33.70% and 6.25% total 
reads mapping to the complete human genome and ribosomal sequences 
respectively, compared to the SISPA protocol which are lower; 17.22% to human and 
0.15% to ribosomal references (Table 3.2).  
  




Figure 3.3 Proportion of reads mapping to the human genome and human ribosomal 
sequences.  
The percentage of total reads mapping to each appropriate reference sequence with read 
percentage mapping to human shown on the left and to ribosomal on the right. 
 
Table 3.2 Description of sequencing mapping data to human and ribosomal sequences for 

















SISPA 2288576 394105 17.22 % 3369 0.15 % 
Ribo-SPIA 1260234 424817 33.70 % 78817 6.25 % 
a 'R1+R2' indicates paired end sequencing 
 
The coverage depth of reads mapped across the segments for each approach 
is shown in Figure 3.4, the actual depth is a function of the total reads sequenced as 
the read levels are not normalised. A 20x depth per location is achieved in both cases 
for all three segments.  
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Figure 3.4 Coverage depth across the HAZV viral genome, (n = 2 samples).  
Each graph corresponds to a HAZV segment. Read depth (y-axis) across the genome (x-axis) 
following reference alignment is shown. SISPA coverage is shown in black and Ribo-SPIA® 
coverage is indicated in grey. Total depth has not been normalised; comparison is to show 
overall pattern of coverage. Dotted horizontal line indicates depth of 20x coverage, used for 
consensus calling. 
3.3.2 Clinical sample assessment 
 
To further evaluate and compare the two protocols using genuine clinical 
samples, four DENV positive clinical samples (two serum and two plasma) were 
selected based on real-time qRT-PCR Ct value from samples identified positive in 
RIPL diagnostic laboratories, PHE, Porton Down. Samples were selected to include 
one low (DENV 3, Ct: 17.76), two medium (DENV 8, Ct: 24.8 and DENV 9, Ct: 25.28) 
and one high (DENV11, Ct: 28.69) Ct value samples. DENV samples selected were 
prepared using both the SISPA and Ribo-SPIA® protocols and sequenced. The 
proportion of reads mapping to the respective DENV viral reference was significant 
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for all four samples (Figure 3.5, Table 3.3, Table 3.4), with the lowest proportions of 
reads mapping observed in the samples prepared with the Ribo-SPIA® approach. 
 
 
Figure 3.5 Comparison of SISPA and Ribo-SPIA® results, as to proportions of reads 
mapping to the appropriate reference viral sequence, and proportion of reference 
genome sequenced at minimum 20-fold and 20-fold coverage (n = 4 samples).  
The percentage of total reads mapping to the appropriate reference sequence is plotted in the 
upper panel. The middle panel displays the percentage of reference genome sequenced to a 
minimum depth of 10-fold in the data generated and the lower panel displays the percentage 
of the reference genome sequenced to a minimum depth of 20-fold in the data generated.  
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Table 3.3 Description of samples positive for DENV with corresponding reference sequences 
used for mapping. 





DENV 3 17.67 Plasma DENV 2 NC_001474.2 10723 
DENV 8 24.8 Serum DENV 3 NC_001475.2 10707 
DENV 9 25.28 Plasma DENV 2 NC_001474.2 10723 
DENV11 28.69 Serum DENV 1 NC_001477.1 10735 
aDENV serotype is also indicated 
 
Table 3.4 Description of samples positive for DENV with corresponding Illumina mapping data 
for SISPA and Ribo-SPIA . 













DENV 3 17.67 
SISPA 738814 691805 93.64 % 99.59 % 99.59 % 
Ribo-SPIA 397712 273045 68.65 % 98.92 % 98.89 % 
DENV 8 24.8 
SISPA 777264 544315 70.03 % 99.59 % 99.56 % 
Ribo-SPIA 90116 6565 7.29 % 76.02 % 60.49 % 
DENV 9 25.28 
SISPA 787728 214347 27.21 % 98.82 % 98.78 % 
Ribo-SPIA 670376 7435 1.11 % 85.78 % 81.65 % 
DENV 11 28.69 
SISPA 1034698 38641 3.73 % 94.71 % 94.45 % 
Ribo-SPIA 459622 943 0.21 % 25.47 % 12.87 % 
a‘R1+R2’ indicates paired-end sequencing 
 
The read proportion per sample showed good concordance with clinical Ct 
values. Sample DENV3 with the lowest Ct value (Ct: 17.67) had the highest mapped 
read percentages observed for both protocols used, 93.63% with SISPA and 68.65% 
with Ribo-SPIA®. In sample DENV8 and DENV9 with mid-Ct values (Ct: 24.8 and Ct: 
25.28 respectively), the percentage of reads mapping was lower, 70% and 27.21% 
with the SISPA protocol and 7.29% and 1.11% with the Ribo-SPIA® protocol 
respectively. Whilst in the high Ct sample (DENV11, Ct: 28.69) the viral proportion 
drop to 3.73% with SISPA and 0.21% with Ribo-SPIA® protocol.  
Figure 3.5 and Table 3.3 show the percentages of reads mapping to the 
appropriate viral reference along with the 10-fold and 20-fold genome coverage 
percentage. Using the Ribo-SPIA® approach only DENV3 (Ct: 17.67) had a genome 
coverage over 90% for both 10x and 20x genome coverage. Using the Ribo-SPIA® 
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protocol, DENV9 (Ct: 25.28) had a genome coverage of 85.78% at 10x and 81.65% 
at 20x, followed by DENV8 (Ct: 24.8) which had 76.92% and 60.49% respectively; 
the lowest genome coverage observed was for DENV11 (Ct: 28.69) with 25.46% at 
10x and 12.87% at 20x. On the contrary, all of the SISPA sequenced DENVsamples 
returned over 90% genome coverage at 10x and 20x, irrespective of lower mapping 
percentages at the mid and high Ct value samples (DENV9 and DENV11).  
Figure 3.6 and Table 3.5 shows the percentages of reads mapping to the 
human genome reference and to human ribosomal sequences for each DENV 
sample and for each protocol. The Ribo-SPIA® protocol yielded a higher percentage 
of reads mapping to both whole human genome and ribosomal sequence across all 
four samples with the higher Ct samples presenting higher percentages mapped for 
both. When mapping to the human genome the lowest percentage observed was for 
sample DENV3 (Ct:17.67), 20,18% with the Ribo-SPIA® approach 1.65% with the 
SISPA approach. The highest percentage for each approach was 80.32% for Ribo-
SPIA® and 56.39% for SISPA, for samples DENV9 (Ct: 25.28) and DENV11 (Ct: 
28.69) respectively. The lowest percentage of total reads mapping to ribosomal 
sequences was 14.8% with the Ribo-SPIA® protocol and 0.75% with the SISPA, both 
resulting from sample DENV3 (Ct: 17.67). The highest percentage observed for the 
Ribo-SPIA® protocol was 92% and for the SISPA protocol 49%, both for sample 
DENV9 (Ct: 25.28).  
 
 
Figure 3.6 Proportion of reads mapping to the human genome and human ribosomal 
sequences in each DENV positive sample (n = 4 samples).  
The percentage of total reads mapping to each appropriate reference sequence with read 
percentage mapping to human shown on the left and to ribosomal on the right. 
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Chapter 3           Method evaluation for metagenomic sequencing of RNA viruses 
 119 
Figure 3.7 shows coverage depth of reads mapped across the relevant genome for 
each sample sequence by both the Ribo-SPIA® and SISPA protocol. Read levels are 
normalised thus depth is a function of the same number of total reads sequenced. 
 
 
Figure 3.7 Coverage depth across the DENV genome (n = 4 samples).  
Each graph corresponds to a given sample defined by its Ct value. Read depth (y-axis) across 
the genome (x-axis) following reference alignment is shown. SISPA coverage is shown in 
black and Ribo-SPIA® coverage is indicated in grey. Total depth has been normalised; 
comparison is to show the comparison in depth of coverage between the two methods. Dotted 
horizontal line indicates depth of 20x coverage, used for consensus calling. 
 
As seen in Table 3.5 all Ribo-SPIA® prepared DENV samples generated a 
lower total number of reads compared to the SISPA prepared DENV samples, thus 
SISPA generated reads were down-sampled randomly using fastq-sample (337) to 
create a corresponding subset normalised to match the number of total reads 
generated by the equivalent Ribo-SPIA® prepared sample (Table 3.6). The SISPA 
protocol percentage of reads mapping to the virus is significantly higher than the Ribo-
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SPIA® protocol and despite the down-size of the SISPA total read number the 20-fold 
depth of the genome is >90% for all four DENV samples (Figure 3.7, Table 3.6). For 
DENV3 (Ct:17.67) both protocols generated comparable 20-fold genome coverage, 
98.89% with Ribo-SPIA® and 99.51% with SISPA. For the remaining three DENV 
samples the Ribo-SPIA® 20-fold genome coverage drops to 60.49% (DENV8, Ct: 
24.8), 81.65% (DENV9, Ct: 25.28) and 12.87% (DENV11, Ct: 28.69). Contrary to the 
Ribo-SPIA® drop in genome coverage at 20-fold the percentage of genome coverage 
for the SISPA remained above 90% for all DENV samples: 98.91% (DENV8, Ct: 24.8), 
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Sequencing of the HAZV mock sample using the SISPA and Ribo-SPIA® 
protocol yielded comparable results and despite their difference in total reads 
mapping to the virus reference sequences both approaches results in >98% genome 
coverage at 20-fold depth for all three segments demonstrating the promising 
potential of the SISPA protocol for metagenomic sequencing of RNA viruses. A higher 
percentage of total reads mapping to the viral reference (Figure 3.1, Table 3.1) and a 
lower percentage of reads mapping to human and ribosomal sequences (Figure 3.2, 
Table 3.2) was observed for the SISPA protocol, explained by the abundance of 
oligo(dT) primers in the first strand cDNA synthesis from template RNA of the Ribo-
SPIA® protocol. Nevertheless, both protocols were successful in generating sufficient 
viral reads for the recovery of complete/near-complete viral genome sequences 
(Figure 3.1, Table 3.1) and good coverage across the viral segments (Figure 3.3).  
The additional evaluation of the two protocols using four DENV positive 
clinical samples demonstrated that the SISPA protocol outperformed the Ribo-SPIA® 
method, both in percentage of total reads mapping and genome consensus coverage 
of the virus of interest. An increase in Ct value coincided with a decreased proportion 
of viral reads in both protocols, however the percentage of SISPA-generated viral 
reads were substantially higher compared to the Ribo-SPIA® ones. The percentage 
of viral reads obtained by the Ribo-SPIA® protocol were 68.65% (DENV3, Ct:17.67), 
7.29% (DENV8, Ct:24.8), 1.11% (DENV9, Ct:25.28) and 0.21% (DENV11, Ct:28.69), 
compared to 93.64%, 70.03%, 27.21% and 3.73% respectively with the SISPA 
approach. A difference in total percentage of reads mapping to the virus was expected 
as it was also observed with the HAZV mock sample, although it was not anticipated 
to be as significant as was observed. The difference between the two methods is 
further highlighted by the depth and coverage of genomic information recovered for 
each sample with each approach. The Ribo-SPIA® protocol achieved 20-fold genome 
coverage of 98.89% (DENV3, Ct:17.67), 60.49% (DENV8, Ct:24.8), 81.65% (DENV9, 
Ct:25.28) and 12.87% (DENV11, Ct:28.69), which is notably less compared to the 
SISPA genome coverage (DENV3: 99.59%, DENV8: 99.56%, DENV9: 98.78%, 
DENV11: 94.45%) particularly for sample DENV8 and DENV11. As expected DENV3 
with the lowest Ct value (Ct: 17.67) had the highest percentage of reads mapping to 
DENV for both protocols and DENV11 with the highest Ct value (Ct: 28.69) had the 
lowest percentage of reads mapping to DENV. Despite the lower percentage of reads 
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mapping to the virus, the number of reads was sufficient to succeed a 20-fold genome 
coverage of >90%.  
To determine the background nucleic acid levels present in each sample, 
reads were mapped to the human genome and to ribosomal sequences; percentages 
of reads mapping to each were higher for samples sequenced with the Ribo-SPIA® 
approach. The lowest percentages were observed for DENV3 (Ct: 17.67) which had 
20.18% reads mapping to human and 14.87% to ribosomal with the Ribo-SPIA® 
protocol, compared to 1.66% and 0.75% respectively with the SISPA protocol. Much 
higher percentages were observed for samples DENV9 and DENV11 particularly with 
the Ribo-SPIA® protocol, for example from the total DENV9 Ribo-SPIA® reads 
generated 80.33% mapped to the human genome and 92.14% to ribosomal 
sequences, notably the respective percentages from the total DENV9 SISPA reads 
were 53.15% and 49.53%. 
The Ribo-SPIA® protocol has been shown to generate full-length genomes 
from clinical samples for HIV, respiratory syncytial virus, West Nile virus (335) and for 
three EBOV samples (336). However, despite these previous findings it was not as 
successful in generating complete viral genomes for all four DENV samples 
investigated. The high yield of viral sequences from clinical DENV samples using the 
SISPA protocol along with the near-complete genome sequences generated for all 
four DENV samples with different Ct values and three different DENV serotypes 
(DENV 3: DENV 2, DENV 8: DENV 3, DENV 9: DENV 2 and DENV 11: DENV 1) 
highlights the benefits and potential of a metagenomic approach to elucidate genomic 
sequences of RNA viruses directly from clinical samples. Evaluation of the two 
protocols on DENV clinical samples demonstrates that the total percentage of viral 
reads and the percentage of viral genome recovery is higher with the SISPA protocol 




The initial comparison of the two methods using the HAZV mock sample 
yielded comparable results and despite a difference in total reads mapping to the 
virus, sufficient viral reads were generated to obtain near-complete viral genomes for 
both methods. The subsequent sequencing of the four DENV diagnostic samples 
allowed for the comparison of the two protocols using genuine clinically relevant 
samples. The SISPA protocol outperformed the Ribo-SPIA®, leading to higher 
percentages of total reads mapping to the virus and near-complete genomes (>95% 
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coverage at 20-fold) for all four DENV samples. The SISPA protocol results 
demonstrate its unbiased sequencing potential for pathogen identification and 
complete viral genome recovery and its previous successful coupling with the MinION 
for viral detection (308) makes it particularly promising for rapid portable 
metagenomic sequencing. To investigate the SISPA protocol capabilities further and 
determine its sensitivity it was taken forward for further testing using a selection of 
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4. Chapter 4. Metagenomic Sequencing for Clinical 
Sample Investigation: Assessing the range of 




To investigate the feasibility of metagenomic sequencing for recovering whole 
genome sequences of CHIKV and DENV from clinical samples, a total of 26 samples 
with a representative range of clinical Ct values were tested. Direct metagenomic 
sequencing of nucleic acid extracts from serum and plasma without viral enrichment 
was performed using both the Illumina MiSeq and the portable Oxford Nanopore 
MinION. The approach successfully allowed for virus and coinfection identification, 
subtype determination and in the majority of cases elucidated complete or near-
complete genomes adequate for phylogenetic analysis.  It was demonstrated that 
metagenomic whole genome sequencing is feasible for the majority of CHIKV and 
DENV PCR-positive patient serum/plasma samples and the use of MinION 
metagenomic sequencing was successful for both viruses, highlighting the 
applicability of this approach to front-line public health and potential portable 
applications utilizing the MinION. 
4.2 Introduction 
 
Human disease outbreaks caused by arboviruses have increased in 
prevalence over recent decades; led by the spread of mosquito-borne arboviruses 
such as YFV, CHIKV, DENV, WNV, and ZIKV viruses across both hemispheres (2). 
CHIKV and DENV are of particular global health concern, as they have lost the need 
for enzootic amplification and consequently have caused extensive epidemics (3). 
Their recent global emergence causes significant human disease and their common 
vectors, symptoms and geographical distribution make their diagnosis both important 
and challenging. Circulation of CHIKV and DENV (and other arboviruses) in the same 
areas leads to challenges in differential diagnosis, especially in endemic regions in 
which diagnosis is predominantly symptom-based and in cases of arboviral 
coinfections, reports of which have increased in recent years (32). Genome 
sequencing using a metagenomic approach could prove useful for their differentiation 
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as it has the potential to both identify a viral pathogen present in a clinical sample and 
provide genomic level data for downstream analysis. 
Metagenomic sequencing of CHIKV was demonstrated in principle on the 
MinION by Greninger et al. in 2015 reporting the detection of CHIKV from a human 
blood sample (28). Additionally, metagenomics identified CHIKV coinfections within 
a ZIKV sample cohort (29), with a high proportion of CHIKV reads present making it 
a promising target for the approach. To test the feasibility of direct metagenomic 
sequencing for both DENV and CHIKV genomes across a representative range of 
viral loads a cohort of clinical serum and plasma samples across a representative 
range of viral loads were selected. The objective was to assess the proportion of viral 
nucleic acid present in each sample and determine the sequencing limits for whole 
genome retrieval using both the laboratory based Illumina technology and the 
portable MinION platform.  
4.3 Results 
4.3.1 Clinical samples viral load distribution 
 
A total of 73 samples tested during 2016 in RIPL, PHE Porton Down, were 
positive by real-time qRT-PCR for CHIKV, and 368 were positive for DENV. Median 
Ct for CHIKV was 26.1, for DENV it was 26.8. To assess the feasibility of direct 
metagenomic sequencing of CHIKV and DENV genomes from patient serum/plasma, 
a set of positive samples were selected from samples collected during 2016 in the 
RIPL, PHE, Porton Down. For each virus, samples representing the range of viral 
titres seen during 2016 were selected, based on Ct value (Figure 4.1). CHIKV 
samples selected (n = 14) ranged from Ct 14.72 to Ct 32.57, corresponding to 1010 
and 105 genome copies per ml of plasma or serum. DENV samples selected (n = 12) 
ranged from Ct 16.29 to Ct 31.29, corresponding to 109 and 105 genome copies per 
ml (Table 4.1).  
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Figure 4.1 Cycle threshold values distribution of CHIKV (n = 73) and DENV (n = 368) 
positive samples from the Rare and Imported Pathogens Laboratory (n = 441 total 
samples).  
The 14 CHIKV and 12 DENV samples selected for this work are indicated by circles. For each 
virus, the median Ct value of positive samples by quantitative real-time PCR is shown 
(horizontal line inside box), as well as, 25th and 75th percentiles (box lower and upper 
boundaries) and total range (whiskers). 
4.3.2 Metagenomic MiSeq sequencing  
 
To measure the proportion of viral nucleic acid present relative to 
host/background and assess achievable genome coverage, all samples were 
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The proportion of total reads mapping to the respective viral reference was 
higher than anticipated for both viruses (Figure 4.2). In some low Ct samples, over 
90% of reads mapped to the viral reference and proportions over 50% were still 
observed at mid-Ct range (Ct values between 20 and 25). The lowest proportion of 
reads mapping to the viral reference was 5.03% and 0.47% for CHIKV and DENV 
respectively (Table 4.1, Table 4.2, Figure 4.2). The majority of samples returned over 
95% genome coverage at 20x (21/26 samples) and over 98% genome coverage at 
10x (20/26 samples). Irrespective of lower mapping percentages in high Ct value 
samples, genome coverage of 88.5% (20x) and 89.4% (10x) for CHIKV and 75.0% 
(20x) and 77.8% (10x) for DENV was observed.  
 
 
Figure 4.2 Proportion of reads mapping to the appropriate viral reference sequence and 
proportion of reference genome sequenced at minimum 20-fold coverage in each 
CHIKV or DENV positive sample (n = 26 samples).  
The percentage of total reads mapping to the appropriate reference sequence is plotted in the 
upper panel. Lower panels display the percentage of the reference genome sequenced to a 
minimum depth of 20-fold in the MiSeq data. 
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A loose trend is observed between Ct value and proportion of viral reads, with 
a high level of per sample variation. The two lowest viral titre CHIKV samples (13 & 
14) have similar Ct values (32.2 & 32.57) but vary significantly in the proportion of 
reads that are viral in origin (5.03% & 21.72%) (Figure 4.2, Table 4.1). The 5.03% 
viral reads in CHIKV13 is the lowest for CHIKV, yet still sufficient to generate 88.5% 
of the CHIKV genome at 20x depth from just ~662,000 paired-end reads. This amount 
of genomic information is highly informative and further sequencing would very likely 
increase coverage. Of all diagnostic samples tested in 2016 only 7 of the 73 CHIKV 
samples had a Ct greater than 32.2 (including sample CHIKV14) (Figure 4.1), which 
clearly indicates that for the great majority (>90%) of CHIKV PCR positive samples 
the viral load is sufficient for genome sequencing directly from patient samples 
without further enrichment beyond a simple DNAse digestion (Figure 4.1). For the 
DENV samples, the lowest viral read proportion observed was 0.47% in DENV 12, Ct 
31.29 (Figure 4.2, Table 4.2). This generated 71.5% coverage at 20x depth 
(increased to 77.8 at 10x depth) from just 687,000 paired end MiSeq reads and 
allowed for DENV serotype identification. Only 62 of the 368 DENV cases in 2016 
had a higher Ct, predicting that >80% of PCR positive DENV samples have a viral 
load sufficient for genome sequencing (Figure 4.1). 
4.3.3 Metagenomic MinION sequencing  
 
 Four representative samples for each virus were selected for MinION 
sequencing. Samples were selected with low, mid and high Ct values. CHIKV 1, 
CHIKV 3, CHIKV 4 and CHIKV 9 (Ct values: 14.72, 21.41, 22.74 and 30.08) and 
DENV 1, DENV 2, DENV 6, DENV 11 (Ct values: 16.29, 16.85, 21.22 and 28.69). 
Total cDNA from the SISPA preparation was used as input for the sequencing library 
preparation and sequenced individually on a single flow cell. Details on total input 
amounts, sequencing kit and flow cell information for each sample can be found in 
Table 4.3. Total 1D reads generated for each run varied between 203,000 and 
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Figure 4.3 shows the percentages of reads mapping to viral reference which 
were generally concordant with the MiSeq data, although a slight decrease is 
observed across the range of Ct values. In the MinION data the highest mapped read 
percentages observed were 85.12% and 72.14% for CHIKV 9 and DENV 2 
respectively, compared to 95.23% and 92.56% in the MiSeq data from the same 
samples. Whilst in high Ct samples the viral proportion drops to 4.08% for CHIKV 9 
and 2.90% for DENV 11, from 6.66% and 3.73% in the MiSeq data. Despite the 
decrease in proportion of mapped viral reads, comparable genome coverage is 
observed at both 20x and 10x (Figure 4.3, Table 4.4) and is even increased compared 
to MiSeq data at lower viral titres, e.g. 100% at 20x for CHIKV 9 compared to 95.98% 
in the MiSeq data and 95.25% for the high Ct DENV 11 sample which generated 
94.44% coverage from the MiSeq data. Differences in precise proportions of viral 
reads seen are likely due to inter-library variation. Differences in genome coverage 
achieved are due to both differences in total reads generated per sample (not 
normalised between platforms) as well as differences in average read length. 
Average read lengths in MinION data ranged from 564 to 886 bp (Table 4.3). 




Figure 4.3 Comparison of MinION and MiSeq results, as to proportions of reads 
mapping to the appropriate reference viral sequence, and proportions of reference 
genome sequenced at minimum 20-fold coverage (n = 8 samples).  
The percentage of total reads mapping to the appropriate reference sequence is plotted in the 
upper panel. Lower panels display the percentage of the reference genome sequenced to a 
minimum depth of 20-fold in the data generated, in dark blue or dark green for the MiSeq 
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Figure 4.4 shows coverage depth of reads mapped across the relevant 
genome for each sample sequenced by both MiSeq and MinION. Read levels are not 
normalised thus actual depth is a function of total reads sequenced, but the pattern 
of coverage seen is highly similar suggesting it is more dependent upon the SISPA 
methodology than sequencing library preparation. From MinION consensus genome 
sequences, between 99.93% and 100% of bases called per sample agreed with the 
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4.3.4 Metagenomic data analysis and co-infection 
identification 
To test the applicability of a metagenomic analysis approach to the data, we 
assessed read taxonomic classification using Kraken (Figure 4.5). The distribution of 
reads classified as CHIKV, DENV, other viruses, bacteria, and archaea/eukaryota 
show a similar pattern for MiSeq and MinION data. The proportion of unclassified 
reads for each sample increased with Ct value, as the proportion of human origin 
reads is higher and the human genome is not represented in the Kraken database 
used. A decrease in the percentage of CHIKV and DENV classified reads is observed 
for MinION data compared to MiSeq, but was sufficient to identify the correct 
predominant virus in all samples. 
  





Figure 4.5 Kraken classification of reads from metagenomic sequencing in (A) CHIKV 
and (B) DENV real-time reverse transcription-PCR positive samples (n = 8 samples).  
Kraken classification distribution comparison for MiSeq (cross-hatched) and MinION data. 
Reads grouped as either CHIKV (blue in panel A), DENV (green in panel B), other viruses 
(brown), archea/eukaryota (orange), bacteria (brown) or unclassified (grey). 
 
Kraken analysis also allowed for the identification of a DENV co-infection in 
sample CHIKV 3, the consensus sequence of which was unique in the sample set, 
A. 
B. 
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eliminating cross-contamination from the DENV positive samples as potential source. 
Kraken classified 0.08% of MiSeq reads and 0.15% of MinION reads as DENV. Using 
reference mapping to validate the finding, 0.22% of MiSeq reads and 0.43% of 
MinION reads mapped to a DENV-1 reference genome. Genome coverage at 20x of 
99.73% and 95.99% was achieved for the primary CHIKV and secondary DENV co-
infection respectively, with a single MinION flow cell.  
4.3.5 De novo assembly 
 
An alternative reference-free approach to read classification de novo 
assembly of the data was attempted using Canu (338) and contig identification using 
Basic Local Alignment Search Tool against the GenBank nt database (BLASTn). 
Table 4.4 lists the longest viral contig length identified in each sample, ranging from 
4.2 Kb (36% of reference genome size) to 10.8 Kb (91%) for CHIKV and 4.7 Kb (44%) 
to 10.1 Kb (95%) for DENV. Identification of the pathogen present without prior 
knowledge would have therefore been possible for all samples. 
4.3.6 Updated MinION library kits 
 
In order to keep up with the rapidly evolving MinION chemistries and flowcell 
developments we repeated the sequencing of the co-infected CHIKV 3 sample 
utilising the MinION 1D2 (SQK-LSK308) and Rapid (SQK-RBK001) kits, currently the 
most accurate and the fastest library preparation kits available, respectively. Using 
the 1D2 kit 74.5% of reads generated mapped to CHIKV and 0.37% to DENV, while 
from the Rapid kit the result was 66.26% and 0.29% respectively (both lower than 
observed in the 2D chemistry). Coverage at 20x for CHIKV was above 99% for both 
kits, and for DENV was 95.04% from the 1D2 and 81.09% from the Rapid kit (Table 
4.5). Coverage depth pattern across the genome for both viruses (Figure 4.6) was 
similar for all library kits tested. Near-maximum coverage for both viruses was 
obtained within 2000 sec (~30 minutes) with the 2D kit, 500 sec (~8 minutes) with the 
1D2 kit and 5000 sec (~85 minutes) with the Rapid kit (Figure 4.7). De novo assembly 
(Table 4.5) produced best CHIKV contigs of 10.7, 11.3 and 11.4 Kb for the 2D, 1D2 
and Rapid libraries respectively and the longest contigs generated for DENV were 
7.5, 2.3 and 4.2 Kb.   
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Read depth across both CHIKV and DENV genomes following reference alignment 
is shown for coinfection sample CHIKV 3, sequenced using four different sequencing 
library preparation/sequencing methods. Total coverage depth has not been 
normalised; comparison is to show overall pattern of coverage is highly similar across 




Figure 4.7 Proportion of genome covered over the course of each sequencing run.  
The percentage of the CHIKV or DENV genome sequenced plotted over the course of the 
MinION sequencing run for each kit version tested. 
 
The 1D data from the Rapid kit was sufficient to call a consensus from 11647/11826 
bases of the CHIKV reference with 179/11826 bases called as ambiguous or too low 
coverage. All bases called were concordant with the MiSeq consensus. A polishing 
step using Nanopolish (320)(320) with a subset of the mapped reads (~100x 
coverage depth) significantly reduced ambiguous calls to 90/11826, introducing a 
single disagreement with the MiSeq consensus (99.99% concordance). Despite 
considerably greater read depth the 1D2 kit called only 11082/11826 due to a higher 
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proportion, 744/11826, of ambiguous base calls. Suggesting 1D reads are most 
suitable for this approach. 
 4.4 Discussion 
 
These results clearly show that there are considerable levels of viral nucleic 
acid present in a large proportion of CHIKV and DENV real-time qRT-PCR positive 
clinical samples, and demonstrate that relatively modest metagenomic sequencing is 
capable of elucidating significant portions of viral genome even for samples with Ct 
values at the higher end of clinical range. A decreased Ct value coincided with an 
increased proportion of viral reads, with a considerable level of variation between 
samples, likely because of the total level of non-viral host/background nucleic acid 
present due to variability between patients or in sample handling during collection, 
storage and testing. For example, the two lowest viral titre CHIKV samples (13 and 
14) have similar Ct values (32.2 and 32.57) but varied significantly in the proportion 
of viral reads (5.03% and 21.72%). The 5.03% viral reads in CHIKV13 is the lowest 
for CHIKV, yet still sufficient to generate 88.5% of the CHIKV genome at 20x depth 
from just ca 662,000 paired-end MiSeq reads. This amount of genomic information is 
highly informative and further sequencing would likely increase coverage. Only seven 
of the 73 total CHIKV diagnostic samples tested in 2016 had a Ct greater than 32.2 
(including sample CHIKV14) (Table 4.1), which suggests that for the majority (> 90%) 
of CHIKV PCR positive samples, viral load is sufficient for genome sequencing 
directly from patient samples without further viral enrichment beyond a simple DNAse 
digestion (Figure 4.4). The lowest viral read proportion observed in the DENV 
samples was 0.47% in DENV12, Ct 31.29, which generated 71.5% coverage at 20x 
depth (increased to 77.8 at 10x depth) from just 687,000 paired end MiSeq reads and 
allowed for DENV serotype identification. Only 62 of 368 DENV cases in 2016 had a 
higher Ct, predicting that > 80% of PCR positive DENV samples have a viral load 
sufficient for genome sequencing (Figure 4.4). These estimates are based on Ct 
range distribution from a single year, results may vary from year to year. 
The high yield of viral sequences from clinical CHIKV and DENV samples 
make the exciting prospect of metagenomic MinION viral whole-genome-sequencing 
feasible, even for lower viral titre samples. Evaluating this on a representative subset 
of our samples demonstrates that viral read proportions are in general agreement 
with that seen for MiSeq sequencing, predicting a similar proportion of real-time qRT-
PCR positive patient samples would be suitable for direct metagenomic sequencing 
on the MinION. Differences in precise proportions of viral reads seen between MiSeq 
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and MinION are likely due to inter-library variation. Differences in genome coverage 
achieved are due to both differences in total reads generated per sample (not 
normalised between platforms) as well as differences in average read length. Of the 
samples tested on the MinION, the lowest titre samples CHIKV 9 and DENV 11 both 
generated near complete genome coverage. 
We repeated the sequencing of the coinfected CHIKV 3 sample using the 
MinION 1D2 (SQK-LSK308) and Rapid (SQK-RBK001) kits. A reduction in viral 
proportion of total reads was observed compared with the 2D kit, which may be due 
partly to the extended storage time of the original samples before retesting. In the 
case of the 1D2 kit, the lower proportion was outweighed by a substantial increase in 
total data generated per flow cell (5 M vs 1.8 M reads). For the Rapid kit, the total 
data produced should be considered in the light of the greatly simplified sample 
workflow and turnaround-time. 
The use of metagenomics to elucidate genomic sequences of RNA viruses 
directly from clinical samples has several obvious benefits in public health 
applications. The primary benefit over targeted methods is the hypothesis-free nature 
of the assay, which allows identification and genomic characterisation of novel or 
unexpected RNA viral agents, either as primary or coinfectants (demonstrated here 
in the CHIKV/DENV coinfection sample), without any prior clinical knowledge. It also 
removes the need for laboratory optimisation of targeted methods, such as primer or 
bait-probe design and testing, and is not subject to escape mutations in target sites 
that afflict targeted sequencing and diagnostic methods. This issue is particularly 
relevant for highly diverse RNA viruses, such as LASV, which are difficult to assess 
using targeted methods, without regular reappraisal (48). 
The principal limitation of the metagenomic approach is the limit of detection. 
The data generated here show that viral titres as low as 105 are sufficient for 
significant genome recovery by this method, but ZIKV is a recent example of a 
pathogen typically present at lower clinical titres, for which targeted methods are an 
absolute requirement (156, 218). For diagnostic purposes real-time qRT-PCR has a 
lower limit of detection, provided the target site is conserved in the pathogen isolate 
tested. Clearly no single method is most suitable for both detection and genotyping 
of all pathogens and each has a role to play in differing circumstances. 
  




These results demonstrate that across the clinically relevant range of viral 
loads an unexpectedly high proportion of reads generated metagenomically from 
CHIKV and DENV clinical samples are viral in origin. Direct metagenomic sequencing 
of nucleic acid extracts from serum and plasma without viral enrichment allowed for 
virus and coinfection identification, subtype determination and in the majority of cases 
elucidated complete or near-complete genomes adequate for phylogenetic analysis. 
Therefore, metagenomic sequencing provides an effective approach for the analysis 
of CHIKV and DENV genomes directly from the majority of real-time qRT-PCR 
positive serum and plasma samples, without the need for culture or viral nucleic acid 
enrichment beyond a simple DNA digestion. The results presented in this chapter 
along with recent improvements in sequencing library preparation and total read 
numbers generated by the MinION, make metagenomic sequencing uniquely 
valuable for whole genome sequencing of these and likely other RNA viruses; 
particularly valuable due to its portability, enabling diagnostic and outbreak support 
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5. Chapter 5. Metagenomic sequencing at the 
epicentre of the Nigeria 2018 Lassa fever outbreak 
5.1 Overview 
 
To evaluate metagenomic nanopore sequencing for the recovery of whole 
viral genome sequences from clinical samples of a divergent virus in a remote and 
resource-limited setting, metagenomic nanopore sequencing of LASV was 
implemented at ISTH, Edo State, Nigeria during the 2018 season. The original pilot-
scale study was expedited as the 2018 Nigerian Lassa fever season saw the largest 
ever recorded upsurge of cases, raising concerns over the emergence of a strain with 
increased transmission rate. A total of 120 samples were sequenced in-country and 
on-site computational analysis facilitated the generation of 36 near-complete LASV 
genomes. The real-time analysis of the 36 genomes and the subsequent confirmation 
using all 120 samples sequenced in the country of origin revealed extensive diversity 
and phylogenetic intermingling with strains from previous years, suggesting 
independent zoonotic transmission events and thus allaying concerns of an emergent 
strain or extensive human-to-human transmission. 
5.2 Introduction 
 
Portable field methodologies are vital for pathogen monitoring, especially 
when epidemics and outbreaks occur in resource-limited settings. Real-time field 
nanopore sequencing utilising PCR-amplicon based approaches provided important 
data during the 2014-2016 EBOV outbreak in West Africa (147) the 2015-2016 ZIKV 
epidemic (218) and the 2016-2017 YFV outbreak in Brazil (156, 219). However such 
an approach is extremely challenging for highly variable pathogens such as LASV, 
for which even PCR-based laboratory diagnosis poses a significant challenge, due to 
its high inter-strain nucleic acid sequence variation (48). Designing targeted whole-
genome sequencing approaches, such as PCR amplicons or bait/capture probes, 
without prior knowledge of the specific LASV lineage to target is therefore impractical. 
Chapters 3 and 4 highlighted the feasibility of retrieving complete viral genomes 
directly from patient samples at clinically relevant viral titres using this approach for 
DENV and CHIKV (339).  
A pilot study was designed to establish and evaluate field metagenomic 
sequencing using the MinION in a resource limited setting during a LASV season in 
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an endemic region of Nigeria. The aim was to test and troubleshoot metagenomic 
MinION sequencing on-site, alongside conventional diagnostic capacity and to 
generate complete consensus sequences for this highly diverse pathogen. Our pilot 
study was expedited, due to a large upsurge in the number of cases compared to 
previous years, which raised concerns over the emergence of a strain with increased 
transmission rate. This chapter describes the application of metagenomic sequencing 
for LASV in a resource-limited setting during a seven-week deployment at ISTH, Edo 
State, concurrent with the 2018 LASV season. A total of 120 LASV positive samples 
were sequenced during the seven week deployment, selected from the 376 cases 
reported by ISTH between 1st January and 16th March 2018. To reflect the 
geographic case distribution of the outbreak, the majority of samples originated from 
Edo state followed by Ondo and Ebonyi. Samples selected covered the wide range 
of clinical viral loads observed, including several samples testing negative in one of 
the two real-time qRT-PCR assays used. To understand the molecular epidemiology 
of this upsurge metagenomic nanopore sequencing was performed directly on this 
representative set of patient samples and genomic data along with phylogenetic 
reconstructions were communicated immediately to Nigerian authorities and the 
WHO to inform the public health response.  
5.3 Results 
5.3.1 Metagenomic MiSeq Sequencing 
 
Positive LASV samples were selected from a cohort of samples collected 
during the Nigerian endemic seasons of LASV in 2014, 2016 and 2017. Samples (n 
= 15) were selected to represent the range of Ct values observed during the endemic 
seasons, based on the Altona real-time qRT-PCR assay Ct values and ranged from 
Ct 14.55 to Ct 33.44 (Table 5.1). To measure the proportion of viral nucleic acid 
present relative to host/background and assess the genome coverage, all samples 
were processed as described in Section 2.8 and MiSeq sequenced as described in 
Section 2.9.  
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Table 5.1 Description of samples positive for LASV by Altona real-time reverse transcription-
PCR and Ct values for the ones also tested by Nikisins real-time reverse transcription-PCR (if 
none is stated information is not available) with corresponding MiSeq reads (n = 15 samples) 









LASV01 2016 14.55 None Serum 480136 
LASV02 2017 16.75 18.34 Serum 726608 
LASV03 2016 16.92 None Serum 648097 
LASV04 2014 18.66 None Serum 641387 
LASV05 2017 19.42 19.25 Serum 559097 
LASV06 2017 21.01 21.22 Serum 758812 
LASV07 2017 23.07 None CSF 850114 
LASV08 2017 24.50 None Serum 487299 
LASV09 2017 25.66 None Serum 567651 
LASV10 2017 26.07 None Serum 868797 
LASV11 2017 28.97 19.02 Serum 790793 
LASV12 2017 30.71 None Serum 724618 
LASV13 2017 31.82 None CSF 446391 
LASV14 2017 32.32 None Serum 633164 
LASV15 2017 33.44 None Serum 839807 
a ‘R1+R2’ indicates paired-end sequencing 
 
Due to the diversity of LASV a de novo approach was used to assemble the 
data and the generated contigs were entered in a blastn search to identify the most 
suitable reference for read mapping to generate consensus. Six samples assembled 
a substantial proportion of the L Segment (>50%) and 5 generated significant contigs 
(>14% of the L Segment). For the majority of the samples (n = 11) near complete (> 
75%) S Segments were de novo assembled. Contigs generated were sufficient for 
the identification of L segment reference sequences for 14 samples and for the 
identification of S segment reference sequences for all 15 samples (Table 5.2).  
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Table 5.2 Summary of LASV positive sample de novo assemblies and reference identification 





Max de novo 
contig L 
segment 







LASV01 14.55 6942 3591 KM822052.1 KM822014.1 
LASV02 16.75 3196 3329 LC387475.1 GU481068.1 
LASV03 16.92 6066 3417 KM822087.1 KM822088.1 
LASV04 18.66 5726 3496 KM821956.1 KM821957.1 
LASV05 19.42 1066 411 KT992433.1 MK107930.1 
LASV06 21.01 3090 2945 MH053570.1 MH053573.1 
LASV07 23.07 7321 3458 KM822048.1 KM822049.1 
LASV08 24.50 647 2630 MH053547.1 MH053575.1 
LASV09 25.66 279 1247 MH053479.1 MH053468.1 
LASV10 26.07 1482 3409 MH053547.1 MH053586.1 
LASV11 28.97 6982 3447 MH053469.1 MH053472.1 
LASV12 30.71 4592 2832 KM822061.1 KM822089.1 
LASV13 31.82 2337 2758 MH887950.1 KM822101.1 
LASV14 32.32 410 860 KM822083.1 GU481076.1 
LASV15 33.44 - 815 NA MH053528.1 
 
The proportion of total reads mapping to the respective reference was low 
across the whole range of Ct values (Table 5.3, Figure 5.1). For both segments 
combined the highest proportion (41.18%) was observed for sample LASV01 with Ct 
value 14.55, followed by sample LASV11 (Ct value: 28.97, reads mapping: 12.69%), 
LASV07 (Ct value: 23.07, reads mapping: 6.27%) and LASV04 (Ct value: 18.66, 
reads mapping: 4.10%). Figure 5.1 shows the percentages of reads mapping to the 
respective viral reference for each segment separately along with the 20x percentage 
genome coverage succeeded for each. Irrespective of the relatively low amount of 
total reads mapping to LASV, genome coverage (20x) of >80% was observed for 7 
samples for the L segment and 9 samples for the S segment. A genome recovery of 
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Figure 5.1 Proportion of reads mapping to the appropriate viral reference for each 
segment separately and proportion of reference genome recovered at minimum 20-fold 
coverage for each segment (n = 15 samples).  
The percentage of total reads mapping to each segment reference is plotted in the upper 
panel. Lower panels display the percentage of the segment reference genome sequenced to 
a minimum depth of 20-fold in the MiSeq data. 
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5.3.2 Platform comparison and nanopore method validation 
 
A subset of LASV samples were selected from the cohort of samples identified 
positive during the 2018 Nigerian outbreak. A total of 14 samples were randomly 
selected for sequencing on both platforms, with samples covering a range of Altona 
real-time qRT-PCR assay Ct values (Ct: 14.4 - 27.49) and one LASV positive sample 
that was not tested by Altona real-time qRT-PCR assay. To measure the proportion 
of LASV nucleic acid present, assess the genome coverage and to optimise the 
MinION data analysis pipeline by comparing the consensus sequences generated 
with both the MinION (Oxford Nanopore) and MiSeq (Illumina) platform, all samples 
were processed as described in Section 2.8, Nanopore sequenced as described in 
Section 2.10 and MiSeq sequenced as described in Section 2.9 (Table 5.4). Reads 
were de novo assembled following data processing as described in Section 2.11 and 
Section 2.20.3 and contigs generated were used for the identification of appropriate 
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For both segments combined the total percentage of reads mapping to LASV 
were comparable with the majority of samples presenting with less than 5% difference 
between the two platforms (Table 5.4). Sample ISTH-2018-72 (Altona Ct: 22.63) was 
the only sample to present with a percentage difference of reads mapping to LASV 
above 10%, with 16.48% for the MinION and 0.22% for MiSeq. The least difference 
was observed for sample ISTH-18-021 (Altona Ct: 23.82), with 2.97% for MinION and 
2.94% for MiSeq. Figure 5.2 shows the percentage of reads mapping to the respective 
viral reference for both platforms used and for each segment separately, additional 
information with the 20x percentage genome coverage succeeded for each can be 
found in Figure S2, Table S1 and Table S2. Genome recovery of >95% was 
succeeded for all MinION generated genomes and for all MiSeq ones except the L 
segment sequences of sample ISTH-2018-75, ISTH-2018-72 and ISTH-2018-074 
which had a 20x genome coverage of 87.43%, 87.2% and 72.69% respectively.  
 
 
Figure 5.2 Proportion of reads mapping to the appropriate viral reference for each 
segment separately (n = 14 samples).  
The percentage of total reads mapping to each segment is plotted for each sample and for both 
platforms.  
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Consensus sequences were generated for all MiSeq samples as described in 
Section 2.12.2 and for the MinION data two analysis options were investigated to 
identify the best approach for the generation of high-confidence consensus 
sequences for phylogenetic inference. Both basecalled reads and raw signal data 
were mapped to the reference sequence identified and variants were called using 
Nanopolish software, as developed for the West African Ebola virus disease outbreak 
(147); an additional consensus sequence was generated using the Nanopolish 
consensus and remapping basecalled reads to apply a further round of correction, 
the pileup script called bases at a minimum depth of 20x and 70% support fraction 
(Section 2.12.2). Consensus sequences generated from the MinION sequencing data 
were compared to the MiSeq generated consensus sequences. The Nanopolish 
MinION consensus sequences reached an accuracy level of >99% for the L Segment 
and >98% for the S segment and the Nanopolish/pileup consensus sequences 
reached ≥ 99.9%, matching their MiSeq counterparts with little to no divergence and 
confirming the accuracy of the Oxford Nanopore using this approach (Table 5.5, 
Table S3). Following these results, the MinION data analysis pipeline was finalised 
and Figure 5.3 presents the workflow used for the MinION consensus generation. 
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Table 5.5 Summary of nucleotide differences between MiSeq generated consensus and 
MinION generated consensus sequences using Nanopolish and Nanopolish with an 








Length Nanopolish Nanopolish/Pileup 
L Segment 
ISTH-2018-073 14.4 21.18 7260 59 4 
ISTH-2018-119 17.33 16.36 7258 49 2 
ISTH-2018-126 17.96 20.5 7245 33 0 
ISTH-2018-066 18.74 26.73 7135 3 1 
ISTH-2018-014 19.16 26.42 7245 10 1 
ISTH-2018-131 20.57 25.68 7238 0 0 
ISTH-2018-115 21.00 26.55 7183 6 3 
ISTH-2018-075 22.39 29.74 7256 10 0 
ISTH-2018-072 22.63 34.3 7250 5 0 
ISTH-2018-021 23.82 31.76 7237 5 0 
ISTH-2018-013 24.01 26.02 7230 36 0 
ISTH-2018-074 26.87 32.9 7238 9 0 
ISTH-2018-001 27.49 23.75 7196 37 2 
ISTH-2018-036 None 28.44 7261 7 1 
S Segment 
ISTH-2018-073 14.4 21.18 3406 36 1 
ISTH-2018-119 17.33 16.36 3403 13 2 
ISTH-2018-126 17.96 20.5 3407 2 1 
ISTH-2018-066 18.74 26.73 3393 21 0 
ISTH-2018-014 19.16 26.42 3407 0 1 
ISTH-2018-131 20.57 25.68 3389 5 0 
ISTH-2018-115 21.00 26.55 3387 0 0 
ISTH-2018-075 22.39 29.74 3412 1 0 
ISTH-2018-072 22.63 34.3 3398 0 6 
ISTH-2018-021 23.82 31.76 3385 4 0 
ISTH-2018-013 24.01 26.02 3367 9 0 
ISTH-2018-074 26.87 32.9 3367 1 0 
ISTH-2018-001 27.49 23.75 3490 0 0 
ISTH-2018-036 None 28.44 3387 2 0 
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Figure 5.3 Workflow of consensus sequence generation.  
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5.3.3 Metagenomic MinION Sequencing in a resource-limited setting 
 
A total of 120 samples were sequenced, selected based on Ct value and 
location from the 341 positive cases reported by ISTH between 1st January and 18th 
March 2018. Samples tested positive for LASV by either or both Altona real-time RT-
PCR (targeting S segment) and Nikisins real-time RT-PCR (targeting L segment) and 
represented a diverse range of Ct values. Altona Ct values ranged from 14.4 to 37.87 
and Nikisins Ct values from 16.36 to 41.32 (Figure 5.4). Selected samples covered 
the wide range of clinical viral loads observed, including several samples testing 
negative in one of the two real-time RT-PCR assays used.  
 
 
Figure 5.4 Cycle threshold values distribution of LASV samples tested positive by the 
Altona assay (n = 286) and the Nikisins assay (n = 228) from the Institute of Lassa Fever, 
Research and Control, Irrua Specialist Teaching Hospital (n = 341 first test samples).  
First test samples sequenced (total = 105) are indicated by circles, 97 samples were positive 
by the Altona assay and 101 samples were positive by the Nikisins assay. For each assay, 
the median Ct value of positive samples by quantitative real-time PCR is shown (horizontal 
line inside box), as well as, 25th and 75th percentiles (box lower and upper boundaries) and 
total range (whiskers). 
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The virus diversity and the challenge of LASV diagnosis is highlighted when 
correlating the results of the two diagnostic assays used. Figure 5.5 shows the 
relation of Ct value distributions of the samples sequenced for both assays (n = 103 
for samples that were tested by both assays and found positive in both). An average 
Ct value difference of 5.9 is observed between Altona Ct value and Nikisins Ct value 
for samples that are positive for both assays. A total of 105 samples sequenced were 
first test samples and the remaining 15 samples sequenced were follow-up samples. 
From the 120 samples sequenced, 103 were positive for both assays, 9 were not 
tested and one was found negative by the Altona assay and 8 were negative in the 
Nikisins assay (Table 5.6). 
 
 
Figure 5.5 Cycle threshold value distribution of sequenced LASV positive samples from 
the Institute of Lassa Fever, Research and Control, Irrua Specialist Teaching Hospital 
(n = 120 sequenced samples).  
The distribution of sequenced positive LASV samples Ct values tested with the Altona assay 
are depicted in light grey and with the Nikisins assay in dark grey. 
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Table 5.6 Description of LASV positive samples sequenced 
 PCR Positive –  
First test 
First Test 
Sequenced Total Sequenced 
Sample Number 341 105 120 
Number of samples per results 
Result 
 Altona Nikisins Altona Nikisins Altona Nikisins 
Positive 286 228 97 101 110 112 
Negative 9 111 1 4 1 8 
No real-time RT-PCR results 
(gel-based or not done) 45 2 7 0 9 0 
Number of samples per range of Ct value 
Ct value range Altona Nikisins Altona Nikisins Altona Nikisins 
14 to 30 110 58 88 49 97 55 
30 to 35 87 50 8 34 11 35 
35 to 45 89 120 1 18 2 22 
 
From the total of first sample tests concluded positive (1st of January and the 
18th of March 2018), 80% (88/110) of Altona positive samples with Ct range 14 to 30 
and 77% (83/108) of Nikisins positive samples with Ct range 14 to 35 were sequenced 
(Table 5.6). The correlation between Ct values of the positive samples sequenced for 
the two PCR assays is shown in Figures 5.6, one sample tested negative in the Altona 
assay and eight samples tested negative in the Nikisins assay, demonstrating the 
importance of combined use of both assays for diagnosis of acute Lassa fever and 
subsequent evaluation for sequencing.  
  




Figure 5.6 Correlation between Ct values from Altona and Nikisins real-time RT-PCR 
assays. 
Scatter plot correlating the two assays and including categorisation of the data based on 
patient outcome. Values for samples from survivors are plotted in grey, and those from 
deceased patients in black. One sample tested negative in the Altona assay and eight samples 
tested negative in the Nikisins assay. Negative results have been assigned a Ct value of 45 
to facilitate visualisation. 
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Samples selected showed an even distribution over the different states 
affected during the endemic season. Total first samples tested at ISTH during the 
period of 1st January until the 18th of March and their distribution across the different 
states can be found in Table 5.7. The samples we sequenced correlate with this 
distribution (Table 5.7). Figure 5.7 shows the sample distribution over the different 
states with a choropleth representation of the total positive LASV cases during the 
period we were in-country and orange markers depicting the location of the samples 
sequenced. The majority of the samples originated from Edo state followed by Ondo 
and Ebunyi (Table 5.7, Figure 5.7) 
 
Table 5.7 Distribution of first test positive samples and samples sequenced across the 
different states. 
State 
First test positive 
samples 
(n = 341) 
Samples Sequenced 
(n = 105) 
Taraba 1 0 
Benue 2 0 
Ondo 95 29 
Delta 7 2 
Abia 1 0 
Ebonyi 42 14 
Anambra 6 5 
Edo 162 42 
Bauchi 6 5 
Nasarawa 1 1 
Kogi 10 4 
Imo 4 2 
Ekiti 2 1 
Federal Capital Territory 2 0 
 
 
Chapter 5         Metagenomic sequencing at the epicentre of the Nigeria 2018 Lassa fever outbreak 
 166 
 
Figure 5.7 Annotated map of confirmed Lassa fever cases between 1st January and 
18th of March and of samples sequenced  
(A) Affected states and choropleth annotation per number of cases (B-C) geographical origin 
of patients from whom samples were sequenced (orange markers) 
 
A notable proportion of total reads generated per sample were LASV (L and 
S segment) at an average frequency of 4.26% with a maximum of 42.9% (Figure 5.8). 
Average frequency for the L segment was 2.09% and for the S segment 2,16% and 
a maximum of 20.60% and 24.29% was observed for each segment respectively 
(Figure 5.9), allowing for sufficient genomic sequence (>70%) for phylogenetic 
comparison of at least one segment in 91 of the samples tested (Figure 5.10). 
A B 
C 
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Figure 5.8 Percentage of reads mapping to LASV (L and S segment) depending on Ct 
value in Altona and Nikisins real-time RT-PCR assay.  
Negative results have been assigned a Ct value of 45 to facilitate visualisation. Values of 
samples from survivors are plotted in grey and those from deceased patients are in black.  
  




Figure 5.9 Percentage of reads mapping to each LASV segment depending on Ct value 
in Altona and Nikisins real-time RT-PCR assay.  
The percentage of total reads mapping to the L segment id plotted in the upper panel and to 
the S segment in the lower panel. Values of samples from survivors are plotted in grey and 
those from deceased patients are in black. 
 
The proportion of total reads mapping to LASV reference with a minimum 
depth of 20 reads (20x) is shown in Figure 5.7 for both segments and both assays. 
The pattern is more consistent with samples presenting with a Ct value of 25 and 
below in Altona and Ct value of 30 and below of Nikisins are more consistently 
expected to return sufficient reads for 20x coverage of the reference genome.  
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Figure 5.10 The proportion of total reads mapping to LASV L segment and S segment 
with a minimum depth of 20 reads (20x) depending on Ct value in Altona and Nikisins 
real-time RT-PCR assay.  
The percentage of total reads mapping to the L segment is plotted in the upper panel and to 
the S segment in the lower panel. Values of samples from survivors are plotted in grey and 
those from deceased patients are in black. 
 
Metagenomic classification using the Centrifuge software (326) identified 
0.10% of reads from sample 110 as originating from hepatitis A virus, with read 
mapping providing 74% genome coverage at 20-fold depth. LASV accounted for 
0.83% of reads in the same sample, providing 96% genome coverage. These findings 
demonstrate the potential of this simple approach to identify multiple RNA viruses, 
including those present as co-infections. In all other samples tested, LASV was the 
sole pathogen identified despite a small number of reads classified as other viruses 
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5.3.4 Metagenomic MinION sequencing during the 2018 outbreak 
 
The upsurge of Lassa fever cases during the 2018 endemic season in Nigeria 
was the largest on record, reaching 1,495 suspected cases and 376 confirmed cases 
and affecting more than 18 states by 18 March (Figure 5.12). This notably exceeds 
the 102 confirmed cases reported during the same period in 2017 (Figure 5.12) (340). 
The unprecedented scale of the outbreak raised fears of the emergence of a strain 
with a higher rate of transmission. Due to these concerns, on 28 February the Nigeria 
Centre for Disease Control (NCDC) and the WHO urgently requested sequencing 
information and preliminary results from our pilot-scale study, in which the 
metagenomic approach with the MinION device (Oxford Nanopore Technologies) 
was used to conduct in-country, mid-outbreak viral genome sequencing. This 




Figure 5.12 Epidemiology of the Lassa fever outbreak and timeline of sequencing in 
Nigeria. 
Figure taken from Kafetzopoulou et.al. (303) and generated by S. Duraffour 
(A) Epidemiological curve for 2018. ISTH confirmed 341 of the 376 Lassa fever cases reported 
by Nigeria Center of Disease Control (NCDC) between 1st January and 18th March 2018. The 
epidemiological curve shows the 341 confirmed cases according to patient outcome. (B) 
Number of cases diagnosed and reported by ISTH from 2015 through 2018. (C) Number of 
samples sequenced per epidemiological week in 2018. 
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The request from NCDC for information on circulating strains was made on 28 
February at the height of the outbreak; within 10 days, our pilot study was expedited 
and the initial analysis completed. The total 120 LASV-positive samples selected on 
the basis of cycle threshold value and location of the 341 cases reported by ISTH 
between 1 January and 18 March 2018 were sequenced during a 7-week mission. 
Rapid sequencing and real-time analysis of 35 genomes revealed sequence diversity, 
suggesting independent zoonotic transmission events as the cause; allaying 
concerns of an emergent novel strain. Subsequent analysis of 85 further samples 
sequenced during the outbreak confirmed these findings highlighting the power of 
real-time metagenomic sequencing in outbreaks. The fact that the 2018 outbreak was 
fueled by the circulating LASV diversity and not by transmission of a new or divergent 
lineage was already evident from the first seven genomes generated by 10 March 
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This information was promptly communicated to the NCDC, forming the basis 
of its report released on 12 March 2018 (341). Whereas this first small sample was 
restricted to genotype II, the final collection of 36 LASV genome sequences 
generated on-site also included a representative of genotype III (Figure 5.14), further 
supporting the spillover of long-standing LASV diversity in the outbreak. Consensus 
sequences generated on-site were communicated in four different releases, with the 
first sequences from 7 samples released online on March 12th (342), the following 
from 8 samples on March 15th (343), an additional 12 on the 21st of March and the 
final report on the 4th of April with the total 35 samples sequenced and analysed on 
site (343).  
  




Figure 5.14 Phylogenetic reconstruction of the S segment data.  
(Figure taken from Kafetzopoulou et.al. (303) and generated by P. Lemey).  
The circular tree includes 96 sequences from 2012 to 2017, 88 sequences from 2018, and 
sequences available from GenBank. The rectangular tree focuses on the genotype II clade (in 
blue in the circular tree), which includes most of the 2018 sequences. The six genotypes are 
indicated with different colours and roman numerals. Bootstrap support >90% is indicated with 
a small grey circle at the middle of their respective branches. The colour strip highlights the 
human LASV sequences obtained from previous years (light grey); sequences obtained from 
rodent samples (dark grey); and, for 2018, the first seven sequences generated in Nigeria 
(light pink), the remaining 28 sequences analysed on-site (medium pink), and the remaining 
sequences finalized in Europe (dark pink). The same colour code is used in the genotype II 
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5.4 Discussion 
5.4.1 Pre-deployment testing 
 
The level of viral reads corresponding to LASV are significantly lower 
compared to the ones observed for CHIKV and DENV positive samples (Chapter 4), 
nevertheless metagenomic MiSeq sequencing of the 15 historical LASV samples 
(Section 5.3.1) achieved genome coverage (20x) of >80% for 7 samples for the L 
segment and 9 samples for the S segment. A genome recovery of >50% was 
successful for 9 samples for the L segment and 12 samples for the S segment. The 
Ct values do not directly correlate with the percentage of reads mapping to LASV for 
each sample and despite the low percent of viral reads observed, successful recovery 
of more than 50% of the genome was achieved for 80% of the samples sequenced 
for at least one segment and 60% for both segments (Figure 5.2). The principal 
limitation of the metagenomic approach is the limit of detection, however the results 
presented clearly show the benefit of using this approach for a genetically diverse 
RNA virus, particularly when the diagnostic assay sensitivity is variable due to the 
high inter-strain nucleic acid sequence variation of LASV. Sequencing a Ct value 
range of LASV positive samples allowed for the generation of genomic sequences for 
the majority of the samples tested and provided information on the variation in the 
proportion of reads corresponding to LASV for each sample. Notably samples 
LASV04 (Ct:18.66), LASV07 (Ct: 23.07) and LASV11 (Ct:28.97) with mid-to-high Ct 
values exhibit higher % of LASV than expected with 4.10%, 6.27% and 12.69% of 
reads respectively corresponding to LASV. The high degree of genetic variability of 
the virus, with strain variation up to 32% and 25% for the L and S segment 
respectively (48), creates challenges for its detection and can explain the unexpected 
pattern in read mapping observed. The application of metagenomic sequencing has 
allowed for sufficient genome recovery from the majority of the samples sequenced 
which can provide useful information for assay optimisation and further understanding 
of the virus diversity. 
5.4.2 Nanopore pipeline testing and validation 
 
Cross platform comparison of the 14 positive samples randomly selected from 
the 2018 Nigeria outbreak cohort allowed for the refinement of the MinION analysis 
pipeline. The total percentage of reads mapping to LASV was comparable between 
both sequencing platforms, with the majority of samples presenting a cross-platform 
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difference of less than 5% (Table 5.4, Figure 5.2). Genome recovery of >95% was 
successful for all S segments and of >70% for all L segments allowing for sufficient 
genomic sequence recovery (>70%) for sequence comparison (Figure S2, Table S1, 
Table S2). Consensus sequences generated from both platforms were compared, the 
Nanopolish MinION consensus reached an identity level of ≥99% for the L Segment 
and >98% for the S segment. The Nanopolish/pileup consensus sequences were 
≥99.9% identical to their illumina counterpart with the majority of sequences reaching 
100% or having only one nucleotide difference (no differences: 16/28, single 
nucleotide difference:6/28). Nanopolish/pileup consensus sequences matched their 
MiSeq counterparts with little to no divergence, confirming the accuracy of the Oxford 
Nanopore using this approach. The nucleotide differences identified between the 
MiSeq and the MinION consensus sequences were further interrogated to identify the 
nucleotide disagreements within the coding regions, which were used in phylogenetic 
analysis. Ten of 14 had zero differences in both S or L segment coding regions, whilst 
four had 1-3 nucleotide disagreements in total across the combined S and L coding 
regions. Visual inspection of these regions suggested the basecalling was consistent 
within the read alignment for both the Illumina and Nanopore data and so does not 
appear to be the result of the extra “noise” within the Nanopore signal (Table S4). 
Integrating the additional correction step post Nanopolish generated the most 
accurate consensus, leading to the refined MinION analysis pipeline used (Figure 
5.3). 
5.4.3 In-country sequencing 
 
Demonstrating the utility of metagenomic sequencing for LASV patient 
samples, allowed for the design of a pilot study to evaluate metagenomic sequencing 
in a resource-limited setting using the Oxford Nanopore MinION. Metagenomic 
MinION results clearly show that the amount of viral reads generated are sufficient to 
successfully generate near complete viral genomes for both segments. More than 
70% of each segment was recovered for the majority of the 120 samples sequenced, 
demonstrating that the metagenomic sequencing approach employed is capable of 
elucidating significant portions of viral genome of LASV, a highly divergent RNA virus. 
Ct value does not directly correlate with the proportion of sequencing reads observed, 
presenting with a considerable level of variation between samples, especially within 
the Ct range of 20 to 30 in the Altona assay and 25 to 35 in the Nikisins assay (Figure 
5.9). This variation is most likely attributed to the diversity of LASV and the difficulty 
of designing a RT-PCR which maintains a high sensitivity in detection across all the 
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different LASV circulating LASV. This is highlighted with sample ISTH-2018-025 
which has an Altona Ct value of 21.11 and a Nikisins Ct value of 31.62 but resulted 
in the highest percentage of reads mapping (42.86%) to LASV observed in the whole 
cohort of samples sequenced. From this percentage, 18.57% of the reads were 
attributed to the L segment and 24.29% to the S segment, percentages observed in 
the majority of samples in the lower Ct value range (<20 in Altona and <25 in Nikisins) 
of PCR positive LASV samples. The lowest amount of viral reads observed was 
0.06% for three different samples (ISTH-2018-058, ISTH-2018-080, ISTH-2018-142), 
yet still sufficient to generate 73.49%, 35.97% and 83.45% of the L segment and 
65.95%, 80.11% and 90.78% of the S segment at 20x for each sample respectively. 
Only 29 samples failed to produce sufficient genomic information, the Ct value 
distribution for these samples ranged from 18.76 to 37.87 for the Altona assay and 
from 24.74 to 37.73 for the Nikisins assay, emphasizing the difficulty of using Ct value 
as a successful predictor of read percentage corresponding to LASV. Sufficient 
genomic sequence (>70%) for phylogenetic comparison was successful for at least 
one segment in 91 samples tested and for both segments in 76 of those samples. 
The Ct value range of the successfully sequenced samples ranged between 14.4 to 
33.24 for the Altona assay and 16.36 to 41.32 for the Nikisins assay. Given the 
multiplexing of 6 samples per flow cell and an average of 990,206 reads per sample 
the amount of genomic information generated was highly informative and more 
sequencing depth of the samples with less complete consensus sequences would 
likely increase coverage. These results suggest that for the majority of LASV PCR 
positive samples (> 75%), viral load is sufficient for metagenomic sequencing directly 
from patient samples without further viral enrichment beyond a DNase digestion.  
 
  




Metagenomic nanopore sequencing directly from patient samples was 
deployed for the first time in an outbreak epicentre, during the 2018 Lassa outbreak 
in Nigeria. Genomic data and phylogenetic reconstructions were communicated 
immediately to the Nigerian Centre for Disease Control and the World Health 
Organization to inform the public health response. Real-time analysis of 36 genomes 
and subsequent confirmation using all 120 samples sequenced in the country of origin 
revealed extensive diversity and phylogenetic intermingling with strains from previous 
years, suggesting independent zoonotic transmission events and thus allaying 
concerns of an emergent strain or extensive human-to-human transmission. The 
ruling out of case linkage and the emergence of a novel strain in real-time, during the 
outbreak progression was of major importance in determining the required public 
health response. The response was focused on intensified community engagement 
on rodent control, environmental sanitation, and safe food storage. Further research 
is needed to evaluate whether improved diagnostics and disease awareness and/or 
ecological and climate factors promoting transmission are the drivers behind the 
changing epidemiology of Lassa fever in Nigeria. 
This chapter clearly highlights the importance of MinION metagenomic 
sequencing, which was shown here for the first time to be a feasible approach to 
rapidly characterise an ongoing outbreak in a resource limited setting. Therefore, 
portable metagenomic sequencing of genetically diverse RNA viruses, directly from 
patient samples, without the need to export material outside the country of origin and 
with no pathogen-specific enrichment, can enable real-time characterization of 
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6. Chapter 6: Discussion 
 
 The aim of this thesis was to investigate metagenomic sequencing for the 
identification and complete genome recovery of pathogenic RNA viruses directly from 
clinical samples, with the ambition of applying it coupled with the Oxford Nanopore 
MinION in resource-limited settings for real-time genomic surveillance and outbreak 
molecular epidemiology. This was ultimately realised and led to the first ever 
metagenomic sequencing to be successfully performed at the heart of an on-going 
outbreak in real-time, in Nigeria during the 2018 Lassa virus outbreak.  
6.1 Summary 
 
Two sequence-independent methods for viral metagenomics were initially 
compared as described in Chapter 3 using a mock-sample and four DENV clinical 
samples which were sequenced on an Illumina MiSeq to assess the proportion of viral 
reads generated and the consensus sequence recovery. The SISPA protocol 
demonstrated successful viral identification and complete genome recovery for all 
samples tested, which in combination with its previously successful coupling with the 
MinION for viral detection, made it particularly promising for rapid portable 
metagenomic sequencing. The SISPA protocol feasibility and sensitivity for individual 
clinical samples were further investigated in Chapter 4 using a selection of CHIKV 
and DENV positive clinical samples with a representative range of viral titres (339). 
Whole genome sequencing was successful for both viruses, directly from nucleic acid 
extracts of serum and plasma samples without the need for culture or viral enrichment 
beyond a simple DNA digestion. In Chapter 5, metagenomic nanopore sequencing 
was evaluated in a remote and resource-limited setting. Metagenomic nanopore 
sequencing of LASV virus was implemented in Nigeria during the 2018 endemic 
season, which enabled outbreak support for LASV during the 2018 outbreak (303). 
Genomic data and phylogenetic reconstructions were communicated immediately to 
the NCDC and the WHO to inform the public health response (341). 
Metagenomic sequencing was therefore demonstrated to be a feasible 
approach for the recovery of viral genomes directly from clinical samples for CHIKV, 
DENV and LASV within the clinical range of viral titres, and the feasibility of applying 
it in the field for real-time outbreak analysis proven.  
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6.2 Sequencing platforms 
 
Advances in the field of whole genome sequencing over the last decade have 
allowed for genomics-informed surveillance and outbreak response. The main 
disadvantages of sequencing platforms for outbreak support was until recently was 
the size of the equipment required, the speed at which data was generated and the 
operation complexity, particularly when an outbreak occurs in a resource-limited 
setting.  
The development of the MinION platform, has already introduced sequencing 
in real time in the field and overcomes many limitations of its predecessors (147, 344), 
providing a highly accessible sequencing device, with low start-up costs, that can be 
implemented in remote locations and requires little device maintenance. One of the 
most important benefits of MinION sequencing, coupled to its portability, is the 
capacity to sequence samples locally, directly in the country of origin without the need 
of shipping and transporting samples to a secondary location. This is a major 
advantage for sample preservation (eliminating additional freeze-thaw cycles or 
possible damage), removes political and logistical concerns over sample 
transportation and more importantly allows for the establishment and advancement 
of research locally in resource limited locations. However despite its major portability 
advantage, the benefit of long reads and direct "reading" of the input DNA, it also 
presents quite a few challenges which are currently being addressed. These 
challenges include the per read accuracy of the data generated, the cost per sample 
sequenced. Data analysis complexity, data volume generated and data management 
were also difficulties that were encountered for the duration of this thesis. In Chapter 
4, for example, a low number (n = 4) of samples were screened using the MinION, 
this was due to the lack of a compatible barcoding kit and low data output per flow 
cell at the time which did not allow for sample multiplexing. The cost per sample was 
initially much higher compared to sequencing experiments conducted later, in 
Chapter 5, at which stage the barcoding kit was available and the data output was 
significantly higher, allowing for 5 samples to be multiplexed on a single flow cell. The 
comparison of the Illumina generated data versus the Nanopore counterparts showed 
excellent agreement for the recovered consensus sequences matching with >99.9% 
identity, which was sufficient for the needs of this project. However this is on the 
consensus level and requires a minimum of 30-fold depth MinION reads to achieve 
(345), which introduces its own limitations, particularly when encountering samples 
that have a low viral load and subsequently generate a much lower percentage of 
viral reads which in multiple cases are not sufficient to call a consensus. Once 
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improvements are made in the library preparation and the base calling algorithms the 
accuracy per read and total data yield should increase, which might then allow for an 
improved recovery of near-complete (>70%) consensus genomes from the total 
samples sequenced.  
The main difficulties encountered during this work were due to challenges 
presented when using a new and fast growing technology with ongoing improvement 
and upgrades. Software updates, need for internet connection and consumable 
changes were all aspects that had to be considered for the duration of this project. 
An important challenge was data analysis and management. The data load produced 
initially, at the time of Chapter 3, was considerable but still easily manageable. 
However, by the time of the experiments in Chapter 5, the data output was at least 
5x more and the experiments were generating hundreds of gigabytes worth of data. 
This was of course a great improvement in kit and flow cell chemistry but basecalling 
was still at this stage done using CPU power which meant an average of 1 week to 
basecall a full sequencing run and a big data storage requirement to make sure the 
data is saved and backed up appropriately. On the whole, these challenges were 
manageable but added a level of complexity, particularly compared to other 
commonly used sequencing platforms which have been in the market for longer and 
subsequently are more established.  
 6.3 Sequencing approaches 
 
Amplicon sequencing has been used in combination with Nanopore and 
Illumina platforms to successfully sequencing EBOV (147), ZIKV (156, 218), YVF 
(219) and WNV (219, 220) for virus surveillance and outbreak support. Amplicon 
sequencing provides a sensitive cost effective approach and is particularly important 
for samples with low viral titre. It has subsequently been used to successfully 
sequence single lineage outbreaks, where the viral pathogen is previously known and 
conserved. However, despite its cost and sensitivity amplicon sequencing presents a 
lot of limitations, particularly in the cases of co-circulating pathogens, co-infections 
and highly divergent pathogens. The utility of a metagenomic approach is already 
highlighted in Chapter 4, in which the metagenomic protocol used was successfully 
applied for samples with different DENV serotypes and more importantly was able to 
identify a co-infection. Both of these would have not been possible via targeted 
methods without further screening or without using multiple primer pools to assure 
coverage of all four DENV serotypes. The utility of metagenomic sequencing was 
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further highlighted in this work through its application for sequencing a divergent 
pathogen as described in Chapter 5. This would not have been possible without the 
use of a metagenomic approach, as multiple primers sets would have to be designed 
for each clade subset and screening would have been much more labour intensive 
and expensive. Metagenomic sequencing of course has its own difficulties and 
limitations particularly due to a more complex data analysis requirement. This was 
the case for LASV, as the data generated has to be analysed using an approach 
incorporating an initial de novo assembly to allow for the identification of the 
appropriate reference to be used downstream for the consensus generation. The 
additional complexity of the analysis adds mainly to the sample-receipt-to-consensus 
sequence time, which in this case given the utility of the information generated is a 
small price to pay.  
6.4 Clinical Metagenomics 
 
Clinical metagenomics, which specifically refers to the application of 
metagenomics directly to clinical samples, is identified here as a suitable approach 
for the whole genome sequencing of three pathogenic RNA viruses of major 
importance (CHIKV, DENV and LASV). However, despite the successful application 
for these pathogens and the significant benefit of non-targeted sequencing, the 
extensive application of clinical metagenomics is hindered by the challenges it 
presents. Its sensitivity depends on the sample type, background (i.e. any non target) 
nucleic acid abundance and the level of pathogen present which is highly variable 
between samples; additionally the analysis sensitivity for the data generated is also 
restricted by the tools and databases available (160). The majority of reads generated 
from a sample correspond in most cases to the host, which remains to date one of 
the biggest challenges for clinical metagenomics. This did not seem to be the case 
for the low Ct value CHIKV and DENV samples but was definitely the case for all 
LASV samples (Chapter 4 and Chapter 5). Host background along with environmental 
and kit contaminants (102) can compromise viral detection as they dominate the 
sample composition, this was particularly the case with LASV sample for which only 
one sample was identified with as high as 40% of the reads corresponding to LASV 
and all remaining samples had a much lower percentage of reads mapping to the 
virus.  
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6.5 In-country Sequencing 
 
Emerging viruses are causing debilitating diseases affecting the human 
population and creating devastating effects globally. Their expansion in prevalence 
and incidence has led these viral pathogens to cause outbreaks, become endemic 
and spread to different continents causing increase in mortality and morbidity rates. 
Rapid and unbiased methods in pathogen surveillance are vital when developing a 
strategy for the identification, eradication and treatment of an emerging virus; more 
importantly in the containment of an outbreak. Genomic epidemiology in particular 
can provide important information to assist with knowledge gaps present when 
encountering emerging pathogens and their occurring outbreaks. Sequencing of 
emerging viruses and their circulating strains can locate their source and characterise 
the virus to identify any genetic changes that might have driven their emergence (73). 
Understanding chains of infections and transmission can assist in spread reduction 
and outbreak management. Sequencing can provide essential information 
particularly during an outbreak for the understanding of viral epidemiology and for the 
prompt identification of human-to-human transmission chains. The utility of 
metagenomic sequencing for genomic epidemiology and outbreak response was 
highlighted with the implementation of real-time metagenomic MinION sequencing 
during the 2018 LASV outbreak in Nigeria. The sequencing results allowed public 
health authorities to rule out the emergence of a new strain or the possibility of 
increased human-to-human transmission. Sequences and phylogenetic 
reconstructions were directly communicated to the Nigerian authorities and WHO 
allowing for the suitable allocation of resources for the informed public health 
response (Figure 6.1).  
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Figure 6.1 Sequencing report released by the Nigerian Centre for Disease Control.  
Early Results of LASV Sequencing & Implications for Current Outbreak Response in Nigeria 
(341). Full report is included in the supplementary. 
 
A mechanism for data and information sharing was formulated consisting of 
an internal report directly to the NCDC and the WHO and a simultaneous public 
release was made available online on virological.org (342). Data sharing is critical 
during outbreaks and epidemics allowing for input from the scientific community to 
provide additional expertise and the possibility for global pathogen surveillance. 
MinION genome sequencing utilising a metagenomic approach has the potential for 
both rapid viral identification and genomic level data acquisition. Shown in this work 
for the first time in the context of an unfolding LASV outbreak, during the 2018 
Nigerian endemic season, is the application of metagenomic MinION sequencing for 
the generation of real-time data used for downstream analysis in virus surveillance, 
epidemiology and viral evolution. Additionally, the sequencing information generated 
provides an important impact on design and improvement of diagnostics, particularly 
so given the LASV diversity. Currently positive diagnosis of the LASV is done using 
two PCR assays, due to its diversity positive cases can be missed with a single assay 
and using two assays increases the sensitivity of detection. The sequences 
generated can be used to re-design and improve the current diagnostic approaches, 
increasing the number of sequences used for their design and subsequently 
expanding the assays targets.  
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6.6 Future Work 
 
An important outcome of this project is identifying the need to improve data 
management in the future. The vast amount of data generated creates a huge issue 
when having to manage quick sequencing run turnovers in a resource-limited setting. 
The metagenomic approach requires as much sequencing depth as possible so the 
runs are left for 24hr-48hr, easily producing 200-300 gigabytes of data, which need 
to be basecalled, transferred and backed-up. The biggest problem encountered was 
the slow speed of data transfers due to the huge number of files generated per run. 
The folder structure along with the file system of the nanopore data produced created 
significant handling difficulties. However, this is something that will be improved and 
easier to manage in the future, as the technology improves and the data generated 
is output in an easier to handle format. Currently major advancements have already 
been made since 2018, with a much simpler folder architecture and data generated 
in batches of 4,000 reads per file instead of one read per file, massively reducing data 
transfer times. Additionally, an important development is the MinIT, a preconfigured, 
small-footprint computer that supports MinION runs as it allows for the integration of 
live basecalling to the sequencing experiment. The ability to live basecall and the 
development of the flip-flop basecaller which now runs on GPU, provides faster data 
analysis and higher accuracy. Live basecalling and increased accuracy allow for 
improvements in the data analysis pipeline, with faster generation of fastq files and 
higher per read accuracy slowly moving towards making real-time analysis a reality. 
The improved per read accuracy leads to more accurate consensus generation 
without the need to use the raw fast5 files to polish the consensus sequence, 
eliminating the need to transfer the fast5 files and making data handling easier. Future 
improvements will streamline and optimise protocols for ease of use and will identify 
aspects of the current pipeline, both laboratory and analysis, which can be designed 
to be less time-consuming and more user-friendly. Developing a real-time automated 
pipeline will increase the data analysis efficiency and increase the ease of use. This 
will enable the completion of easy-to-follow protocols and standard operating 
procedures allowing for standardisation and training possibilities, particularly in-
country. Capacity building is an important element, particularly when research such 
as in Chapter 5 takes place. During the 2018 outbreak the sequencing efforts were 
intensified and instead of the original pilot study, activities were increased and 
focused towards outbreak response. This led to limited opportunities to invest in 
developing standard operating procedures to allow for training and capacity building 
as all efforts were focused on outbreak support. Corresponding capacities must be 
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built in Nigeria and other African countries, allowing for the training of laboratory staff 
locally to enable sequencing expertise locally and allow for sequencing experiments 
to take place independently. This not only allows for capacity building and expanding 
expertise in-country but will also provide the opportunity for year-round surveillance 
to enhance our understanding of the virus epidemiology. 
6.7 Conclusions 
 
It is evident that mobile sequencing has an important role to play in disease 
management and response during outbreaks, epidemics and ultimately in ongoing 
surveillance. Mobile sequencing establishment in the heart of an unfolding viral 
outbreak or in locations with significant risk of a probable outbreak will have a major 
role in future case management and public health responses. Mobile sequencing 
should be standardly incorporated in support of response efforts of such future 
incidents, allowing for prompt implementation of genomic surveillance. Targeted 
methods will continue to provide large scale, high depth analysis of clonal outbreaks, 
nevertheless this thesis clearly highlights the role metagenomic methods can play in 
surveillance studies, outbreak of diverse pathogens and rapid response to 
novel/unexpected viral pathogens. Finally, it is apparent that sequencing efforts and 
the data generated from real-time mobile sequencing should be communicated in as 

















Figure S1 Pileup script  
# run: python scriptname.py filename(without_bam_extention) fastafile(ref) 
# filename = sys.argv[1] 
# fastafile = sys.argv[2] 
 
filename = sys.argv[1] 
reference = sys.argv[2] 
csvname = sys.argv[3] 
fastaname = sys.argv[4] 
 
header = ['Position', 'A', 'C', 'G', 'T', 'Insertions', 'Deletions', 'Consensus'] 
bamfile = pysam.AlignmentFile('{}.bam'.format(filename)) 
results = [] 
consensus = [] 
for record in pysamstats.stat_variation(bamfile, 
                                        fafile= sys.argv[2]): 
    rec = 
[record['pos'],record['A'],record['C'],record['G'],record['T'],record['insertions'],record['deletions']] 
    if rec[1]+rec[2]+rec[3]+rec[4]: 
        percentage = float(max(rec[1:5])) / (rec[1]+rec[2]+rec[3]+rec[4]) 
    else: 
        percentage = 0 
        #print(record['pos']) 
    ind = rec.index(max(rec[1:5])) 
    if ind==1: 
        found='A' 
    elif ind==2: 
        found='C' 
    elif ind==3: 
        found='G' 
    elif ind==4: 
        found='T' 
    else: 
        found='N' 
    if max(rec[1:5])>19 and percentage>=0.7: 
        rec.append(found) 
        consensus.append(found) 
    else: 
        rec.append('N') 
        consensus.append('N') 
    results.append(rec) 
    seq = ''.join(consensus) # create a string of GTACN 
     
with open('{}.csv'.format(csvname), 'w', newline='') as csvfile: 
    writer = csv.writer(csvname, delimiter=',') 
    writer.writerow(i for i in header) 
    writer.writerows(results) 
with open('{}.fasta'.format(fastaname), 'w') as fastafile: 
    fastafile.write('>{}\n'.format(filename)) 







Figure S2 Proportion of reference genome recovered at minimum 20-fold 
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073 14.4 21.18 7260 4 3 5792G>T, 5793A>G, 5795G>A, 7258C>T 
119 17.33 16.36 7258 2 0 404C>T, 407C>T 
126 17.96 20.5 7245 0 0  
066 18.74 26.73 7135 1 1 274G>T 
014 19.16 26.42 7245 1 0 445G>A 
131 20.57 25.68 7238 0 0  
115 21.00 26.55 7183 3 3 727C>T, 728T>C,  731C>T 
075 22.39 29.74 7256 0 0  
072 22.63 34.3 7250 0 0  
021 23.82 31.76 7237 0 0  
013 24.01 26.02 7230 0 0  
074 26.87 32.9 7238 0 0  
001 27.49 23.75 7196 2 0 2A>T, 416T>G 
036 None 28.44 7261 1 0 7209T>C 
S Segment 
073 14.4 21.18 3406 1 0 3422C>G 
119 17.33 16.36 3403 2 2 596C>A, 597A>C 
126 17.96 20.5 3407 1 0 2C>G 
066 18.74 26.73 3393 0 0  
014 19.16 26.42 3407 1 0 1587T>G 
131 20.57 25.68 3389 0 0  
115 21.00 26.55 3387 0 0  
075 22.39 29.74 3412 0 0  




021 23.82 31.76 3385 0 0  
013 24.01 26.02 3367 0 0  
074 26.87 32.9 3367 0 0  
001 27.49 23.75 3490 0 0  







NCDC full report. Early Results of Lassa Virus Sequencing & Implications for 
Current Outbreak Response in Nigeria 
12 March, 2018 | Abuja – EARLY RESULTS OF LASSA VIRUS SEQUENCING 
AND IMPLICATIONS FOR CURRENT OUTBREAK RESPONSE IN NIGERIA 
The Nigeria Centre for Disease Control continues to lead a multi-agency, multi-
partner response to the on-going Lassa fever outbreak in Nigeria. The response is 
now gathering steam with an escalation of efforts to control spread in all the foci of 
infections across the country. A critical aspect of outbreak control is research, to 
rapidly understand the drivers of infection and opportunities for control. 
A relatively new tool available to epidemiologists and researchers is the use of 
whole genome sequencing during outbreaks. Real-time sequencing of viruses can 
reveal crucial details that contribute to the understanding and the control of 
infectious disease outbreaks. It is now possible to resolve chains of transmission to 
a level of detail otherwise unachievable using traditional methods. 
Researchers at the Irrua Specialist Teaching Hospital, Edo State, in collaboration 
with partners from the Bernhard-Nocht Institute for Tropical Medicine, Germany, 
and others (see below) have deployed real-time sequencing of Lassa fever viruses 
from the on-going outbreak to learn key lessons to influence control efforts. The 
real-time availability of sequencing information for the current 2018 Lassa fever 
viruses will support the response to the on-going Lassa fever outbreak. 
On the 10th March 2018, the analysis of a first set of seven Lassa virus draft 
sequences derived from the blood of seven laboratory-confirmed Lassa fever 
patients from Edo, Ondo, Ebonyi, and Imo States was completed. In addition, 83 
unpublished sequences obtained during previous years from various parts of 
Nigeria were made available for comparison with the sequences of the 2018 
outbreak. From the analysis of these results, we can draw the following preliminary 
conclusions: 
• No new virus lineages have so far been detected, meaning that the circulating 
viruses appear to be very similar to the viruses from previous years; 
• Lassa fever cases appear to be mostly caused by viruses that are not 
epidemiologically linked; 
• The viruses circulating in 2018 appear to originate from the pool of lineages and 
strains known to be circulating in Nigeria and are consistent with previous 
outbreaks; 
• The most likely route of transmission continues to be spill over of viruses from the 
rodent reservoir to humans rather than extensive human-to-human transmission. 
The most important question being investigated at the moment is what has caused 
an outbreak of this magnitude, at this time? One of the possible answers to this 
question is the emergence of a new Lassa virus lineage or strain with increased 
virulence or transmissibility. Evidence from this work, although limited to seven 
viruses at the moment suggests that this is unlikely to be the case. 
Over the last year, the Nigeria Centre for Disease Control has improved its disease 
surveillance, detection and response system. This includes the operationalisation 
of the National Reference Laboratory in Abuja, to add to existing diagnostic 
capacity, with its capacity to test for Lassa fever in ISTH and Lagos University 
Teaching Hospital (LUTH). According to Chief Executive Office, Dr. Chikwe 
Ihekweazu, “As the system continues to be strengthened, there is likely to be an 
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increase in the number of cases detected and reported. Sequencing provides an 
exciting additional tool for the outbreak response. As we learn more, we become 
better equipped to respond.” 
To support the public health response as well as the development and evaluation 
of Lassa fever diagnostics or therapeutics, the researchers are sharing the 
sequences via the website virological.org. 
The NCDC would like to thank the following institutions and partners for their 
continued support to the Government of Nigeria: 
• Irrua Specialist Teaching Hospital (ISTH), Institute of Lassa Fever Research and 
Control (ILFRC), Irrua, Edo State, Nigeria (Prof. Sylvanus Okogbenin, Dr. Ephraim 
Ogbaini, Dr. Adomeh Donatus) 
• Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany 
(Prof. Stephan Günther, Liana Kafetzopoulou, Dr. Deborah Ehichioya, Dr. Meike 
Pahlmann, Dr. Lisa Oestereich, Dr. Sophie Duraffour, Anke Thielebein, Julia 
Hinzmann) 
• Public Health England (PHE), Salisbury, United Kingdom (Prof. Miles Carroll, 
Liana Kafetzopoulou, Dr. Steven Pullan, Dr. Richard Vipond, Dr. Roger Hewson) 
• KU Leuven, Leuven, Belgium (Dr. Philippe Lemey) 
• University of Liverpool, United Kingdom (Dr. Julian Hiscox) 
• World Health Organisation (WHO) 
Contacts 
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Background: The recent global emergence and re-
emergence of arboviruses has caused significant 
human disease. Common vectors, symptoms and geo-
graphical distribution make differential diagnosis both 
important and challenging. Aim: To investigate the 
feasibility of metagenomic sequencing for recovering 
whole genome sequences of chikungunya and dengue 
viruses from clinical samples. Methods: We performed 
metagenomic sequencing using both the Illumina 
MiSeq and the portable Oxford Nanopore MinION on 
clinical samples which were real-time reverse tran-
scription-PCR (qRT-PCR) positive for chikungunya 
(CHIKV) or dengue virus (DENV), two of the most impor-
tant arboviruses. A total of 26 samples with a range 
of representative clinical Ct values were included in 
the study. Results: Direct metagenomic sequencing 
of nucleic acid extracts from serum or plasma with-
out viral enrichment allowed for virus identification, 
subtype determination and elucidated complete or 
near-complete genomes adequate for phylogenetic 
analysis. One PCR-positive CHIKV sample was also 
found to be coinfected with DENV. Conclusions: This 
work demonstrates that metagenomic whole genome 
sequencing is feasible for the majority of CHIKV and 
DENV PCR-positive patient serum or plasma samples. 
Additionally, it explores the use of Nanopore metagen-
omic sequencing for DENV and CHIKV, which can likely 
be applied to other RNA viruses, highlighting the appli-
cability of this approach to front-line public health and 
potential portable applications using the MinION.
Introduction
Arboviruses are predominantly RNA viruses that rep-
licate in haematophagous (blood-sucking) arthropod 
vectors such as ticks, mosquitoes and other biting flies 
to maintain their transmission cycle [1]. Human disease 
outbreaks caused by arboviruses have increased in 
prevalence since the 2000’s, led by the spread of mos-
quito-borne arboviruses such as chikungunya (CHIKV), 
dengue (DENV), West Nile (WNV), yellow fever (YFV) and 
Zika (ZIKV) viruses across both hemispheres [2]. CHIKV 
and DENV are of particular global health concern, as 
they have lost the need for enzootic amplification and 
consequently have caused extensive epidemics [3].
CHIKV is a single-stranded positive-sense RNA virus 
of the alphavirus genus, which causes the debilitating 
arthritic disease, chikungunya [4]. It has spread glob-
ally and been designated a serious emerging disease 
by the World Health Organization [5]. Outbreaks of 
CHIKV since 2005 have been associated with increased 
morbidity and possibly mortality [6,7].
DENV, which causes dengue, is a single-stranded pos-
itive-sense RNA virus of the flavivirus genus and the 
most prevalent human arboviral pathogen. Dengue 
occurs following infection with one of four DENV sero-
types (DENV1–4). A minority of cases develop acute 
haemorrhagic manifestations and multi-organ failure. 
Despite DENV cases being under-reported, a 143.1% 
increased global incidence was estimated between 
2005 and 2015 [8]. Approximately 500,000 DENV 
infected patients worldwide require hospitalisation 
annually [9].
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Both CHIKV and DENV are predominantly transmitted to 
humans via Aedes species mosquitoes, particularly Ae. 
aegypti  and  Ae. albopictus  [10,11], and share clini-
cal presentations of arthralgia, headache, high fever, 
myalgia and rash. Circulation of CHIKV, DENV (and 
other arboviruses) in the same areas leads to chal-
lenges in differential diagnosis, especially in endemic 
regions in which diagnosis is predominantly symptom-
based [12]. Additionally, reports of arboviral coinfec-
tions are increasingly common [13-16].
Metagenomic RNA sequencing allows for identification 
of multiple pathogens within a sample in a non-tar-
geted and unbiased manner. It has identified causative 
agents in outbreaks, e.g. Lujo virus in South Africa [17], 
Bundibugyo ebolavirus in Uganda [18] and lead to novel 
virus discovery such as a rhabdovirus causing haem-
orrhagic fever in central Africa [19]. It also provides 
genomic information for typing and surveillance. Real-
time genomic surveillance was facilitated on-site by 
the portable Oxford Nanopore MinION sequencer dur-
ing the 2014–16 Ebola virus (EBOV) epidemic in West 
Africa and the 2015-16 ZIKV outbreak in the Americas 
[20-23] for epidemiological and transmission chain 
investigations [24]. In both examples, an amplicon 
sequencing approach was used, but viruses and bac-
teria from clinical, environmental and vector samples 
have been sequenced using metagenomic approaches 
on the MinION [25-28]. Metagenomic sequencing of 
CHIKV was demonstrated in principle on the MinION 
by Greninger et al. in 2015 reporting the detection of 
CHIKV from a human blood sample [28]. Additionally, 
Illumina-based metagenomics identified CHIKV coin-
fections within a ZIKV sample cohort [29], with the high 
proportion of CHIKV reads present making it a promis-
ing target for the approach.
In this study we set out to test the feasibility of direct 
metagenomic sequencing of DENV and CHIKV genomes 
from a cohort of clinical serum and plasma samples 
across a representative range of viral loads. The objec-
tive was to assess the proportion of viral nucleic acid 
relative to patient/background present in each sample 
and determine the sequencing limits for whole genome 
retrieval using both the laboratory-based Illumina tech-
nology and the portable MinION platform.
Methods
Sample collection and nucleic acid extraction
Twenty-six routine diagnostic samples, nine plasma 
and 17 serum, were obtained from the Rare and 
Imported Pathogens Laboratory (RIPL), Public Health 
England (PHE), Porton Down. All had previously tested 
positive by real-time reverse transcription-PCR (qRT-
PCR) for chikungunya or dengue virus, with a maximum 
cut-off value of cycle threshold (Ct) 35. These samples 
had been selected based on their Ct values, among a 
larger set of 441 samples, so as to represent a Ct clini-
cal range. Total nucleic acid was extracted from 140 µL 
of each using the QIAamp viral RNA kit (Qiagen, Hilden, 
Germany) replacing carrier RNA with linear polyacryla-
mide and eluting in 60 µL elution buffer provided in the 
kit, followed by treatment with TURBO DNase (Thermo 
Fisher Scientific, Waltham, United States (US)) at 37 °C 
for 30 min. RNA was purified and concentrated to 8 
µL using the RNA Clean and Concentrator-5 kit (Zymo 
Research, Irvine, US).
Molecular confirmation and quantification
Drosten et al. [30] and Edwards et al. [31] RT-PCR 
assays were used for confirmation of DENV and CHIKV 
respectively. RNA oligomers were used as standards 
for genome copy quantitation.
Figure 1
Cycle threshold (Ct) values distribution of chikungunya 
(n = 73) and dengue virus (n = 368) positive samples from 
the Rare and Imported Pathogens Laboratory, Public 
















CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.
The 14 CHIKV and 12 DENV samples selected for this work are 
indicated by circles. For each virus, the median Ct value of positive 
samples by quantitative real-time PCR is shown (horizontal line 
inside the box), as well as 25th and 75th percentiles (box lower and 
upper boundaries) and total range (whiskers).
3www.eurosurveillance.org
Metagenomic cDNA reparation
Complementary DNA (cDNA) was prepared using a 
Sequence Independent Single Primer Amplification 
(SISPA) approach adapted from Greninger et al. [28]. 
Reverse transcription and second strand cDNA syn-
thesis were as described [28]. cDNA amplification was 
performed using AccuTaq LA (Sigma, Poole, United 
Kingdom), in which 5µL of cDNA and 1 µL (100 pmol/µL) 
Primer B (5’-GTTTCCCACTGGAGGATA-3’) were added to 
a 50 µL reaction, according to manufacturer’s instruc-
tions. PCR conditions were 98 °C for 30s, followed by 
30 cycles of 94 °C for 15 s, 50 °C for 20 s, and 68 °C for 
5 min, and a final step of 68 °C for 10 min. Amplified 
cDNA was purified using a 1:1 ratio of AMPure XP beads 
(Beckman Coulter, Brea, California (CA)) and quantified 
using the Qubit High Sensitivity dsDNA kit (Thermo 
Fisher, Waltham, US).
MinION library preparation and sequencing
MinION sequencing libraries were prepared using total 
amplified cDNA of each sample to a maximum of 1 µg. 
Oxford Nanopore kits SQK-NSK007 or SQK-LSK208 
(2D), SQK-LSK308 (1D2) and SQK-RBK001 (Rapid) were 
used and each sample was run individually on the 
appropriate flow cell (FLO-MIN105, FLO-MIN106 or FLO-
MIN107) using the 48hr run script. Base calling was 
performed using Metrichor (ONT) for SQK-NSK007 and 
SQK-LSK208 or Albacore v1.2 for SQK-LSK308 and SQK-
RBK001. Poretools [32] was used to extract FASTQ files 
from Metrichor FAST5 files.
Illumina library preparation and sequencing
Nextera XT V2 kit (Illumina) sequencing libraries were 
prepared using 1.5 ng of amplified cDNA as per man-
ufacturer’s instructions. Samples were multiplexed 
in batches of a maximum of 16 samples per run and 
Table 1
Description of samples positive for chikungunya and dengue virus by real-time reverse transcription-PCR with 























CHIKV 1 14.72 2.12E + 10 Plasma 1,113,560 78.32 99.59 99.72 CHIKV 11,826
CHIKV 2 20.06 5.49E + 08 Serum 1,278,624 98.48 99.14 99.47 CHIKV 11,826
CHIKV 3 21.41 2.18E + 08 Plasma 1,391,258 95.23 98.86 99.37 CHIKV 11,826
CHIKV 4 22.74 8.76E + 07 Plasma 888,968 19.16 97.08 97.32 CHIKV 11,826
CHIKV 5 23.77 4.33E + 07 Plasma 1,357,606 97.13 99.16 99.58 CHIKV 11,826
CHIKV 6 25.4 1.42E + 07 Serum 3,236,848 34.88 97.80 98.40 CHIKV 11,826
CHIKV 7 25.76 1.11E + 07 Plasma 3,748,070 72.77 99.04 99.56 CHIKV 11,826
CHIKV 8 28.17 2.13E + 06 Plasma 1,499,952 28.41 98.69 99.00 CHIKV 11,826
CHIKV 9 30.08 5.76E + 05 Serum 1,035,026 6.66 95.98 98.22 CHIKV 11,826
CHIKV 10 30.37 4.72E + 05 Serum 1,575,222 16.84 97.39 98.01 CHIKV 11,826
CHIKV 11 30.66 3.87E + 05 Serum 1,143,054 13.52 95.36 96.96 CHIKV 11,826
CHIKV 12 30.95 3.17E + 05 Serum 1,507,380 10.93 96.11 96.52 CHIKV 11,826
CHIKV 13 32.2 1.35E + 05 Serum 1,323,920 5.03 88.47 89.38 CHIKV 11,826
CHIKV 14 32.57 1.05E + 05 Serum 1,479,404 21.72 96.32 96.93 CHIKV 11,826
DENV 1 16.29 4.21E + 09 Plasma 439,292 93.44 99.51 99.58 DENV 1 10,735
DENV 2 16.85 2.83E + 09 Serum 513,472 92.56 99.40 99.58 DENV 1 10,735
DENV 3 17.67 1.58E + 09 Plasma 738,814 92.53 99.58 99.58 DENV 2 10,723
DENV 4 18.20 1.09E + 09 Serum 477,368 93.97 98.73 99.12 DENV 2 10,723
DENV 5 19.73 3.67E + 08 Serum 915554 89.65 99.14 99.40 DENV 2 10,723
DENV 6 21.22 3.61E + 07 Serum 3,587,926 83.87 99.68 99.69 DENV 4 10,649
DENV 7 23.76 2.11E + 07 Serum 4,146,678 2.17 86.99 89.13 DENV 1 10,735
DENV 8 24.8 1.01E + 07 Serum 777,264 69.23 99.56 99.58 DENV 3 10,707
DENV 9 25.28 7.17E + 06 Plasma 787,728 26.97 98.77 98.81 DENV 2 10,723
DENV 10 26.98 2.15E + 06 Serum 596,240 6.58 93.47 93.97 DENV 3 10,707
DENV 11 28.69 6.39E + 05 Serum 1,034,698 3.73 94.44 94.70 DENV 1 10,735
DENV 12 31.29 1.01E + 05 Serum 1,374,766 0.47 71.46 77.76 DENV 1 10,735
CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.
a The Illumina mapping data presented in the table were obtained in 2017 on samples that had been collected and found positive for 
chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.
b ‘R1 + R2’ indicates paired-end sequencing.
c For DENV the serotype is also indicated.
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Figure 2
Proportion of reads mapping to the appropriate viral reference sequence and proportion of reference genome sequenced at 



















































































a The Illumina data presented in the figure were obtained in 2017 on samples that had been collected and found positive for chikungunya or 
dengue virus by real-time reverse transcription-PCR in 2016.
The percentage of total reads mapping to the appropriate reference sequence is plotted in the upper panel. Lower panels display the 
percentage of the reference genome sequenced to a minimum depth of 20-fold in the Illumina data.
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sequenced on a 2x150 bp-paired end Illumina MiSeq 
run, by Genomics Services Development Unit, PHE.
Data handling
BWA MEM v0.7.15 [33] was used to align reads to the 
following references (GenBank ID): DENV Serotype 
1 (NC_001477.1), DENV Serotype 2 (NC_001474.2), 
DENV Serotype 3 (NC_001475.2), DENV Serotype 4 
(NC_002640.1) and CHIKV (NC_004162.2) using -x 
ont2d mode for Nanopore and MEM defaults for Illumina 
reads. Samtools v1.4 [34] was used to compute per-
centage reads mapped and coverage depth. Bedtools 
v2.26.0 [35] was used to calculate genome coverage 
at 10x and 20x. Mapping consensuses for Illumina 
were generated using in-house software QuasiBam 
[36] and for MinION using a simple pileup with bases 
called at a minimum depth of 20x and 70% support 
fraction. Nanopolish variants [24,37] was used in con-
sensus mode to compute an error-corrected consensus 
sequence from the Rapid kit data. Taxonomic classifi-
cation was performed using Kraken (0.10.4-beta) [38] 
and a locally built database populated with all RefSeq 
bacterial, viral, and archaeal genomes plus additional 
sequences [39]. De novo assemblies were generated 
using Spades 3.8.2 [40] in combination with SSPACE 
Standard v3.0 [41] for Illumina generated sequences 
and Canu v1.6 [41,42] for Nanopore sequences (set-
tings: corOutCoverage = 1,000; genomeSize = 12,000; 
minReadLength = 300, minOverlapLength = 50).
Consensus sequences for all samples tested are avail-
able in Genbank, raw fast5 files from 1D2 and 1D data 




A total of 73 samples tested during 2016 in RIPL diag-
nostic laboratories, PHE Porton Down, were positive 
by qRT-PCR for CHIKV, and 368 were positive for DENV. 
Median Ct for CHIKV was 26.1, for DENV it was 26.8. 
For each virus, samples representing the range of viral 
titres seen during 2016 were selected, based on qRT-
PCR Ct value (Figure 1). CHIKV samples selected (n = 14) 
ranged from Ct 14.72 to Ct 32.57, corresponding to 
1010 and 105 genome copies per mL of plasma or serum. 
DENV samples selected (n = 12) ranged from Ct 16.29 to 
Ct 31.29, corresponding to 109 and 105 genome copies 
per mL (Table 1). To measure the proportion of viral 
nucleic acid present relative to host/background and 
assess genome coverage, all samples were processed 
as described in methods and Illumina sequenced (Table 
1). The proportion of total reads mapping to the respec-
tive viral reference was high for both viruses (Figure 2). 
In some low Ct samples, over 90% of reads mapped 
to the viral reference and proportions over 50% were 
still observed at mid-Ct range. The lowest proportions 
observed were 5.03% and 0.47% for CHIKV and DENV 
respectively (Table 1,  Figure 2). The majority of sam-
ples returned over 95% genome coverage at 20x (21/26 
samples) and over 98% genome coverage at 10x (20/26 
samples). Irrespective of lower mapping percentages 
in high Ct value samples, genome coverage of 88.5% 
(20x) and 89.4% (10x) for CHIKV and 75.0% (20x) and 
77.8% (10x) for DENV was observed.
Metagenomic MinION sequencing
Four representative samples for each virus were 
selected for Nanopore sequencing (Table 2).
Figure 3 shows percentages of reads mapping to viral 
reference, which were generally concordant with the 
Table 2
Description of chikungunya and dengue virus positive samples by real-time reverse transcription-PCR and corresponding 
Nanopore sequencing data, United Kingdom, 2017a (n = 8 samples)














CHIKV 1 14.7 431.5 SQK-NSK007 MIN105 1.51E + 08 267,171 564 92,712
CHIKV 3 21.4 928.8 SQK-LSK208 MIN106 1.63E + 09 1,891,028 862 99,031
CHIKV 4 22.7 113.4 SQK-NSK007 MIN105 1.74E + 08 216,493 805 125,387
CHIKV 9 30.1 212.4 SQK-LSK208 MIN106 2.12E + 09 3,481,358 608 121,711
DENV 1 16.3 1,626.0 SQK-NSK007 MIN105 2.42E + 08 284,622 851 115,494
DENV 2 16.9 1,626.0 SQK-NSK007 MIN105 1.55E + 08 203,700 760 52,157
DENV 6 21.2 475.0 SQK-LSK208 MIN106 1.22E + 09 1,377,721 886 118,733
DENV 11 28.7 65.8 SQK-LSK208 MIN106 7.07E + 08 1,111,566 636 119,438
Ct: cycle threshold.
a The Nanopore data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or 
dengue virus by real-time reverse transcription-PCR in 2016.
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Figure 3
Comparison of Nanopore and Illumina results, as to proportions of reads mapping to the appropriate reference viral 







































Ct: cycle threshold; TC: template/complement.
a The Nanopore and Illumina data presented in the figure were obtained in 2017 on samples that had been collected and found positive for 
chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.
The percentage of total reads mapping to the appropriate reference sequence is plotted in the upper panel. Lower panels display the 
percentage of the reference genome sequenced to a minimum depth of 20-fold in the data generated, in dark blue or dark green for the 
Illumina sequence data, in light blue or light green for Nanopore data (MinION_TC).
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Illumina data, although a slight decrease is observed 
across the range of Ct values. In the Nanopore data, 
the highest mapped read percentages observed were 
85.12% and 72.14% for CHIKV3 and DENV 2 respec-
tively, compared with 95.23% and 92.56% in the 
Illumina data from the same samples. While in high Ct 
samples the viral proportion drops to 4.08% for CHIKV 
9 and 2.90% for DENV 11, from 6.66% and 3.73% in the 
Illumina data.
Despite the decrease in proportion of mapped viral 
reads, comparable genome coverage is observed 
at both 20x and 10x (Figure 3,  Table 3) and is even 
increased compared with Illumina data at lower viral 
titres, e.g. 100% at 20x for CHIKV 9 compared with 
95.98% in the Illumina data and 95.25% for the high 
Ct DENV 11 sample, which generated 94.44% cover-
age from the Illumina data. Average read lengths in 
Nanopore data ranged from 564 to 886 bp (Table 2).
Figure 4 shows coverage depth of reads mapped across 
the relevant genome for each sample sequenced by 
both Illumina and Nanopore. Read levels are not nor-
malised thus actual depth is a function of total reads 
sequenced, but the pattern of coverage seen is highly 
similar suggesting it is more dependent upon the 
SISPA methodology than sequencing library prepara-
tion. From Nanopore consensus genome sequences, 
between 99.93% and 100% of bases called per sample 
agreed with the Illumina generated sequence.
Metagenomic data analysis and coinfection 
identification
To test the applicability of a metagenomic analysis 
approach to the data, we assessed read taxonomic 
classification using Kraken (Figure 5). The distribu-
tion of reads classified as CHIKV, DENV, other viruses, 
bacteria, and archaea/eukaryota show a similar pat-
tern for Illumina and Nanopore data. The proportion 
of unclassified reads for each sample increased with 
Ct value, as the proportion of human origin reads is 
higher and the human genome is not represented in 
our Kraken database. A decrease in the percentage 
of CHIKV and DENV classified reads is observed for 
MinION data compared with Illumina, but was suf-
ficient to identify the correct predominant virus in all 
samples.
Kraken analysis also allowed for the identification of 
a DENV coinfection in sample CHIKV 3, the consensus 
sequence of which was unique in the sample set, elimi-
nating cross-contamination from the DENV positive 
samples as potential source. Kraken classified 0.08% 
of Illumina reads and 0.15% of MinION reads as DENV. 
Using reference mapping to validate the finding, 0.22% 
of Illumina reads and 0.43% of MinION reads mapped 
to a DENV-1 reference genome. Genome coverage at 
20x of 99.73% and 95.99% was achieved for the pri-
mary CHIKV and secondary DENV coinfection respec-
tively, with a single MinION flow cell.
De novo assembly
De novo assembly of the data was attempted using Canu 
[42] and contigs identified using Basic Local Alignment 
Search Tool against a Nt database (BLASTn).  Table 
3 lists the longest viral contig length identified in each 
sample, ranging from 4.2 Kb (36% of reference genome 
size) to 10.8 Kb (91%) for CHIKV and 4.7 Kb (44%) to 
10.1 Kb (95%) for DENV. Identification of the pathogen 
present without prior knowledge would have therefore 
been possible for all samples.
Table 3
Summary of Nanopore mapping data on chikungunya and dengue virus positive samples by real-time reverse transcription-




















CHIKV 1 14.7 267,171 65.1 98.57 11,658 99.2 CHIKV 11,826 5,263
CHIKV 3 21.4 1,891,028 85.1 99.76 11,798 99.9 CHIKV 11,826 10,793
CHIKV 4 22.7 216,493 11.6 94.11 11,130 97.2 CHIKV 11,826 4,256
CHIKV 9 30.08 3,481,358 4.08 100 11,826 100 CHIKV 11,826 9,860
DENV 1 16.3 284,622 71.3 99.9 10,719 99.9 DENV 1 10,735 8,281
DENV 2 16.9 203,700 72.1 99.6 10,692 99.6 DENV 1 10,735 10,157
DENV 6 21.2 1,377,721 71.1 99.9 10,634 99.9 DENV 4 10,649 7,877
DENV 11 28.7 1,111,566 2.9 95.3 10,226 96.3 DENV 1 10,735 4,699
CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.
a The Nanopore data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or 
dengue virus by real-time reverse transcription-PCR in 2016.
b For DENV the serotype is also indicated.
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Updated MinION library kits
We repeated the sequencing of the coinfected CHIKV 3 
sample using the MinION 1D2 (SQK-LSK308) and Rapid 
(SQK-RBK001) kits, currently the most accurate and the 
fastest library preparation kits available, respectively. 
Using the 1D2kit 74.5% of reads generated mapped to 
CHIKV and 0.37% to DENV, while from the Rapid kit 
the result was 66.26% and 0.29% respectively (both 
lower than observed in the 2D chemistry). Coverage 
at 20x for CHIKV was above 99% for both kits, and for 
DENV was 95.04% from the 1D2 and 81.09% from the 
Rapid kit (Table 4). Coverage depth pattern across the 
genome for both viruses (Figure 6) was similar for all 
library kits tested. Near-maximum coverage for both 
viruses was obtained within 30 min with the 2D kit, 
8 min with the 1D2  kit and 85 min with the Rapid kit 
(Supplementary Figure 1). De novo assembly (Table 4) 
produced best CHIKV contigs of 10.7, 11.3 and 11.4 Kb 
for the 2D, 1D2 and Rapid libraries respectively and the 
longest contigs generated for DENV were 7.5, 2.2 and 
4.2 Kb.
The 1D data from the Rapid kit was sufficient to call a 
consensus from 11,647/11,826 bases of the CHIKV refer-
ence with 179/11,826 bases called as ambiguous or too 
low coverage. All bases called were concordant with the 
Illumina consensus. A polishing step using Nanopolish 
[37] with a subset of the mapped reads (ca 100x cov-
erage depth) significantly reduced ambiguous calls to 
90/11,826, introducing a single disagreement with the 
Illumina consensus (99.99% concordance). Despite 
considerably greater read depth, the 1D2 kit called only 
Figure 4
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Chikungunya virus samples Dengue virus samples
Ct: cycle threshold.
a The Nanopore and Illumina data presented in the figure were obtained in 2017 on samples that had been collected and found positive for 
chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.
Each graph corresponds to a given sample, defined by its Ct value. Read depth (y-axis) across the genome (x-axis) following reference 
alignment is shown. Illumina coverage is shown in darker blue and darker green for chikugunya and dengue virus positive samples 
respectively. Nanopore (MinION) coverage is indicated in lighter blue or lighter green for chikungunya and dengue virus positive samples 
respectively. Total depth has not been normalised; comparison is to show overall pattern of coverage is highly similar across the methods. 
Dotted horizontal line indicates depth of 20x coverage, used for consensus calling.
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11,082/11,826 due to a higher proportion, 744/11826, 
of ambiguous base calls, suggesting 1D reads are most 
suitable for this approach.
Discussion
These results clearly show that there are considerable 
levels of viral nucleic acid present in a large proportion 
of CHIKV and DENV qRT-PCR positive clinical samples, 
and demonstrate that relatively modest metagenomic 
sequencing is capable of elucidating significant por-
tions of viral genome even for samples with Ct values 
at the higher end of clinical range. A decreased Ct value 
coincided with an increased proportion of viral reads, 
with a considerable level of variation between samples, 
likely because of the total level of non-viral host/back-
ground nucleic acid present due to variability between 
patients or in sample handling during collection, stor-
age and testing. For example, the two lowest viral titre 
CHIKV samples (13 and 14) have similar Ct values (32.2 
and 32.57) but varied significantly in the proportion of 
viral reads (5.03% and 21.72%). The 5.03% viral reads 
in CHIKV13 is the lowest for CHIKV, yet still sufficient 
to generate 88.5% of the CHIKV genome at 20x depth 
from just ca 662,000 paired-end Illumina reads. This 
amount of genomic information is highly informative 
and further sequencing would likely increase coverage. 
Only seven of the 73 total CHIKV diagnostic samples 
tested in 2016 had a Ct greater than 32.2 (including 
sample CHIKV14) (Table 1), which suggests that for 
the majority (> 90%) of CHIKV PCR positive samples, 
viral load is sufficient for genome sequencing directly 
from patient samples without further viral enrichment 
beyond a simple DNAse digestion (Figure 1). The low-
est viral read proportion observed in the DENV sam-
ples was 0.47% in DENV12, Ct 31.29, which generated 
71.5% coverage at 20x depth (increased to 77.8 at 10x 
Figure 5
Kraken classification of reads from metagenomic sequencing in (A) chikungunya and (B) dengue real-time reverse 
transcription-PCR positive samples, United Kingdom, 2017a (n = 8 samples)

















































a Read taxonomic classification using Kraken was conducted in 2017 on samples that had been collected and found positive for chikungunya 
or dengue virus by real-time reverse transcription-PCR in 2016.
Kraken classification distribution comparison for Illumina (cross-hatched) and Nanopore data. Reads grouped as either chikungunya virus 
(blue in panel A), dengue virus (green in panel B), other viruses (brown), archea/eukaryota (orange), bacteria (brown) or unclassified (grey).
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depth) from just 687,000 paired end Illumina reads 
and allowed for DENV serotype identification. Only 62 
of 368 DENV cases in 2016 had a higher Ct, predicting 
that > 80% of PCR positive DENV samples have a viral 
load sufficient for genome sequencing (Figure 1). These 
estimates are based on Ct range distribution from a 
single year, results may vary from year to year.
The high yield of viral sequences from clinical CHIKV 
and DENV samples make the exciting prospect of 
metagenomic MinION viral whole-genome-sequencing 
feasible, even for lower viral titre samples. Evaluating 
this on a representative subset of our samples demon-
strates that viral read proportions are in general agree-
ment with that seen for Illumina sequencing, predicting 
a similar proportion of qRT-PCR positive patient sam-
ples would be suitable for direct metagenomic sequenc-
ing on the MinION. Differences in precise proportions 
of viral reads seen between Illumina and MinION are 
likely due to inter-library variation. Differences in 
genome coverage achieved are due to both differences 
in total reads generated per sample (not normalised 
between platforms) as well as differences in average 
read length. Of the samples tested on the MinION, the 
lowest titre samples CHIKV 9 and DENV 11 both gener-
ated near complete genome coverage.
We repeated the sequencing of the coinfected CHIKV 3 
sample using the MinION 1D2 (SQK-LSK308) and Rapid 
(SQK-RBK001) kits. A reduction in viral proportion of 
total reads was observed compared with the 2D kit, 
which may be due partly to the extended storage time 
of the original samples before retesting. In the case 
of the 1D2  kit, the lower proportion was outweighed 
by a substantial increase in total data generated per 
flow cell (5 M vs 1.8 M reads). For the Rapid kit, the 
total data produced should be considered in the 
light of the greatly simplified sample workflow and 
turnaround-time.
The use of metagenomics to elucidate genomic 
sequences of RNA viruses directly from clinical samples 
has several obvious benefits in public health applica-
tions. The primary benefit over targeted methods is 
the hypothesis-free nature of the assay, which allows 
identification and genomic characterisation of novel or 
unexpected RNA viral agents, either as primary or coin-
fectants (demonstrated here in the CHIKV/DENV coin-
fection sample), without any prior clinical knowledge. 
It also removes the need for laboratory optimisation of 
targeted methods, such as primer or bait-probe design 
and testing, and is not subject to escape mutations in 
target sites that afflict targeted sequencing and diag-
nostic methods. This issue particularly relevant for 
highly diverse RNA viruses, such as Lassa virus, which 
are difficult to assess using targeted methods, without 
regular reappraisal [43].
The principal limitation of the metagenomic approach 
is the limit of detection. The data generated here 
show that viral titres as low as 105  are sufficient for 
significant genome recovery by this method, but ZIKV 
is a recent example of a pathogen typically present at 
lower clinical titres, for which targeted methods are an 
absolute requirement [22,23]. For diagnostic purposes 
qRT-PCR has a lower limit of detection, provided the 
target site is conserved in the pathogen isolate tested. 
Clearly no single method is most suitable for both 
detection and genotyping of all pathogens and each 
has a role to play in differing circumstances.
The ability to generate genomic data directly from 
patient samples is clearly of great benefit to public 
Table 4



















Illumina Nextera XT NA CHIKV 1,391,258 95.23 98.86 99.37 CHIKV 11,826 7,321
Illumina Nextera XT NA DENV 1,391,258 0.22 63.66 77.82 DENV1 10,735 6,613
MinION 2D SQK-LSK208 MIN106 CHIKV 1,891,028 85.12 99.73 99.91 CHIKV 11,826 10,793
MinION 2D SQK-LSK208 MIN106 DENV 1,891,028 0.43 95.99 96.09 DENV1 10,735 7,549
MinION 1D2 SQK-LSK308 MIN107 CHIKV 5,080,906 74.50 99.94 100 CHIKV 11,826 11,369
MinION 1D2 SQK-LSK308 MIN107 DENV 5,080,906 0.37 95.04 96.42 DENV1 10,735 2,199
MinION Rapid SQK-RBK001 MIN106 CHIKV 611,110 66.26 99.66 99.68 CHIKV 11,826 11,473
MinION Rapid SQK-RBK001 MIN106 DENV 611,110 0.29 81.09 90.83 DENV1 10,735 4,227
CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus. NA: not applicable.
a Results presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus 
by real-time reverse transcription-PCR in 2016.
b For DENV the serotype is also indicated.
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health (reviewed in detail [44]). It can be used in a rou-
tine surveillance capacity or early during suspected 
outbreaks to link related cases who may be missed 
by traditional epidemiology [45] and identify outbreak 
cases distinct from typically circulating seasonal 
strains, which is key in regions endemic for the patho-
gen in question. The use of whole genome sequences 
offers the greatest precision for these applications, 
compared with typing methods based on specific 
genomic regions [44]. Whole genome sequencing on a 
portable device allows this information to be generated 
rapidly and within the affected region [24], enabling 
timely identification of an outbreak, or allaying fears 
of a potential one if cases are not linked. Furthermore 
mutations relating to viral drug resistance or patho-
genicity can be monitored [44]. Therefore the ability 
Figure 6
Comparison of genome coverage depth across the chikungunya virus or dengue virus genome for different sequencing 





























































Reference genome position Reference genome position 
a Results presented in the Figure were obtained in 2017 on a sample that had been collected and found positive for chikungunya virus by 
real-time reverse transcription-PCR in 2016. In 2017, the sample was further found to be coinfected with CHIKV and DENV by metagenomic 
sequencing.
Read depth across both CHIKV and DENV genomes following reference alignment is shown for coinfection sample CHIKV 3, sequenced using 
four different sequencing library preparation/sequencing methods. Total coverage depth has not been normalised; comparison is to show 
overall pattern of coverage is highly similar across the methods. Dotted horizontal line indicates depth of 20x coverage, used for consensus 
calling.
to generate near-complete viral genome sequences 
directly from clinical samples on a portable sequenc-
ing device has many potential applications.
Conclusions
We demonstrate that across the clinically relevant 
range of viral loads an unexpectedly high proportion 
of reads generated metagenomically from CHIKV and 
DENV clinical samples are viral in origin. Therefore 
metagenomic sequencing provides an effective 
approach for the analysis of CHIKV and DENV genomes 
directly from the majority of qRT-PCR positive serum 
and plasma samples, without the need for culture or 
viral nucleic acid enrichment beyond a simple DNA 
digestion. We demonstrate this is equally possible on 
the Oxford Nanopore MinION, making metagenomic 
12 www.eurosurveillance.org
whole genome sequencing potentially feasible in the 
field.
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Metagenomic sequencing at the
epicenter of the Nigeria 2018 Lassa
fever outbreak
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M. Pahlmann3,6, A. Thielebein3,6, J. Hinzmann3,6, L. Oestereich3,6, D. M. Wozniak3,6,
K. Efthymiadis7, D. Schachten3, F. Koenig3, J. Matjeschk3, S. Lorenzen3, S. Lumley1,
Y. Ighodalo8, D. I. Adomeh8, T. Olokor8, E. Omomoh8, R. Omiunu8, J. Agbukor8,
B. Ebo8, J. Aiyepada8, P. Ebhodaghe8, B. Osiemi8, S. Ehikhametalor8, P. Akhilomen8,
M. Airende8, R. Esumeh8, E. Muoebonam8, R. Giwa8, A. Ekanem8, G. Igenegbale8,
G. Odigie8, G. Okonofua8, R. Enigbe8, J. Oyakhilome8, E. O. Yerumoh8, I. Odia8,
C. Aire8, M. Okonofua8, R. Atafo8, E. Tobin8, D. Asogun8,9, N. Akpede8,
P. O. Okokhere8,9, M. O. Rafiu8, K. O. Iraoyah8, C. O. Iruolagbe8, P. Akhideno8,
C. Erameh8, G. Akpede8,9, E. Isibor8, D. Naidoo10, R. Hewson1,2,11,12, J. A. Hiscox2,13,14,
R. Vipond1,2, M. W. Carroll1,2, C. Ihekweazu15, P. Formenty10, S. Okogbenin8,9,
E. Ogbaini-Emovon8*, S. Günther3,6*†, S. Duraffour3,6*
The 2018 Nigerian Lassa fever season saw the largest ever recorded upsurge of cases, raising
concerns over the emergence of a strain with increased transmission rate.To understand the
molecular epidemiology of this upsurge, we performed, for the first time at the epicenter of an
unfolding outbreak, metagenomic nanopore sequencing directly from patient samples, an
approach dictated by the highly variable genome of the target pathogen. Genomic data and
phylogenetic reconstructions were communicated immediately to Nigerian authorities and the
World Health Organization to inform the public health response. Real-time analysis of 36
genomes and subsequent confirmation usingall 120 samples sequenced in the countryof origin
revealed extensive diversity and phylogenetic intermingling with strains from previous years,
suggesting independent zoonotic transmission events and thus allaying concerns of an
emergent strain or extensive human-to-human transmission.
L
assa fever is an acute viral hemorrhagic
illness, first described in 1969 in the town of
Lassa, Nigeria (1). It is contracted primarily
through exposure to urine or feces of in-
fected Mastomys spp. rodents or, less fre-
quently, through the bodily fluids of infected
humans. Lassa virus (LASV) is endemic in parts
of West Africa, including Nigeria, Benin, Côte
d’Ivoire, Mali, Sierra Leone, Guinea, and Liberia
(2). The upsurge of Lassa fever cases during the
2018 endemic season in Nigeria—referred to
here as the 2018 Lassa fever outbreak—has been
the largest on record, reaching 1495 suspected
cases and 376 confirmed cases and affecting
more than 18 states by 18 March (fig. S1). This
notably exceeds the 102 confirmed cases reported
during the same period in 2017 (fig. S1) (3). The
unprecedented scale of the outbreak raised fears
of the emergence of a strain with a higher rate
of transmission. Because of these concerns, on
28 February the Nigeria Centre for Disease Con-
trol (NCDC) and the World Health Organization
(WHO) urgently requested sequencing informa-
tion and preliminary results from our pilot-scale
study, in which we used a metagenomic ap-
proach with the Oxford Nanopore MinION de-
vice (Oxford Nanopore Technologies) to conduct
in-country, mid-outbreak viral genome sequencing.
This instigated amajor uptick in sequencing efforts,
leading to the sequencing of 120 samples.
Nanopore sequencing is an emerging technol-
ogy with great potential. The MinION is a small,
robust sequencing device suited for the genetic
analysis of pathogens in remote or resource-
limited settings (4). Nanopore sequencing of
polymerase chain reaction (PCR) amplicons of
Ebola virus genomes provided important data
from the field in real time during the 2014–2016
Ebola virus disease outbreak in West Africa (5),
and a more sophisticatedmultiplex amplicon se-
quencing methodology (6) has been used effective-
ly during recent Zika and yellow fever outbreaks
inBrazil (7,8).However, highly variable pathogens
such as LASV present a substantial challenge
for this type of amplicon-based approach. Owing
to an interstrain nucleic acid sequence variation
of up to 32 and 25% for the L (large segment en-
coding the RNA polymerase and the zinc-binding
protein) and S (small segment encoding the
glycoprotein and the nucleoprotein) segments,
respectively (9), even PCR-based laboratory
diagnosis poses a serious challenge. Designing
targeted whole-genome sequencing approaches,
such as those using PCR amplicons or bait-and-
capture probes, without prior knowledge of the
targeted LASV lineage is therefore cumbersome.
Random reverse-transcription (RT) and am-
plificationby sequence-independent single primer
amplification (SISPA) formetagenomic sequenc-
ing to identify RNA viruses has been demon-
strated to work on the MinION (10), and our
previous work highlighted the feasibility of re-
trieving complete viral genomes directly from
patient samples at clinically relevant viral
titers using this approach for dengue and
chikungunya viruses (11). We describe here the
application of field metagenomic sequencing of
LASV at the Irrua Specialist Teaching Hospital
(ISTH), Edo State, during the 2018 Lassa fever
season.
A total of 120 LASV-positive samples were se-
quenced during a 7-week mission; these were
selected on the basis of cycle threshold value
and location of the 341 cases reported by ISTH
between 1 January and 18 March 2018 (figs. S1
and S2). Themajority of samples originated from
Edo State followed by Ondo and Ebonyi (fig. S2).
Selected samples covered the wide range of
clinical viral loads observed, including several
samples testing negative in one of the two real-
time RT-PCR assays used (fig. S3 and data S1).
Up to six samples were run in multiplex per
MinION flow cell, along with a negative con-
trol. To produce high-confidence consensus se-
quences for phylogenetic inference, we chose
to map both basecalled reads and raw signal
data to a reference sequence and call variants
using Nanopolish software, as developed for
the West African Ebola virus disease outbreak
(5); basecalled reads were then remapped to
the consensus and a further round of correc-
tion was applied (fig. S4). Owing to the di-
versity of LASV, selection of an individual
reference genome for read alignment was re-
quired for each sample. To select the closest
existing LASV reference genome, nonhuman
reads from each sample were assembled de
novo using Canu (12). A notable proportion of
reads generated per sample were LASV at an
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average frequency of 4.26%with amaximum of
42.9%, allowing for sufficient genomic sequence
(>70%) for phylogenetic comparison of at least
one segment in 91 of the samples tested (figs.
S3 to S6).
Additionally, sequences were validated by
Illumina resequencing of 14 SISPA prepara-
tions, which matched with their Oxford Nano-
pore counterparts with little to no divergence,
confirming the accuracy of the Oxford Nano-
pore approach (table S1).
Metagenomic classification using the Centri-
fuge software system (13) identified 0.10% of
reads from sample 110 as originating from hepa-
titis A virus, providing 74% genome coverage
at 20-fold depth. LASV accounted for 0.83% of
reads in the same sample, providing 96% genome
coverage. These findings demonstrate the po-
tential of this simple approach to identify mul-
tiple RNA viruses, including those present as
co-infections. In all other samples tested, LASV
was the sole pathogen identified despite a small
number of reads classified as other viruses (fig.
S7 and data S1).
To dissect the molecular epidemiology of the
2018 Lassa fever outbreak in Nigeria, we per-
formed phylogenetic analysis of all newly gen-
erated LASV sequences together with unpublished
sequences from previous years (data S2) and
sequences available in GenBank. We used this
as a frame of reference to document how the
genomic data generated in real time (made pub-
licly available at virological.org) provided valu-
able epidemiological insights into the unfolding
outbreak dynamics.
Maximum likelihood phylogenetic reconstruc-
tion of the S segment sequences indicates that all
2018 viruses fall within the Nigerian LASV
diversity, specifically within genotypes II and
III, and they are phylogenetically interspersed
with Nigerian LASV sequences from previous
years (Fig. 1). This phylogenetic pattern is
mimicked by the L segment reconstruction
(fig. S8). Only seven viruses in the entire genome
dataset (n = 348) were identified as clustering
















Fig. 1. Phylogenetic reconstruction of the S segment data. The circular
tree includes 96 sequences from 2012 to 2017, 88 sequences from 2018,
and sequences available from GenBank. The rectangular tree focuses on
the genotype II clade (in blue in the circular tree), which includes most of
the 2018 sequences. The six genotypes are indicated with different colors
and roman numerals. Bootstrap support >90% is indicated with a small
gray circle at the middle of their respective branches. The color strip
highlights the human LASV sequences obtained from previous years
(light gray); sequences obtained from rodent samples (dark gray); and, for
2018, the first seven sequences generated in Nigeria (light pink), the
remaining 28 sequences analyzed on-site (medium pink), and the
remaining sequences finalized in Europe (dark pink). The same color code
is used in the genotype II rectangular tree. Bootstrap values >80% are









significantly differently in the L and S segments
(supplementary methods), which is in line with
the small number of potential LASV reassort-
ments identified previously (9). The phylogenetic
pattern implicates independent spillover from
rodent hosts as the major driver of Lassa
fever incidence during the outbreak (Fig. 1 and
fig. S8).
However, a number of sequences from the
2018 outbreak clustered as pairs in the phyloge-
netic reconstructions, raising concerns over
human-to-human transmission. We illustrate
such cluster pairs in a Bayesian time-measured
tree estimated from genotype II S (Fig. 2) and L
segment sequences (fig. S9). These analyses
resulted in highly similar evolutionary rate
estimates for both segments (mean, ~1.2 × 10−3
substitutions per site per year) (Fig. 2 and
figs. S9 and S10), in agreement with previous
estimates (9). We used these rate estimates
together with an estimate of the time be-
tween successive cases in a transmission chain
to assess how many substitutions can be ex-
pected between directly linked infections. We
compared conservative to more liberal expec-
tations, the latter accommodating an indepen-
dent upper estimate of potential sequencing
errors (Fig. 2 and fig. S9). In the S segment, for
example, more than two substitutions between
sequences from directly linked infections is
highly unlikely (P<0.01 andP=0.03, respectively,
for the conservative and liberal probability es-
timates). This expectation is consistent with
the low number of substitutions observed in the
coding region of human-to-human LASV trans-
mission (14). Four clusters of sequences showing
≤4 and ≤12 nucleotide differences in the S and L
segments, respectively, were identified (035-045,
035-058, 137-138, and 053-089-106; for some of
them, only the S or L segment sequence was
available). Retrospective tracing revealed that
the sequences for pairs 137-138 and 035-058
were derived from the same patients. Epide-
miological investigation of the remaining clus-
ters did not provide evidence for transmission
chains, though direct linkage cannot be ex-
cluded. Even when applying liberal assumptions
for the number of mutations during human-to-
human transmission, the vast majority of cases
during the 2018 outbreak resulted from spillover
from the natural reservoir.





















































Fig. 2. Assessing the potential for direct linkage between pairs of 2018
sequences in the S segment.The maximum clade credibility tree
summarizes a Bayesian evolutionary inference for the genotype II sequences
in the S segment. A time scale and a marginal posterior distribution for the
time to the most recent common ancestor are shown to the left. The size of
the internal node circles reflects posterior probability support values. 2018
sequences clustering as pairs are indicated in dark pink; the number of
substitutions between them is indicated at their respective tips. A posterior
estimate of the evolutionary rate and probability distributions for observing
a given number of substitutions during a human-to-human transmission
event are shown as insets. The distribution represented by gray bars is based
on the mean evolutionary rate estimate and a mean estimate for the
generation time, whereas the light blue distribution is based on upper
estimates and also incorporates an upper estimate for the MinION
sequencing error (supplementary methods). At the bottom of the tree,
clusters of sequences for which human-to-human transmission cannot be
excluded according to the upper estimates of generation time are indicated.
A pair of identical sequences (137-138) that was retrospectively found
to be derived from the same patient is marked with a gray box. One pair
(096-115) was disregarded as a potential transmission chain because
of 21 differences in the L segment (fig. S9).The temporal signal before BEAST









A request for information on circulating
strains was made on 28 February at the height
of the outbreak; within 10 days, our pilot study
was expedited and the initial analysis com-
pleted. The fact that the 2018 outbreak was
fueled by the circulating LASV diversity and
not by transmission of a new or divergent lin-
eage was already evident from the first seven
genomes generated by 10 March (fig. S1). This
information was promptly communicated
to the NCDC, forming the basis of its report
released on 12 March 2018 (15). Whereas this
small sample was restricted to genotype II,
the final collection of 36 LASV genome se-
quences generated on-site also included a
representative of genotype III (Fig. 1 and fig.
S9), further supporting the spillover of long-
standing LASV diversity in the outbreak. The
conclusions drawn from the first set of ge-
nome sequences immediately eased fears of
extensive human-to-human transmission and
allowed public health resources to be allo-
cated appropriately. The response was focused
on intensified community engagement on ro-
dent control, environmental sanitation, and
safe food storage. Further research is needed
to evaluate whether improved diagnostics and
disease awareness and/or ecological and cli-
mate factors promoting transmission are the
drivers behind the changing epidemiology of
Lassa fever in Nigeria.
Portable metagenomic sequencing of genet-
ically diverse RNA viruses on the MinION, di-
rect from patient samples without the need to
export material outside of the country of origin
and with no pathogen-specific enrichment, is
shown to be a feasible methodology enabling
a real-time characterization of potential out-
breaks in the field.
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future escalation of this disease, we need to understand what triggers the irruption of rodents into human dwellings.
strain emerging nor of person-to-person transmission; rather, rodent contamination was the main source. To prevent
directly from samples from 120 patients (see the Perspective by Bhadelia). Results showed no strong evidence of a new 
 performed metagenomic nanopore sequencinget al.in Nigeria in 2018 signaled an incipient outbreak, Kafetzopoulou 
cases reported, but hospitalized patients risk a 15% chance of death. Responding to fears that a 10-fold surge in cases 
Lassa fever is a hemorrhagic viral disease endemic to West Africa. Usually, each year sees only a smattering of
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